Characterization of antibodies to coagulation factor VIII by Kallas, Ade
DISSERTATIONES MEDICINAE UNIVERSITATIS TARTUENSIS
72
CHARACTERIZATION OF ANTIBODIES 
TO COAGULATION FACTOR VIII
ADE KALLAS
TARTU 2002
DISSERTATIONES MEDICINAE UNIVERSITATIS TARTUENSIS
DISSERTATIONES MEDICINAE UNIVERSITATIS TARTUENSIS
72
CH ARACTERIZATION OF ANTIBODIES 
TO COAGULATION FACTOR VIII
ADE KALLAS
Department of Pharmacy, University of Tartu, Tartu, Estonia
Dissertation is accepted for the commencement of the degree of Doctor of 
Pharmaceutical Sciences on April 24, 2002 by the Council of the Faculty of 
Medicine, University of Tartu.
Oppenent: Professor J0rgen Mogens Ingerslev, M.D., Ph.D.
Centre for Haemophilia and Thrombosis 
Department of Clinical Immunology 
University Hospital Aarhus at Skejby 
Denmark
Commencement: June 17, 2002
Publication of this dissertation is granted by the University of Tartu.
© Ade Kallas, 2002 Tartu Ülikooli Kirjastuse trükikoda 
Tiigi 78, Tartu 50410 
Tellimus nr. 353
“Blut ist ein ganz besonderes Saft” 
Goethe, Faust
CONTENTS
List of original publications..............................................................................  10
Abbreviations...................................................................................................... 11
1. INTRODUCTION........................................................................................ 15
2. REVIEW OF LITERATURE...................................................................... 16
2.1. Occurrence of haemophilia A ..............................................................  16
2.2. Phenotype of haemophilia A ...............................................................  17
2.3. Structure and function of FV m ...........................................................  18
2.4. FVIII gene and common mutations..................................................... 21
2.5. Treatment with FVIII preparations......................................................  22
2.6. Structure and function of the von Willebrand factor.........................  23
2.7. Factor VIII antibodies...........................................................................  26
2.7.1. Prevalence and incidence of FVIII antibodies among 
haemophilia A patients  26
2.7.2. Treatment of haemophilia A patients possessing FVIII 
antibodies.......................................  30
2.7.3. Properties of FVIII antibodies................................................... 33
2.7.4. Epitope specificity of FVIII antibodies and relation to the 
mechanism of inhibition of FVIII biological activity  34
2.7.5. VH repertoire of human immunoglobulins directed
to FVIII........................................................................................ 36
2.7.6. Immune response to human FVIII in murine
model of haemophilia A ............................................................  37
3. AIMS OF THE STUDY..............................................................................  39
4. MATERIALS AND METHODS...............................................................  40
4.1. Study subjects........................................................................................ 40
4.1.1. Haemophilia A patients with persistent
FVIII antibodies (Papers I and III)..........................................  40
4.1.2. Patient undergoing immune tolerance treatment (II, III).......  40
4.2. Reagents................................................................................................  41
4.3. Assays for studying the functional activity
of FVIII antibodies...............................................................................  42
4.3.1. Bethesda assay (I—III)...............................................................  42
4.3.2. Inhibition of FVIILC activity by antibodies
in the presence and absence of VWF (I—III)...........................  42
4.3 .3. Purification of IgG from plasma samples (II).........................  43
4.3.4. Tagging of recombinant FVIII with biotin (II).......................  43
7
4.3.5. Inhibition of FVIII binding to phospholipids
by the antibodies of the patient (II)..........................................  44
4.3.6. Inhibition of FVIII binding to the von Willebrand factor
by the antibodies of the patient (II)..........................................  44
4.3.7. Chromogenic method for measuring FXa generation (II)......  45
4.3.8. Inhibition of FX binding to FVIII by
the antibodies of the patient (II)...............................................  46
4.4. Assays for characterization of epitope specificity
of VIII antibodies.................................................................................  46
4.4.1. Immunoblotting analysis (I—III)...............................................  46
4.4.2. ELISA for the quantification of antibodies
recognizing the light chain or heavy chain of FVIII (I—III)_ 47
4.4.3. Chromogenic method for the quantification
of antibodies recognizing the light chain or heavy chain
of FVIII (I-III)........................................................................... 48
4.4.4. Recombinant FVIII fragments (II)...........................................  48
4.4.5. Binding of FVIII antibodies to recombinant
FVIII fragments (II).....................!............................................ 49
4.4.6. Competitive binding to FVIII between the antibodies
of the patient and monoclonal antibodies with the known
epitope (II).................................................................................  50
4.5. Characterization of IgG subclasses of FVIII antibodies..... ..............  51
4.5.1. IgG 1-4 subclasses of FVIII antibodies (III)..........................  51
4.5.2. IgG l-4 subclasses of FVIII-light-chain-specific
antibodies (III)..........................................................................  52
4.6. Characterization of VWF content in FVIII preparation (IV)............. 52
4.6.1. FVIII preparations (IV)............................................................. 52
4.6.2. ELISA for the quantification of the VWF antigen (IV).........  52
4.6.3. Estimation of FVIII coagulation activity (IV )........................  53
4.6.4. Ristocetin cofactor assay (IV)..................................................  53
4.6.5. Characterization of VWF multimers (IV)................................ 53
4.6.6. ELISA for the quantification of VWF binding
to collagen (IV).........................................................................  54
4.7. Statistical analyses (I-TV)....................................................................  54
5. RESULTS......................................................................................................  55
5.1. Inhibition of FVIII.C activity by FVIII antibodies
in the presence of VWF (Paper I ) ....................................................... 55
5.2. Characterization of the patient’s FVIII antibodies
during immune tolerance treatment with VWF containing FVIII
preparation (II, III)............................................................................... 57
5.2.1. The amount of FVIII-light-chain- and FVIII-heavy-chain-specific
antibodies (II, III)......................................................................  57
5.2.2. Epitope specificity of FVIII-light-chain-specific
antibodies (II).............................................................................  60
5.2.3. Epitope specificity of FVIH-heavy-chain-specific
antibodies (IT).............................................................................  62
5.2.4. IgG subclasses of FVIII antibodies (III)..................................  64
5.2.4.1. IgG subclasses of FVIII antibodies in patients with 
persistent FVIII antibodies (III).................................. 64
5.2.4.2. Changes in the IgG subclass distribution of FVIII 
antibodies during immune tolerance treatment (III).. 65
5.3. Inhibition of FVIII:C activity by the patient’s antibodies,
the putative mechanism (II)................................................................  68
5.4. Characterization of VWF in FVIII preparations (IV)........................  71
6. DISCUSSION................................................................................................  73
6.1. Inactivation of FVIII by antibodies,
the protective effect of V W F..............................................................  73
6.2. Characterization of the patient’s FVIII antibodies during immune 
tolerance treatment with FVIII preparation containing VWF........... 74
6.2.1. Epitope specificity of FVIII antibodies....................................  74
6.2.2. The IgG subclass distribution of FVIII antibodies..................  78
6.3. Inhibition of FVIII:C activity by the patient’s antibodies,
the putative mechanism........................................................................ 80
6.4. The von Willebrand factor content in FVIII preparations................. 82
7. CONCLUSIONS......................................................................................... 85
REFERENCES..................................................................................................  87
SUMMARY IN ESTONIAN............................................................................  110
ACKNOWLEDGEMENTS............................................................... ..............  114
PUBLICATIONS...............................................................................................  117
3 9
LIST OF ORIGINAL PUBLICATIONS
This dissertation is based on the following publications and some unpublished
data:
I Kallas A, Talpsep T. Von Willebrand factor in factor VIII concentrates 
protects against neutralization by factor VIII antibodies of haemophilia A 
patients. Haemophilia 2001; 7 (4): 375-380
II Kallas A, Pooga M, Benhida A, Jacquemin M, Saint-Remy J-M. Epitope 
specificity of anti-FVIII antibodies during immune tolerance therapy with 
FVIII preparation containing von Willebrand factor. Submitted for publi­
cation
III Kallas A, Talpsep T, Everaus H. Changes in epitope specificity and in 
distribution of IgG subtypes of FVIII antibodies during immune tolerance 
therapy (ITT) in hemophilia A patients with FVIII antibodies -  a case 
report. In Scharrer I., Schramm W. (eds.) 31st Hemophilia Symposium. 
Springer Verlag Berlin Heidelberg, 2001, 23-40
IV Kallas A, Talpsep T. The von Willebrand factor collagen-binding activity 
assay: clinical application. Annals o f Hematology 2001; 80 (8): 466-471
Related papers
Kallas A, Everaus H. Ülevaade desmopressiini kasutamisest verehüübimishäire- 
te ravis. Eesti Arst 1998; 2: 119-126
Kallas A, Viires M, Everaus H, Hinrikus T. Faktor VIII -  von Willebrandi 
faktori kompleks hemofiilia A asendusteraapias kasutatavates erinevates faktor 
VIII preparaatides. Eesti Arst 1997; 5: 417-424
Articles are reprinted with the permission of copyright owners.
ABBREVIATIONS
aa amino acid(s)
AP alkaline phosphatase
APC activated protein C
APCC activated prothrombin complex concentrate
Arg arginine
BCIP 5-bromo-4-chloro-3-indolyl-phosphate
BSA bovine serum albumin
BU Bethesda unit(s)
CRM cross reacting material
DNA deoxyribonycleic acid
EDTA ethylenediaminetetreaacetic acid
ELISA enzyme-linked immunosorbent assay
FII factor II, prothrombin
FIX factor EX
FIXa activated factor IX
FVII factor VII
FVIIa activated factor VII
FVIII factor VIII
FVIII:Ag factor VIII antigen
FVIII:C factor VIII coagulation activity
FVIIIa activated factor VIII
FVIII-VWF
preparation FVIII preparation, which contains VWF
FX factor X
FXa activated factor X
GBS glycine-buffered saline
GP glycoprotein
GST glutathione S-transferase
HCh heavy chain
HEPES N-(2-hydroxyethyl)piperazine-N’ -(2-ethanesulforic acid)
hFVIII human factor VIII
HIV human immunodeficiency virus
HLA human leucocyte antigen
HRP horseradish peroxidase
IC50% IgG concentration yielding 50% of inhibition of FXa generation
induced by FVIII
ICH intracranial haemorrhage
ID50% dilution of plasma sample neutralizing 50% of FVIILC activity
Ig A, G, M immunoglobulin class A, G, M
IL interleukin
IFN-y interferon-y
ii
IP immunoprecipitation assay
IT immune tolerance
ITT immune tolerance treatment
IU international unit(s)
kb kilobase
kDa kiloDalton(s)
LCh light chain
mAb monoclonal antibody
n.d. not determined
OPD o-phenylene-diaminedihydrochloride
OD optical density
P p value
PBS phosphate-buffered saline
PCB postcircumcisional bleeding
PCC prothrombin complex concentrate
pdFVIII plasma-derived factor VIII concentrate
PL phospholipid
pNA p-nitroaniline
pNPP p-nitrophenylphosphate
PS L-(-phosphatidyl)-l-serine
PUP previosly untreated patients
PTP previosly treated patients
r correlation coefficient
rFVIIa recombinant activated factor VII
rFVIII recombinant factor VIII
rHCh recombinant heavy chain of factor VIII
rLCh recombinant light chain of factor VIII
RT room temperature
RVV Russell’s viper venom
scFv single chain variable domain
SD standard deviation
SDS-PAGE sodium-dodecylsulfate polyacrylamide gel electrophoresis
Ser serine
TBS Tris-buffered saline
TGF-(3 transforming growth factor (3
Th helper T cell
TNF tumor necrosis factor
Tris tris(hydroxymethyl)-aminomethane
U unit(s)
WFH World Federation of Haemophilia
VH immunoglobulin heavy chain variable domain
WHO World Health Organisation
VWD von Willebrand’s disease
VWF MM von Willebrand factor multimers
12
VWF von Willebrand factor
VWF: Ag von Willebrand factor antigen
VWF:CB von Willebrand factor collagen binding
VWF:RCo von Willebrand factor ristocetin cofactor activity
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1. INTRODUCTION
Haemophilia A is a bleeding disorder caused by congenital deficiency in 
coagulation factor VIII (FVIII). The disease was first recognised as a familial 
bleeding disorder observed as excessive bleeding following circumcision 
already in Talmud in the 2nd century AD. Haemophilia as an inheritable 
disorder, occurring only in males, was first mentioned in literature in 1803 by 
J.C. Otto (Otto, 1803). Later two different coagulation disorders were distin­
guished: haemophilia A (classic haemophilia, caused by FVIII deficiency) and 
haemophilia B (Christmas disorder, caused by the Christmas factor, FIX 
deficiency), which was first described by A. Pavlovsky in 1947 (Pavlovsky, 
1947). A novel bleeding disorder caused by the FVIII-related protein, now 
known as the von Willebrand factor (Weiss and Hoyer, 1973), which circulates 
in plasma in a non-covalent complex with FVIII, was described by Dr. Erik von 
Willebrand (von Willebrand, 1926). In 1959, the International Committee on 
Nomenclature systematized the names of all clotting factors and the anti­
haemophiliac factor was designated as factor VIII (Wright, 1959).
The care and treatment of haemophilia have improved in parallel with 
scientific progress yielding the first gene transfer in the 21st century. FVIII gene 
was cloned in 1984 (Gitschier et al., 1984; Toole et al., 1984), allowing the 
identification of various mutations, deletions, and inversion within a gene 
enabling prenatal diagnosis and carrier detection. At present, the substitution of 
a deficient clotting factor by the administration of FVIII obtained by plasma 
fractionation or prepared by recombinant DNA technology is available as a 
treatment option for all haemophilia patients in the world. However, the issues 
of optimal and cost-effective care of both, the disease and the complications are 
still unsolved today. The development of antibodies against the administered 
FVIII is the most common and the most serious complication of haemophilia A 
replacement therapy. The ability of these antibodies to inhibit FVIII coagulation 
activity is the main reason for the failure to treat the disease with FVIII 
preparations. It is generally acknowledged that the development of FVIII anti­
bodies is highly patient-specific and depends on the nature of the administered 
FVIII preparation. The reasons why some patients develop antibodies and 
others do not, are still unknown.
The occurrence of anti-FVIII antibodies in healthy persons causing acquired 
haemophilia, the presence of anti-idiotypic antibodies in healthy individuals and 
anti-FVIII antibodies in haemophilia A patients provide a unique opportunity to 
study the relationship between natural autoreactivity, autoimmunity in the 
disease and antigen-driven immune responses to a single protein. Therefore, this 
thesis presents a study on the ability of FVIII antibodies to inhibit FVIII coagu­
lation activity and on the changes in immune response to FVIII in the course of 
immune tolerance therapy.
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2. REVIEW OF LITERATURE
2.1. Occurrence of haemophilia A
Haemophilia A occurs with an incidence of approximately 1 in 5,000 male 
births, and the prevalence is 1 in 10,000 persons (Larsson, 1984). Based on 
FVIII coagulation activity (FVIII:C) haemophilia patients could be classified as 
having a severe, moderate or mild form of the disease according to the 
recommendation by Factor VIII and Factor IX Subcommittee (White et al., 
2001) (Table 1). In the year 2000, 34 haemophilia A patients were registered in 
Estonia, and most of them were diagnosed to have a severe form (n=24, 70%). 
The expected number of haemophilia A patients based on prevalence studies 
should be around 150, which is significantly higher than the number of patients 
diagnosed. The proportion of severe cases among patients (70%) is remarkably 
higher than in Sweden and in The Netherlands, where 30% and 40% of 
haemophiliacs, respectively, have a severe form of the disease, and 50% of 
patients have a mild form (Larsson, 1984; Rosendaal et al., 1991). The diffe­
rence could stem from the possibility that only severe cases have been diag­
nosed and patients with mild and moderate forms of the disease manage without 
a special treatment and care. Haemophilia B caused by the FIX gene defect is 
four-fold less common than haemophilia A (Rosendaal, et a l, 1991). Only 3 
patients with FIX deficiency have been diagnosed in Estonia so far, which 
corresponds to 8% of haemophilia cases, while the expected prevalence is 20% 
of all haemophilia patients. The number of patients with the von Willebrand 
disease (VWD) increases every year and 33 cases had been diagnosed already 
by the year 2000 (Report on the WFH Global Survey 2001, 2001). Three 
patients out of 33 have Type 3 VWD, which fairly corresponds to the average 
prevalence of 2.5 to 3 cases per million of population in the Scandinavian 
countries of Europe and the Middle-East (Mannucci et al., 1984). Since VWD 
Type 3 has similar clinical symptoms with haemophilia A, all haemophilia 
A patients are diagnosed according to the laboratory investigations of FVIII 
coagulation activity and the VWF antigen level. Clinical manifestation of diffe­
rent forms of haemophilia A in relation to the severity of the disease is shown in 
Table 2.
Table 1. The classification of haemophilia A (White et al., 2001).
Factor VIII activity Classification
<0.01 IU/ml (<1% of normal) severe
0.01-0.05 IU/ml (1-5% of normal) moderate
>0.05 -<0.40 IU/ml (5-40% of normal) mild
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Table 2. Clinical manifestation of haemophilia (DiMichele, 1996).
Bleeding
manifestation Severe Moderate Mild
Age of onset <1 year 1-2 years 2 years-adult
Neonatal
symptoms
PCB: usual 
ICH: occasional
PCB: usual 
ICH: uncommon
None
Rare
Muscle/joint
haemorrhage
Spontaneous, 
requires no trauma
Requires minor 
trauma
Requires major 
trauma
CNS hemorrhage High risk (2-8%) Moderate risk Rare
Postsurgical
haemorrhage
(without
prophylaxis)
Frank bleeding, 
severe
Wound bleeding 
common
Wound bleeding 
with FVIII:C 
lower than 
0.3 IU/ml
Oral
haemorrhage
following
trauma,
tooth extraction
Usual Common Frequent
PCB, postcircumcisional bleeding, ICH, intracranial haemorrhage, CNS, central nervous 
system
2.2. Phenotype of haemophilia A
The phenotype of haemophilia A is characterized according to the level of FVIII 
coagulation activity in the patient’s plasma. Factor VIII coagulation activity 
(FVIII.C) can be estimated either by the clotting assay or the chromogenic 
substrate method. Clotting assay measures the time for the clotting of test 
plasma, which is diluted in FVIII-deficient plasma in the presence of clotting 
initiators (CaCl2 and kaolin suspension) by a coagulometer (Kirkwood, 1980; 
Kirkwood and Barrowcliffe, 1978). In the chromogenic assay the test plasma 
dilution in buffer is mixed with a reagent that contains purified factor 
IXa and factor X (Carlebjork et al., 1987; Wagenvoord et al., 1989). In the 
presence of CaCl2 and phospholipids FX is activated by FVIII. Activated FX 
cleaves off p-nitroaniline (pNA) from a chromogenic substrate. The amount of 
the released pNA correlates with the FVIII:C activity of the tested plasma. 
Factor VIILC activity is reported in international units (IU/ml), with 1 IU/ml 
corresponding to 100% of the factor found in 1 ml of normal plasma pool 
(Barrowcliffe et al., 1983). The clotting assay and the chromogenic method both 
use the local plasma standard (plasma pool contains plasma samples of at least
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20 healthy persons), which is calibrated against the international standard. 
Coefficient of variance in the clotting assay is rather high (up to 15%) compared 
to that of the chromogenic assay (below 5%) (Carlebjork et al., 1987; Hubbard 
et al., 1986; Prowse et al., 1986; Rosen et al., 1985). Up to now, both methods 
are accepted for the standardized estimation of FVIII:C activity in plasma for 
the diagnosis of haemophilia A, however, only the chromogenic assay has been 
recommended as a reference method by the European Pharmacopoeia for 
measuring FVIII:C activity in FVIII preparations (Hubbard et al., 2001). 
Compared to the clotting assay, chromogenic assay has been reported to be 
applicable for measuring the residual FVIII:C activity in the presence of FVIII 
antibodies by the Bethesda assay. However, Hutton and co-workers reported no 
significant difference in the results of the Bethesda assay if residual FVIII:C 
activity was measured by the chromogenic method or by the clotting assay 
(Hutton et al., 1991).
Factor VIII antigen level as estimated by the ELISA assay yields additional 
information about FVIII protein in patients that enables researchers to determine 
correlation of the phenotype and genotype more precisely (Girma et al., 1998). 
This assay, in general, is in routine use only in a few haemophilia centres. 
According to the level of FVIII:Ag haemophilia A patients are diagnosed as 
cross reactive material positive (CRM+, FVIILAg normal), reduced (VWF:Ag 
lower than normal), or negative (FVIILAg undetected) (Amano et al., 1998b; 
Hoyer, 1993).
2.3. Structure and function of FVIII
Factor VIII protein consists of three homologous A domains and two C domains 
and a unique B domain (Figure 1). In the FVIII molecule domains are arranged 
in the order A\-al-A2-a2-B-a3-A3-Cl-C2  (Toole et al., 1984; Vehar et al., 
1984; Wood et al., 1984). FVIII is cleaved intracellularly at the B-a3 junction to 
yield several Me2+ linked heterodimers (Fay et al., 1986). The initial cleavage is 
followed by a numerous of additional cleavages within the B domain (Vehar et 
al., 1984) (Figure 1A). These cleavages lead to the generation of the heavy 
chain (HCh) consisting of the A1-A2 and B domains and the light chain (LCh) 
composed of A3, C l and C2 domains. The C-terminal regions of the Al domain 
(amino acids, aa 337-373) and the A2 domain (aa 711-740) as well as the 
N-terminal region of the light chain (aa 1649-1689) contain a high number of 
negatively charged residues and are therefore called acidic regions (al, a2, a3) 
(Eaton and Vehar, 1986).
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Figure 1. Structure of factor VIII. Factor VIII domains defined according to amino acid 
homology are indicated. Major part of factor VIII circulates in plasma as a set of 
heterodimers, consisting of the light chain (a3-A3-Cl-C2) and the heavy chain 
(Al-al-A2-a2-B) (A). Activation (B) and inactivation of FVIII (C) by different serine 
proteases (Lenting etaL, 1998).
The half-life of FVIII in plasma is increased by the ability to form a complex 
with VWF. At least two binding sites within the light chain, the a3 and the 
C-terminal region (aa 2303-2332) of the C2 domain are the main determinants 
of binding to VWF (Saenko and Scandella, 1997; Saenko et al., 1994; Shima et 
al., 1993; Shima et al., 1992). The light chain of FVIII has a 10-fold lower 
binding affinity to VWF in the absence of the heavy chain, which points to an 
important role of the heavy chain of FVIII in retaining the proper conformation 
of the light chain (Saenko et al., 1999a). Recombinant C2 domain itself has an 
even lower binding affinity to VWF compared to the full length of the FVIII 
light chain (Saenko and Scandella, 1997). VWF hinders the FVIII binding to 
phospholipids of the membrane and also to FXa-complex components (FX; 
FlXa) (Lenting et al., 1994). The binding sites for phospholipids and VWF in 
the C2 domain partially overlap and therefore VWF prevents FVIII from 
interacting with phospholipids exposed on the membrane of cells at the site of 
vascular injury (Foster et al., 1990b; Saenko et al., 1994). Even though the 
binding sites for VWF and FlXa within the light chain are different, the 
VWF-FVIII complex cannot bind with FlXa (Lenting et al., 1994). Factor IXa 
possesses comparable affinity for both non-activated and activated FVIII, and 
only VWF can prevent premature binding to FlXa (Duffy et al., 1992).
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However, VWF cannot protect FVIII from activation by thrombin. Cleavage 
by thrombin results in the dissociation of VWF from the complex and the 
conversion of FVIII into active conformation. Thrombin cleaves FVIII at one 
specific site within the light chain, (Argl689) and at two sites in the heavy 
chain (Arg372 and Arg740, Figure IB) (Eaton et a l, 1986). Processing of 
FVIII by FXa involves cleavage at two FXa-specific sites (Arg336, Argl721) 
and three thrombin-specific sites (Arg372, Arg740, and Argl689) (Eaton et al., 
1986). Factor VIII activation by FXa yields FVIIIa with a 4-fold lower activity 
as compared to the thrombin-activated product (Eaton et al., 1986; Lollar et al., 
1985; Neuenschwander and Jesty, 1992), which could be caused by some 
inactivation due to the FXa specific cleavage at Arg336 in the heavy chain. 
Cleavage sites within both the heavy and the light chains of FVIII are equally 
important for activation. Recombinant mutant FVIII, which contains sub­
stitution of either Arg372 or Argl689 cannot be processed correctly and there­
fore is unable to correct or normalize the reduced clotting time in FVIII- 
deficient plasma (Pittman and Kaufman, 1988). Missense mutations of FVIII 
activation sites Arg372, Ser373 and Argl689, found in the FVIII gene of 
patients are associated with haemophilia (Kemball-Cook and Tuddenham,
1997). The activated FVIII associates with FlXa when the coagulation cascade 
has been activated. Factor tenase-complex binds to the membrane surface of 
cells, which serves two different functions: first the induction the association of 
FVIIIa and FlXa at the membrane and secondly the assembly of the active 
complex via structural re-arrangements (Gilbert et al., 1990). In the presence of 
phospholipids FlXa has a 2,000-fold higher affinity for FVIIIa (Gilbert et al.,
1990), and FVIIIa is able to induce conformational changes in a FlXa active site 
(Lamphear and Fay, 1992a). Three sites of FVIII are involved in FlXa binding: 
amino acids 558-565, 698-710 and 1811-1818 (Fay et al., 1994; Fay and 
Scandella, 1999; O'Brien et al., 1995; Lenting et al., 1996; Mertens et al., 
1999). Several mutations have been found in the haemophilia A patient’s gene 
coding these sites of FVIII that lead to bleeding probably due to the impaired 
complexing with FlXa (Kemball-Cook and Tuddenham, 1997). Recombinant 
FVIII mutants with replacements of amino acids at positions 558 and 566 
cannot bind FlXa either (Fay et a l, 1994). The activity of the tenase-complex is 
suppressed by the inhibition of enzyme FlXa or cofactor Villa. Inactivation of 
FVIIIa proceeds by two distinct pathways: proteolytic degradation or spon­
taneous dissociation. Activated FVIII has a very short half-life, 10 min (Curtis 
et al., 1994; Lollar et al., 1992). Instability is caused by the weakness of 
interaction between the A2 domain and the metal ion-linked A1/A3-C1-C2 
dimer. Proteolytic degradation involves cleavage of the heavy chain at positions 
336 and 562 by various enzymes, e.g. FlXa, FXa and activated protein C 
(Figure 1C) (Fay et a l, 1991a; Fay and Walker, 1989; Koedam et al., 1988; 
O'Brien et a l, 1992; Walker et a l, 1987). The cleavage at position 336 leads to 
a release of acidic sequences, which cause a rapid release of the A2 domain 
from FVIIIa heterotrimer (Fay et a l, 1993). This acidic region is responsible for
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the binding of substrate FX into the tenase-complex. Dissociation of the A2 
domain from FVIIIa impairs both intermolecular (A2 domain and heterodimer) 
and intramolecular interactions (FVIIIa-FX). Activated protein C (APC) cleaves 
the FlXa binding site of FVIIIa at Arg562 (Fay et a l, 1991c). It is not clear yet 
whether the spontaneous dissociation or proteolysis dominates in FVIIIa 
inactivation. Some reports support the idea that dissociation predominates 
(Lamphear and Fay, 1992b), however, two different roles found for FlXa in the 
assembly of the FVIHa-FIXa complex complicate the understanding of this 
process even more. Factor IXa stabilises FVIIIa by linking the A2 domain to the 
A3 domain (Fay et al., 1994; Lenting et al., 1996; Lollar et al., 1984), and pro­
tects FVIIIa against inactivation by APC (Bertina et al., 1984). However, in 
certain conditions FlXa can inactivate FVIIIa by cleaving at position 336, a 
motif that is cleaved by FXa and APC (Lamphear and Fay, 1992b; O’Brien et 
al., 1992).
2.4. FVIII gene and common mutations
FVIII gene of 186 kb is one of the largest genes and accounts for 0.1% of the 
whole X-chromosome (Gitschier et al., 1984; Toole et al., 1984; Vehar et al., 
1984; Wood et al., 1984). The coding region is distributed over 26 exons. Fac­
tor VIII mRNA is 9 kb long and encodes a 2,351-amino-acid-long polypeptide, 
from which a hydrophobic signal peptide of 19 amino acids is removed during 
secretion (Gitschier et al., 1984; Toole et al., 1984). 5% of all severe haemo­
philia A patients carry a unique mutation in the FVIII gene (Kemball-Cook and 
Tuddenham, 1997). Changes in intron 22 were identified by failure of poly- 
merase-chain-reaction amplification across the boundary of exon 22 and exon 
23 (Antonarakis, 1995). This inversion is mediated by the presence of three 
copies of a particular DNA sequence (termed sequence A), with one copy being 
located within intron 22 of the FVIII gene and the other two being 400 kb 
telomeric to the first (Levinson et al., 1992a; Levinson et al., 1992b; Freije and 
Schlessinger, 1992). Unequal crossing-over between two of these sequences 
leads to the inversion of a portion of the FVIII gene (exons 1 to 22) so that no 
intact FVIII protein is produced. The crossing-over with the most distal or the 
most proximal sequence A and its homologue in intron 22 results in Type 1 or 
Type 2 inversion, respectively. Some individuals have more than two copies of 
the extragenic sequence A outside the FVIII gene, whose crossing-over leads to 
Type 3 inversions (3A, 3B) (Lakich et al., 1993; Rossiter et a l, 1994). All these 
inversions can be detected by Southern blotting. Type 1 inversion is the most 
common gene defect found in 35% of haemophilia A patients with a severe 
form of the disease (Antonarakis et al., 1995). Type 2 inversion accounts for a 
reason for a severe form in 7% of patients (Antonarakis et a l, 1995). Deletions
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in the FVIII gene ranging from 1000 to several hundred thousand nucleotides 
are quite rare and account only for 5% of the severe form of haemophilia 
(Kemball-Cook and Tuddenham, 1997). In the year 2000 the updated database 
of FVIII gene defects described 309 different mutations, 264 of them were 
single amino-acid substitutions resulting in various severity forms of haemo­
philia. In addition, 28 insertions ranging from 1 kb to 21 kb have been identified 
in the FVIII gene (Kemball-Cook and Tuddenham, 1997).
2.5. Treatment with FVIII preparations
Treatment of haemophilia aims at correcting the haemostatic defect in order to 
treat or prevent haemorrhage. Early treatment at the onset of symptoms dec­
reases both the amount of bleedings and the extent of the ensuing tissue 
damage. The dosing regimen for factor VIII replacement in haemophilia A is 
based on three general pharmacological and therapeutic principles: (1) the 
volume of distribution of the clotting factor within intravascular or extravas- 
cular compartments, which affects in vivo factor recovery in plasma following 
infusion, (2) factor clearance and half-life in plasma, (3) the minimal level of 
the haemostatic factor required to control a particular type of haemorrhage. One 
unit of FVIII raises the plasma level by approximately 0.02 IU/ml (2%). The 
mean elimination half-life of FVIII is 12 h, however, it has to be measured in 
each particular patient because of a large variation in half-lives (Bjorkman et 
al., 1992; Morfini et al., 1992); and the minimum haemostatic plasma factor 
level is 20-30%. The average annual consumption of FVIII preparations for one 
patient with a severe form of the disease is 20,000 IU. The number of annual 
consumption of FVIII preparation per capita reflects the level of haemophilia 
care in the country. According to World Federation of Hemophilia (WFH) 
guidelines, adequate treatment is guaranteed when the number is more than 2.0 
(Jones, 1995). In many countries (Denmark, Sweden, Canada, Ireland) the 
annual consumption of FVIII preparations per capita has reached 
4 to 8 (Report on the WFH Global Survey 2001). Estonia reached the level 1.0 
in 1998 and retained the consumption level slightly higher than 1 for more than 
3 years.
Several FVIII preparations fractionated from plasma or produced by 
recombinant DNA technology are available for treatment nowadays. B-domain- 
deleted recombinant FVIII preparation is the newest on the market, however, it 
possesses comparable efficacy and safety with other recombinant FVIII pre­
parations (Charlebois et al., 2001; Courter and Bedrosian, 2001a; Courter and 
Bedrosian, 2001b; Pittman et al., 1993). Plasma-derived FVIII preparations are 
still used in significant amounts, however, several additional measures have 
been applied in order to increase the safety of the product and to minimise the
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risk of transmitting viruses and transmissive agents (e.g. prions), which may be 
present in plasma. Plasma-derived FVIII preparations can be divided into three 
main groups according to their purity and the manufacturing process: inter­
mediate purity (specific activity 1-50 FVIII IU per mg of protein), high purity 
(50-200 FVIII IU per mg of protein), and monoclonal-antibody-purified con­
centrates (>1000 FVIII IU per mg of protein before adding stabilizing albumin, 
Berntorp, 1994; Bemtorp, 1996). Compared to other plasma-derived products, 
the immuno-affinity purified concentrates contain only a trace amount of the 
von Willebrand factor, the physiological stabilizer of FVIII (Bemtorp and 
Nilsson, 1988).
2.6. Structure and function of the von Willebrand factor
The von Willebrand factor (VWF) is a glycoprotein with an essential role in 
primary haemostasis and in blood coagulation. A VWF subunit consists of 
2,050 amino-acids after the cleavage of the signal peptide (22 residues) and 
large propeptide (741 residues, D1-D2 domains) from the primary translation 
product, pro-VWF. The domains of VWF are arranged in the following 
sequence: D1-D2-D’-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK (Figure 2) (Sad­
ler, 1998). The mature subunit is extensively glycosylated, containing 12 N-lin- 
ked and 10 O-linked oligosaccharides (Matsui et al., 1992). N-linked oligo­
saccharides of VWF are different from other plasma glycoproteins, because 
they contain ABO blood group oligosaccharides (Matsui et al., 1992). After 
glycosylation in the endoplasmatic reticulum, pro-VWF dimerizes by forming 
disulphide bonds near the C-terminus (Marti et al., 1987; Wagner and Marder, 
1984). Dimers of pro-VWF are transported to the Golgi, and there additional 
disulphide bonds form between the N-terminus of subunits. The molecular 
weight of VWF multimers ranges from 500 kDa to 20 000 kDa (Haberichter et 
al., 2000; Jorieux et al., 2000). The removal of the VWF propeptide, comple­
tion of glycosylation and sulfation of N-linked oligosaccharides all take place in 
the Golgi complex. VWF is secreted constitutively (95%) and the remainder of 
it is stored in cytoplasmic granules, Weibel-Palade bodies that are specific of 
endothelium (Bonthron et a l, 1986; Wagner and Marder, 1984). In endothelial 
cells VWF pool consists of large multimers of mature VWF subunits, while 
constitutively secreted VWF consists mostly of small multimers and also of a 
high amount of unprocessed pro-VWF. Pro-VWF half-life in vivo is rather short 
(2 h) compared to the half-life of mature VWF (12 h, Borchiellini et al., 1996).
VWF mediates the adhesion of platelets to subendothelium at the site of 
vascular injury and stabilizes factor VIII by forming a non-covalent complex 
(Sadler, 1998). Healthy persons with blood group O possess a lower VWF 
activity and antigen level (Moeller et a l, 2001; O'Donnell and Laffan, 2001;
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Shima et al., 1995a), which is accompanied by a reduced level of FVIII:C acti­
vity (McLellan et al., 1988). The importance of the pre-infusion level of the 
VWF antigen in haemophilia A patients for the FVEH half-life has been studied 
and patients with blood group O had a lower FVIII half-life as compared to 
patients with blood group A (Vlot et al., 2000). Although each subunit of VWF 
possesses a high affinity binding site for FVIII, in plasma only 20% of the sites 
are occupied by FVIII (Leyte et al., 1989). In addition to the stabilization of 
FVIII in plasma, VWF can alter the intracellular trafficking of FVIII from the 
constitutive to the regulated secretory pathway by producing an intracellular 
storage pool of both proteins (Rosenberg et al., 1998).
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Figure 2. Structure of the von Willebrand factor. The localization of five types of 
conserved structural domains (A). Binding sites of various macromolecules within the 
subunit (B). Dimerization by formation of a disulphide bond between the C-termini and 
multimerization by disulphide bonding near the N-terminal regions of VWF monomers 
(C) (Sadler, 1998).
FVIII dissociates from VWF to participate in coagulation, while VWF mediates 
the formation of a platelet plug. It has been shown that VWF binds to FVIII less 
avidly after the VWF association with collagen and other matrix structures such 
as proteoglycans that cause the conformational change of the FVIII binding site
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of VWF (Bendetowicz et al., 1999). Subendothelium-bound VWF supports 
platelet adhesion by a dual step mechanism (Savage et ah, 1996). The first inter­
action between the A l domain of VWF and the GP Ib-IX-V receptor complex 
on platelets is rapid and VWF attacks platelets near the surface at a high shear 
stress. Rolling platelets make new interactions as different regions of the 
platelet membrane come into closer contact with the vascular surface. Signal 
transduction leads the activation of integrin cxnb(33 on platelets, which mediates 
the secondary adhesion and aggregation of platelets and binding via integrin 
a nbp3 to the C-terminus of the C l domain of VWF. This interaction has a lower 
dissociation constant compared to VWF interaction with the GP Ib-IX-V 
receptor complex and therefore causes an irreversible adhesion of platelets 
(Savage et al., 1996).
The malproduction of the VWF causes the most common inherited bleeding 
disorder -  the von Willebrand’s disease (VWD) with the prevalence of 0.83% 
in general population (Mannucci et al., 1984). The simplified classification of 
VWD distinguishes between three groups i.e. partial quantitative deficiency 
(Type 1), qualitative deficiency (Type 2) and total quantitative deficiency (Type 
3) (Sadler, 1994). A highly variable clinical picture and the presence of many 
different defects in the molecule of VWF complicate the diagnosis of VWD 
(Mazurier and Rodeghiero, 2001; Meyer et al., 1991). To date no single test 
giving simultaneously sufficient information about various functions of VWF is 
available. Several analyses like the ristocetin cofactor aggregation method, the 
VWF antigen assay, the factor VIII coagulation activity assay and others are 
required for diagnosing VWD and for the characterization of the defect in a 
particular patient. Factor VIII coagulation (FVIII:C) activity indirectly reflects 
the level of its stabilizing protein VWF (Sadler, 1998). The VWF antigen level 
is estimated by the ELISA method using polyclonal VWF antibodies and thus it 
does not reflect the functional activity of VWF. The assay of the ristocetin 
cofactor (VWF:RCo) activity has been widely used for measuring VWF ability 
to mediate platelet aggregation. The dimeric form of antibiotic ristocetin 
induces platelet aggregation via binding to both VWF and platelets (Scott et al.,
1991). The drawbacks of this test include poor sensitivity (Rodeghiero and 
Castaman, 1990), difficulties with the standardization (Casonato et al., 1999) 
and the lack of a physiological analogue. The monoclonal VWF antibody based 
commercial ELISA test for evaluating RCof-like activity is less efficient in 
discriminating between VWD subtypes as compared to the collagen binding 
assay (Favaloro, 2000). The binding of VWF to collagen in the subendothelium 
is the first step in initiating primary haemostasis. The binding sites of fibrillar 
collagens Type I and III localize within the A3 domain (Pared et al., 1987; 
Ribba et al., 2001; van der Plas et al., 2000), while the collagen Type VI 
binding site is in the A l domain of the VWF molecule (Cruz et al., 1995; 
Hoylaerts et al., 1997; Romijn et al., 2001; van der Plas et al., 2000). The native 
conformation of VWF is essential for interaction with collagen, and even a
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limited reduction of multimers to their dimeric form results in a decreased 
binding to collagen (Fischer et a l, 1996; Pareti et al., 1987). A recently 
introduced simple ELISA test for collagen binding (VWF:CB) is sensitive and 
seems to be helpful for screening VWD patients (Casonato et al., 1999; Rama- 
samy et al., 1998; Siekmann et al., 1998). Accordingly, in the present study the 
VWF content in FVIII preparations was characterized using the collagen 
binding assay in addition to the other tests for the quantification of VWF.
2.7. Factor VIII antibodies
2.7.1. Prevalence and incidence 
of FVIII antibodies among haemophilia A patients
Mutated FVIII gene of haemophilia A patients results in the expression of 
protein with an impaired functional activity or lack of FVIII protein. Therefore, 
administered FVIII can be recognized by organism as a foreign protein that 
induces the immune system response. The development of FVIII antibodies is 
associated with a risk of dangerous bleeding episodes with possible life- 
threatening or neurological complications, muscle and/or joint impairment and 
consequently increased morbidity and mortality (Kasper, 1989).
The first reports describing the so-called anticoagulant effect in a haemo­
philia patient were published already in 1942 and 1943 (Craddock and Law­
rence, 1947). These case reports described neither correction in bleeding time 
nor improvements in clinical symptoms after repeated infusions of blood to 
haemophilia A patients (Craddock and Lawrence, 1947). Development of the 
“anticoagulant effect” was also recognized as a reason for acquired bleedings in 
healthy persons. In 1954, Houge and Feamley showed that “the anticoagulant 
effect” was caused by an antibody and not by an enzyme as it had been 
suggested earlier (Hougie and Fearnley, 1954). They also found that autoanti­
bodies and alloantibodies have a similar property of inhibiting FVIII, and the 
titer of antibodies fluctuated largely due to the treatment with blood infusions 
(Hougie and Feamley, 1954). Nowadays FVIII preparations of different purity 
rather than blood is used. Haemophilia A patients who have developed FVIII 
antibodies are divided into groups of high responders (>5 Bethesda units per ml, 
BU/ml) and low responders (<5 BU/ml) according to their response to FVIII 
administration (White et al., 2001). One Bethesda unit is defined as an amount 
of FVIII antibodies, which neutralizes FVIII:C activity by 50% after 2 h of 
incubation at 37 °C (Kasper et a l, 1975). Generally antibodies develop after 
relatively few exposure days to the FVIII preparation (a day on which at least 
one dose of the FVIII preparation was administered), the medium being 9-15 
days (Scharrer et a l, 1999). Therefore, most of the antibodies are diagnosed at
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the young age of a patient (0.08-5.2 years). Patients with FVIII.C activity lower 
than 1 IU/ml need more frequent replacement therapy, and antibody develop­
ment is also more frequent among this group of patients (up to 50%) (Scharrer 
et al., 1999). Now it is known that the defect in the FVIII gene is one of the 
main reasons for a FVIII antibody response to occur. According to the updated 
database, up to 60% of patients with intron 22 inversion and 38% of patients 
with large deletions of the FVIII gene develop anti-FVIII antibodies (Kemball- 
Cook and Tuddenham, 1997; Oldenburg et al., 2000; Schwaab et al., 1995a). 
Another patient-specific determinant is the HLA genotype. However, no 
relationship between the FVHI antibody development and the HLA-genotype 
has been demonstrated until now in Caucasians (Aly et al., 1990; Frommel et 
al., 1981; Hay et al., 1997; Lippert et al., 1990; Oldenburg et al., 1997). 
In Japanese haemophilia A patients the absence of HLA-A24 has been demonst­
rated to be one determinant for the FVIII antibody development, and 
HLA-DR4.1, DQ4 and DQA1 *0301=2 were also positively associated with 
patients possessing FVIII antibodies compared with normal subjects (Ohta et 
al., 1999).
The effect of replacement therapy with the FVIII preparation of different 
purity on the FVIII antibody development has been intensively studied in both 
previously untreated (PUP) and previously treated patients (PTP). Factor VIII 
antibodies in all these studies have been measured by the Bethesda assay, which 
estimates the amount of inhibitory antibodies. The antibody frequency of 
published PUP studies is shown in Table 3. Studies conducted on PUPs have 
several methodological differences, but the prevalence of high responder 
patients can be compared. Most of these studies are retrospective and possess a 
lower frequency of the testing of FVIII antibodies compared to prospective 
studies. Therefore, the prevalence of low titer antibodies and transient anti­
bodies may have been overlooked. Furthermore, it was not specified how many 
patients of the study group carried intron 22 inversion in the FVIII gene. The 
administration of plasma-derived concentrates of higher purity and the 
application of recombinant DNA technology for FVIII production did not lead 
to any significant change in the incidence of FVIII antibody formation.
Whether the change of the FVIII preparation leads to a higher risk of 
antibody development has been studied in previously treated patients (PTP). 
Generally patients extensively treated with the pdFVIII preparation developed 
no FVIII antibodies after a change to the rFVIII preparation (Table 4), except a 
single patient due to the treatment with Kogenate (Schwartz et al., 1990) and 
another patient who was treated with ReFacto (Courter and Bedrosian, 2001a). 
Among Canadian haemophilia A patients, the frequency of FVIIII antibody 
development was also low, 2-3% (Giles et al., 1998). However, several case 
reports have shown that the patient treated extensively with an intermediate or 
high purity concentrate has responded to the administration of monoclonal- 
antibody-purified concentrate or the recombinant FVIII preparation by anti- 
FVIII antibody production (Baglin and Beacham, 1998b; van den Berg et al.,
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1999). In two patients the development of FVIII antibodies was reported after 
the change to a high purity FVIII preparation Replenate® (Bio Products Lab- 
ratory, Elstree, UK) (Baglin and Beacham, 1998a). The use of the recombinant 
FVIII product for the first time in continuous infusion during surgery caused the 
development of high titer antibodies (van den Berg et al., 1999). Generally 
antibody response is rather rare in previously treated patients and is probably 
influenced by other simultaneously occurring processes, like continuous infu­
sion of FVIII during surgery, infection or medication.
Table 3. Comparison of frequency of development of inhibitory FVIII antibodies in 
different studies on previously untreated patients (PUP).
Patients FVIII
FVIII
preparation
Study
period
with antibodies
Reference n severe
haemo­
philia
Total HR
Courter and
Bedrosian, ReFacto 1994-99 101 54 32% 16%
2001b
Bray et al., 
1994 Recombinate™ 1990-93
73 55 23% 9%
Gruppo 
et al., 1997 Recombinate™
1990-96 72 72 31% 10%
Lusher 
et al., 1993 Kogenate® 1989-92
81 49 20% 9%
Lusher,
1991
Monoclate 1986-89 38 25 18% 16%
Ehrenforth 
et al., 1992 Various pd 1976-91
63 27 24% 17%
Addiego 
et al., 1993 Various pd
1975-85 89 89 28% 21%
de Biasi 
et al., 1994 Various pd
1975-92 64 48 20% 16%
Peerlinck 
et al., 1993b
Lyophilised
cryoprecipitate 1971-90
67 47 6% 2%
Pd - plasma derived; HR - high responders
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Table 4. FVIII antibody development in patients switched from treatment with pdFVIII 
preparations to rFVIII preparation.
Reference rFVin n FVIII antibodiespreparation %
Courter and Bedrosian, 2001a ReFacto 113 0.9
Schwartz et al., 1990 Kogenate® 72 1.3
Aygoren-Pursun and Scharrer, 
1997 Kogenate® 39 0
Abshire et al., 2000 Kogenate FS 71 0
Giles etal., 1998 Kogenate® 478 2-3
White et al., 1997 Recombinate™ 69 0
Only two concentrates (Bicinact® in Belgium and OctaviSDPlus) which were 
produced by using the treatment with a solvent-detergent and heat pasteuri­
zation for virus inactivation have been exceptions, causing a remarkably higher 
frequency of antibody response in a large group of patients (Gilles et al., 1997; 
Peerlinck et al., 1997). On the other hand, discontinuous use of these concent­
rates was accompanied by the disappearance of FVIII antibodies in treated 
patients. Epitope mapping showed that FVIII antibodies were targeted at the C2 
domain of FVIII (Laub et al., 1999; Sawamoto et al., 1998), and it was 
suggested that the insufficient quality of starting plasma pools with the 
combination of solvent-detergent treatment and pasteurization altered the 
structure of the C2 domain (Saenko et al., 2001), which led to an enhanced 
binding to phospholipids (Raut et al., 1998). FVIII purification by controlled- 
pore silica adsorption and pasteurization (60°C, 10 h) for viral inactivation 
(FVIII CPS-P in the Netherlands and FVIII P in Belgium) also caused changes 
in the FVIII structure and a higher FVIII antibody response in previously treated 
patients (Mauser-Bunschoten et al., 1994; Peerlinck et al., 1993a). However, 
none of these concentrates is in clinical use any more.
Different purity FVIII preparations have various effects on the immune 
system of haemophilia A patients as shown by in vitro and in vivo studies. 
Results of in vitro studies revealed the decreased levels of EL-2, TNF, IFN-y and 
increased levels of IL-4, IL-10 in each different leukocyte subset after stimu­
lation with the FVIII preparation of intermediate purity (Hodge et al., 1999a). 
The immuno-modulatory effect of these concentrates was explained by the 
presence of TGF-J3 (Hodge et al., 1999a). In vivo investigations in HIV-negative 
haemophiliacs without FVIII antibodies have shown an increased number of 
CD8+ cells and a decreased number of CD4+ cells, suggesting that the immuno­
modulatory effect of treatment was probably caused by the presence of TGF-f3
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in FVIII preparations (Hodge et al., 1999b). TGF-p is suggested to have some 
Th2-like effects, analogous to the co-stimulatory effect on CD8+ T-cells. The 
FVIII preparations of intermediate purity in general are more prone to decrease 
the number of CD4+ cells compared to immuno-affinity purified concentrates 
used for the treatment of HIV-positive haemophilia A patients (de Biasi et al., 
1991; Seremetis et al., 1993; Varon, 1995). HIV-negative haemophiliacs who 
developed FVIII antibodies have been investigated only in one multicentre 
study so far (Kaplan et al., 2000). This study showed no difference in IFN-y and 
IL-10 production by the FVIII-induced lymphocytes in haemophilia A patients 
who developed FVIII antibodies and who did not (Kaplan et al., 2000).
2.7.2. Treatment of haemophilia A 
patients possessing FVIII antibodies
Treatment of haemophilia A patients possessing anti-FVIII antibodies has two 
distinct purposes: to prevent or treat bleeding episodes and to induce tolerance 
for FVIII. Bleeding episodes of low responder patients can be treated by 
increased dosages of the FVIII preparation, but this is not an optimal treatment 
for high responders. Factor VIII bypassing agents have been used for almost 
over 25 years. Prothrombin complex concentrates (PCC), activated prothrombin 
complex concentrates (APCC) as well as recombinant FVIIa (rFVIIa) theoreti­
cally overcome the need for FVIII in achieving effective haemostasis. 
Administration of APCC increases the level of factors II, VII, Vila, X, and Xa, 
all of which are responsible for the generation of a significant amount of 
thrombin in the absence of FVIII (Sultan and Loyer, 1993). In animal models 
the administration of a higher amount of factors Xa and prothrombin, the main 
components in APCC, leads to the generation of a significant amount of throm­
bin analogously with the administration of APCC (Turecek et al., 1999). So far 
the administered dose of APCC has been based on empirical observations. Un­
fortunately, APCC also contains trace amounts of FVIII and FIX, therefore 
some patients may respond with an elevated level of FVIII antibodies after 
treatment episodes (Hilgartner and Knatterud, 1983; Kantrowitz et al., 1987; 
Laurian et al., 1984; Mannucci et a l, 1976; Negrier et al., 1997). Compared to 
prothrombin complex concentrates, APCC is not more thrombogenic, probably 
because the coagulation defect is never fully corrected due to the deficiency of 
FVIII or FIX in haemophilia patients. Very rarely has the treatment of a patient 
resulted in myocardial infarction (Chavin et al., 1988; Negrier et al., 1997) or 
disseminated intravascular coagulation (Fukui et al., 1981; Negrier et al., 1997; 
Stenbjerg and Jorgensen, 1977).
An alternative possibility for treatment is the application of recombinant 
FVIIa (NovoSeven, Novo Nordisk, Denmark). The amount of the administered
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rFVIIa is usually given as protein concentration in micrograms per kilogram of 
body weight. Due to the short half-life (2.5-3 h), rFVIIa has to be regularly 
administered after every 2-4 hours (Brinkhous et al., 1989). FVIIa forms a 
complex with the tissue factor and activates FX and FIX on the surface of 
platelets, which also become activated. In the absence of FVIII or FIX, rFVIIa 
is also able to activate FXa if the platelet surface is provided (Hoffman et al.,
1998). At concentrations considerably exceeding the normal level rFVIIa can 
also act independently from the tissue factor (Monroe et al., 2000) and 
overcome the inhibiton of FX generation by physiological factor VII (van't Veer 
and Mann, 2000). It has been reported recently that the administration of rFVIIa 
in high doses induces thrombin generation in healthy volunteers even after pre­
treatment with a specific inhibitor, recombinant nematode anticoagulant protein 
c2, which inhibits the tissue factor-FVIIa complex activity (Freiderich et al., 
2001). A prospective study to compare in vivo efficiency of both bypassing 
agents, APCC and rFVIIa, is in preparation now and hopefully will add 
complementary information as to which concentrate has to be preferentially 
used for particular types of bleedings and for preventing bleeding episodes in 
haemophilia A patients possessing anti-FVIII antibodies.
Factor VIII preparation fractionated from porcine blood is also available for 
the treatment of patients with FVIII antibodies. However, it can only be used in 
patients possessing antibodies with low cross-reactivity to porcine FVIII (Fiks- 
Sigaud et al., 1993). Generally, antibodies recognizing the A2 domain of FVIII 
have a lower affinity to porcine FVIII as compared to human FVIII (Sawamoto 
et al., 1997).
Among various immune tolerance treatment protocols the Bonn regimen 
recommends the administration of high doses of FVIII twice a day and a regular 
dose of APCC (Brackmann and Gormsen, 1977). The overall success rate of the 
Bonn protocol for the desensitisation of haemophilia A patients was 86% 
(52/60), while 13.3% failed (8/60) as reported by Oldenburg (Oldenburg et al.,
1999). The interruption of treatment remarkably prolonged the duration 
of treatment: medium 39.9 months versus 11.6 months by continuous treatment. 
There was also a tendency that patients with intron 22 inversion in the FVIII 
gene needed a longer treatment period as compared to patients with other gene 
defects. The best success rate was achieved by using FVIII dosage 
>200 IU/kg/day (Oldenburg et al., 1999). In a retrospective study of paediatric 
patients good correlations were found between the outcome and length of 
immune tolerance treatment and also between the outcome and interval from the 
first FVIII antibody detection till the onset of treatment (Kreuz et al., 1995b). 
The interruption of therapy was the main reason for the failure of treatment, 
because a subsequent increase of the antibody titer was much more difficult to 
suppress. Antibody elimination was achieved in 19/21 patients during medium 
time of 4 months in high responders and 1.5 months in low responders. As a 
conclusion, Kreuz and colleagues recommended the use of at least 100 IU/kg of 
FVIII per day and the starting of treatment as soon as possible after the
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detection of FVIII antibodies in order to achieve immune tolerance during a 
short treatment period (Kreuz et al., 1995b).
No correlation between the purity of the FVIII preparation used for treatment 
and the effectiveness of the treatment has been established. In most cases the 
patients have been treated with pdFVIII preparations (Oldenburg et al., 1999), 
while rFVHI preparations have also been reported to be effective in making 
patients tolerant to FVIII (Batlle et al., 1999; Rothschild et al., 1998). However, 
Kreuz et al. have reported 4 therapy-resistant patients, who were successfully 
tolerated after a switch from the immuno-affinity-purified FVIII preparation of 
a very high purity to the one of with intermediate purity (Kreuz et al., 1995a). 
Despite of the importance of VWF as a physiological stabilizer of FVIII in 
concentrates, it is still unknown how the presence of VWF could protect FVIII 
by FVIII antibodies in vivo and benefit in achieving tolerance.
Slight modifications of the Bonn protocol are also efficient in inducing 
tolerance to FVIIL Nowadays the administration of APCC is skipped and it is 
included only in cases when a patient has a high bleeding tendency. The 
recommended FVIII dosage is 150 IU/kg/twice a day to shorten the time period 
necessary for successful toleration.
The Malmö protocol is the most radical treatment of high responders to 
rapidly decrease the titer of FVIII antibodies (Carlborg et al., 2000; Nilsson and 
Bemtorp, 1990). It comprises the extracorporal adsorption of IgG antibodies on 
a protein A column (removing IgG from a patient’s blood), followed by the 
administration of a high dose of FVIII, cyclophosphamide (immunosuppressive 
effect) and intravenous immunoglobulin (replacement of the removed IgG). So 
far 15 haemophilia A patients have been treated according to the Malmö proto­
col (Bemtorp, 2001). Although by using intermediate purity FVIII preparations 
in the Malmö protocol successful tolerance was achieved in 10 patients,
3 patients failed to achieve it. Only 2 patients were treated with the monoclonal 
antibody-purified FVIII preparation and the treatment of both patients was 
unsuccessful. The overall success rate of this treatment was 67% (Bemtorp, 
2001).
In addition to sepharose-bound staphylococcal protein A for removing FVIII 
antibodies (Immunosorb™, Sweden), another type of affinity resin has been 
reported to be effective (Knobl et al., 1995). This contains the sepharose-bound 
polyclonal sheep antibody to human immunoglobulins, which removes all 
subclasses of IgG, IgM, and IgA from the patient’s blood (Ig-Therasorb™, 
Germany). Until now, this treatment protocol has been used to reduce the FVIII 
antibody titer in ten patients, however, without long-lasting tolerance (Jansen et 
al., 2001).
Administration of prednisone (Aznar et al., 1983) or cyclophosphamide and 
intravenous immunoglobulin (Nilsson et al., 1988) in addition to FVIII has also 
been successfully applied to achieve tolerance in haemophilia A patients and 
patients with acquired hemophilia.
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In order to facilitate the comparison of the clinical efficacy of different 
immune tolerance treatment (ITT) protocols, three ITT registries have been 
established: international (Mariani and Kroner, 1999), North-American 
(DiMichele and Kroner, 1999) and German (Lenk, 1999). These registries are 
retrospective and in 1999 data of 295 patients, 68% from Europe and 28% from 
North America were included in the international registry. The remaining 4% 
covered the data of patients from Japan and Australia (Mariani and Kroner,
1999). Multivariate analysis was performed to evaluate the variables determi­
ning the success of ITT. A high dose of FVIII as well as the low FVIII antibody 
titer at the beginning of treatment was significant for the successful elimination 
of FVIII antibodies. Two other parameters, the maximal historical titer and the 
time interval from the first detection of the antibody until the start of treatment 
were not decisive in the success rate (Mariani and Kroner, 1999).
2.7.3. Properties of FVIII antibodies
In 1968 anti-FVIII antibodies of anticoagulant activity were found to be of IgG 
and IgM subclasses. These antibodies did not precipitate after the forming of the 
antigen-antibody complex, and the formed complex was not able to activate the 
complement system (Lusher et al., 1968). Further studies revealed the preva­
lence of the IgG4 subclass antibody in a haemophilia A patient (Andersen and 
Terry, 1968). Other investigators have reported predominantly the IgG4 sub­
class, however, a study on the heterogeneous mixture of antibodies has indi­
cated that the isotypic distribution of FVIII antibodies followed the general 
physiological profile of IgG subclasses (Gilles and Saint-Remy, 1994). Accor­
dingly, in the present study IgG subclasses of FVIII antibodies of the haemo­
philia A patient during the immune tolerance treatment have been analysed.
Anderson and Troup studied the neutralization of FVIII:C by antibodies 
developed in haemophilia A patients (Andersen and Troup, 1968). They found 
that there was a linear relationship between the residual FVIILC activity (on a 
logarithmic scale) and time (linear scale) at the higher tested dilutions of the 
anticoagulant, while at lower dilutions linearity was lost. The neutralisation of 
FVIII by antibodies did not follow the first type of kinetics over 2 h of incu­
bation. When the residual FVIILC activity on a logarithmic scale was plotted 
against antibody dilution on a linear scale, the curves of only a few antibody 
samples were linear. It was explained by the heterogeneity of antibodies with 
anticoagulant properties and by a different mechanism of inhibiting FVIII 
(Andersen and Troup, 1968). Now two types of antibodies can be distinguished 
by the neutralizing character of the FVIILC activity (Gawryl and Hoyer, 1982; 
Ling et al., 2001). Type 1 antibodies cause a complete inhibition of FVIILC 
activity and a linear relationship between the residual FVIILC activity (on a
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logarithmic scale) and antibody concentration is observed (Biggs et al., 1972b). 
Type 2 antibodies show a non-linear pattern of this relationship and incomplete 
inactivation of FVIILC even at very high antibody concentrations (Biggs et al., 
1972a). Type 2 inactivation pattern of FVIILC was also suggested to be cha­
racteristic of FVIII-light-chain-specific antibodies that are capable of inhibiting 
the FVm binding to VWF (Peerlinck et al., 1999). Further a more precise epi­
tope mapping showed that the C2 domain was the main target of these anti­
bodies (Peerlinck et al., 1997; Sawamoto et al., 1998).
2.7.4. Epitope specificity of FVIII antibodies and 
relation to the mechanism of inhibition of FVIII biological activity
Immunoblotting analysis using intact or thrombin-digested FVIII enabled the 
researchers to reveal the preferential binding of FVIII antibodies to the light 
chain of FVIII and the A2 domain in up to 68% of haemophilia A patients 
(Foster et al., 1990a; Fulcher et al., 1987; Scandella et al., 1989). However, 
antibodies against conformational epitopes cannot be detected by immuno­
blotting. Therefore, amino acid residues 373-740 of the A2 domain of FVIII 
were expressed from a baculovirus vector in insect cells (Scandella et al., 1993; 
Scandella et al., 1992). Resulting A2 fragment was soluble and suitable for use 
in an immunoprecipitation assay. The immunoprecipitation (BP) assay is sensi­
tive for the detection of a low amount of antibodies and also those A2-domain 
antibodies, which were not detected by immunoblotting. The development of 
the A2-domain-specific antibodies in patients was significantly higher than 
previously estimated by the Western blot (Scandella et al., 1992). Later, in 
addition to the recombinant A2 domain, C2 domain and A3-C1 fragments were 
used in the IP assay (Prescott et al., 1997; Scandella et al., 1995a; Scandella et 
al., 1995b). The immunoprecipitation assay demonstrated that the most immu­
nogenic domains were the C2 and A2 domains, as most of the antibodies were 
targeted at one or both of these regions of FVIII, while some of FVIII-light- 
chain specific antibodies recognized the A3-C1 fragment (Scandella et al., 
2001). The respective FVIII fragments that were used in the IP assay are rather 
large, but antibodies recognize the epitope containing 6-12 amino-acid residues 
(Palmer et al., 1997). Therefore, the fine specificity of antibodies developed in 
patients cannot be assessed with these recombinant FVIII fragments. Taking 
advantage of synthetic peptide arrays, a wide repertoire of antibody epitopes has 
been discovered within all FVIII domains (Palmer et a l ,  1997). This more 
precise technique has demonstrated the presence of binding sites of rare 
antibodies within the Al domain in addition to the localization of most 
immunogenic regions within the C2, A2, A3 and Cl domains (Palmer et al., 
1997). However, this method has also limitations. Firstly, antibody epitopes are
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quite often discontinuous rather than continuous, and secondly, the epitopes that 
are presented by synthetic peptides may actually not be accessible on the native 
FVIII. With synthetic peptides no antibodies targeted at important cleavage sites 
on FVni were detected (Palmer et a l, 1997). The inhibitory activity of FVIII 
antibodies depends largely on the accessibility of the antibody binding site on 
FVIII. Random fragments of FVIII displayed on X phage particles were selected 
to characterize the specificity of antibodies directed to conformational epitopes 
within the C2 domain (Kuwabara et al., 1999). This study showed the impor­
tance of the disulphide bridge in the C2 domain for being recognized by anti­
bodies (Kuwabara et al., 1999).
Antibodies recognizing different domains can neutralize FVIILC activity by 
independent mechanisms (Scandella, 2000). The light chain of FVIII contains 
the binding sites for VWF within the C2 domain (aa 2303-2332) and the a3 
domain (aa 1649-1671) (Saenko and Scandella, 1997; Saenko et al., 1994; 
Shima et al., 1995b; Shima et al., 1993; Vlot et al., 1995). Therefore, it can be 
expected that antibodies against those regions could interfere with the FVIII 
binding to VWF. Indeed, human antibodies directed against epitopes within 
amino acids 2170-2327 of the C2 domain or within amino acids 1670-1684 of 
the a3 domain are capable of inhibiting the FVIII binding to VWF (Foster et al., 
1990b; Healey et al., 1998; Shima et al., 1993). Human anti-FVIII antibody 
2E9, which is Cl-domain specific, obtained by the immortalization of B- 
lymphocytes of a patient with mild haemophilia A, is also able to interfere with 
the FVIII binding to VWF (Jacquemin et al., 2000). On the contrary, some 
FVIII antibodies targeted at amino acids 2218-2307 of the C2 domain have the 
highest inhibitory activity in the presence of VWF (Saenko et al., 1996). These 
antibodies delay the release of FVIII from the FVIII-VWF complex and thereby 
inhibit the biological activity of FVIII (Saenko et al., 1996).
Since the C2 domain of FVIII contains a highly hydrophobic region, which 
contains partially overlapping binding sites for VWF and phospholipids, usually 
C2-domain-specific antibodies are able to interfere with the FVIII binding to PS 
and the FVIII binding to VWF (Foster et al., 1990b). Recently it has been 
shown that C2 domain inhibitory antibodies, such as B02C11, frequently re­
cognize the region containing amino acid residues 2199/2200 and 2251/2252 of 
the C2 domain (Barrow et al., 2001) and interfere with the FVIII binding to 
VWF and PS (Barrow et a l, 2001; Jacquemin et al., 1998).
The A2 domain of the heavy chain of FVIII is a site at which antibodies in 
haemophilia A patients preferentially develop. Theoretically these antibodies 
may interfere with the interaction of the A2 domain with the Al domain or with 
the A1/A3-C1-C2 dimer or block thrombin activation at Arg391 via steric 
hindrance or the conformational effect. A2-domain antibodies could also block 
the interaction of FVIII with FlXa or FX (Fay et a l, 1991b). The A2 domain 
and A3 domain of FVIII contain FlXa binding sites (Fay et a l, 1994; Lenting et 
a l, 1996; Mertens et a l, 1999). The binding of FVIII to FIXa is impaired in the 
presence of VWF (Lenting et a l, 1994). Human A2-domain-specific antibodies
35
specially recognizing region 484-509 inhibit FVIILC activity by disrupting the 
A2 domain binding to FlXa (Fay et al., 2001; Fay and Scandella, 1999). Human 
A3-domain specific antibodies with binding sites within amino-acids 1804- 
1819 (Zhong et al., 1998) and 1778-1823 (Fijnvandraat et al., 1998) and the 
murine monoclonal antibody targeted at amino acids 1778-1840 (Lenting et al., 
1994) are also able to inhibit the interaction of FVIII with FlXa. Zhong with co­
authors has investigated the epitope specificity of 18 FVIII-light-chain anti­
bodies developed in haemophilia A patients (Zhong et al., 1998). These anti­
bodies were partly neutralized by the recombinant C2 domain, and the epitope 
of antibodies was localized within the A3 domain (aa 1804-1819). Three out of 
the 18 tested samples were able to interfere with the FVIII binding to FlXa and 
to abolish the generation of Xa (Zhong et al., 1998).
The development of A 1-domain-specific antibodies is rather rare (Palmer 
et al., 1997; Scandella et al., 2001). The al domain has been shown to contain a 
FX binding site within amino acids 337-372 (Lapan and Fay, 1997). Using 
synthetic peptide arrays a small amount of antibodies recognizing 1-2 different 
FVIII peptides from region 20-349 has been found in haemophilia A patients 
(Palmer et al., 1997). Inhibitory activity of the Al domain antibodies may be 
caused by interfering with the A l domain binding to A2 and/or to the 
A3-C1-C2 fragment by abolishing thrombin cleavage at Arg391 or by blocking 
the binding to other tenase complex components. Human antibodies towards 
regions aa 351-365 and aa 336-372 and the murine monoclonal antibody with 
an epitope within aa 338-362 of the A l domain have been described to inhibit 
FVIILC activity (Foster et al., 1988; Ware et al., 1988). The mechanism of the 
inhibition of the FVIILC activity might be due to the inhibition of cleavage by 
activated protein C (cleavage site at Arg336) or by thrombin (cleavage site at 
Arg372).
The N-terminal and C-terminal regions of the B-domain (aa 760-1667) are 
also targets of several FVIII antibodies. However, the B-domain deleted FVIII 
has a normal FVIILC activity and possesses a normal binding to VWF 
(Sandberg et al., 2001), obviously antibodies against the B-domain have little or 
no influence on FVIILC activity.
2.7.5. VH repertoire of human immunoglobulins 
directed to FVIII
Limited information is available about the primary structure of human anti­
bodies directed to FVIII. Van den Brink with the co-workers have investigated 
which germline gene is responsible for encoding the variable domains of the 
heavy chain of immunoglobulins directed towards the most immunogenic 
regions of FVIII, namely the C2, A2, and A3-C1 domains (van den Brink et al.,
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2000a; van den Brink et al., 2001; van den Brink et al., 2000b). The single 
chain variable domain antibody fragment (scFv) directed to the C2 domain of 
FVIII was derived from the antibodies of a patient with acquired haemophilia. 
Sequence analyses revealed that the heavy chain of scFv was encoded by 
VH genes, the most homologous ones to germline gene segments DP-10, DP-14 
and DP-88 belonging to the VH1 gene family (van den Brink et al., 2000b). An 
earlier report using the Epstein-Barr virus for the immortalization of lym­
phocytes, a monoclonal IgG4 antibody (B02C11) was derived from the 
B-cell repertoire of a haemophilia A patient with inhibitory FVIII antibodies 
(Jacquemin et al., 1998). Gene segment DP-5, which also belongs to the VH1 
gene family, encoded the heavy chain of the C2-domain-specific antibody 
(Jacquemin et al., 1998). These two studies have reported that the antibodies of 
C2-domain specificity are assembled by using VH gene segments derived from 
the VH1 family (Jacquemin et al., 1998; van den Brink et al., 2000b).
Several scFv of the A2 domain antibodies derived from a haemophilia 
A patient have also been characterized (van den Brink et al., 2000a), One 
A2-domain-specific antibody scFv (aa 484-508) was encoded by germline gene 
segment DP-10 of the VH1 gene family. Another A2 domain antibody scFv with 
the binding site within amino acids 712-736, but non-inhibitory to FVIII, was 
encoded by germline gene DP-47 of the VH3 gene family. DP-47 is the most 
frequently rearranged germline gene segment in the human repertoire, which is 
observed in 12% of IgG positive B-cells (van den Brink et al., 2000a).
The third most common immunogenic region lies within the A3-C1 
domains. Six human monoclonal scFv fragments directed towards the A3-C1 
domains were isolated by using the phage display technology (van den Brink et 
al., 2001). Epitope mapping of scFv by using hybrid FVIII/FV light chain 
fragments showed that five out of six scFv were directed towards residues 
1778-1840 within the A3 domain, while one recognized the independent 
region. Sequence analyses revealed that the VH domains of two scFv were 
encoded by germline gene segments of the VH1 gene family and those of four 
by germline gene segments belonging to the VH3 gene family. The authors 
concluded that anti-A3 antibodies are composed of the VH domains derived 
from multiple germline gene segments of the VH1 and VH3 families (van den 
Brink et al., 2001).
2.7.6. Immune response to human FVIII 
in murine model of haemophilia A
Mice with targeted disruption of exon 16 or 17 of the FVIII gene are deficient in 
FVIII, and the clotting assay estimates FVIIIrC activity to be less than 1% of 
normal. These mice have impaired haemostasis, severe bleeding after a minor
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trauma like tail snipping, subcutaneous and intramuscular bleeding after routine 
handling and spontaneous bleeding (Bi et a l, 1995; Bi et al., 1996; Qian et al., 
1999; Qian et al., 2000). FVHI-deficient mice have been used as an animal 
model to study the mechanism of the anti-FVIII antibody response to the 
administered human FVIII (Wu et al., 2001). After four or five intravenous 
infusions of human FVIII, mice developed FVIII antibodies and after 
6 injections FVIII antibodies with inhibitory activity. Most of the antibodies 
were of the IgGl and to a lesser extent of the IgG2 subclass, indicating that both 
Thl and Th2 cells were involved in antibody response. CD4+ enriched 
splenocytes from treated mice proliferated in response to FVIII and secreted 
IL-10 mostly. A human FVIII-specific T-cell line derived from the treated mice 
secreted both IL-4 and IFN-y, suggesting that it included both Thl and Th2 
cells. CD4+ enriched splenocytes of the hFVIII-treated mice recognised all the 
domains of FVIII, when the library of 233 overlapping synthetic peptides (each 
20 amino-acids long) was used to study epitope specificity (Wu et al., 2001). 
The authors concluded that the development of FVIII antibodies in mice was 
analogous to what happens in haemophilia A patients and especially that IL-10 
may drive antibody synthesis. However, CD4+ cells specific of FVIII produced 
both Thl and Th2 cytokines. Using a similar animal model, Qian with the co­
authors have reported, that the FVIII antibody response is T-cell-dependent 
since haemophiliac mice deficient also in the T-cell co-stimulatory ligand B7-2 
showed no such response to hFVIII injections (Qian et al., 1999). In another 
experiment using CTLA4-Ig, the effect of the blocking interaction of CD28 
with B7 on FVIII antibody development was investigated in vivo (Qian et al.,
2000). CTLA4-Ig is a soluble fusion protein in which an extra cellular domain 
CTLA4 binds to B7-1 and B7-2 ligands and thereby blocks B7 interaction with 
CD28 and CTLA4. In haemophilic mice CTLA4-Ig completely blocked a 
primary response to FVIII, and furthermore, it even prevented or diminished a 
further increase in the antibody titer when administered to mice with low titer 
antibodies (Qian et al., 2000). Blocking of another interaction, CD40-CD40L, 
has shown to be also effective in order to prevent FVIII antibody production in 
haemophiliac mice (Rossi et a l, 2001), but without a long-lasting immune 
tolerance effect as expected (Reipert et a l, 2001).
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3. AIMS OF THE STUDY
The main objective of the study was to investigate the ability of FVIII anti­
bodies developed in haemophilia A patients to inhibit FVIII coagulation activity 
and changes in the immune response to FVIII in the course of the immune 
tolerance therapy.
Accordingly, the study had the following aims:
1. To investigate the protective effect of VWF on the inhibition of the 
FVIII coagulation activity by FVIII antibodies in vitro.
2. To study the dynamics of FVIII antibody characteristics of a haemo­
philia A patient during the immune tolerance treatment with the FVIII 
preparation containing VWF
a. To characterize the epitope specificity of FVIII antibodies and the 
changes in epitope specificity during treatment.
b. To characterize the changes in the IgG subclass distribution of FVIII 
antibodies.
3. To investigate the mechanism of FVIII antibody action on the inhibition 
of FVIII coagulation activity.
4. To characterize the von Willebrand factor in FVIII preparations that 
were used in in vitro and in vivo experiments.
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4. MATERIALS AND METHODS
4. Study subjects
4.1. Haemophilia A patients with persistent FVIII antibodies 
(Papers I and III)
Plasma samples from 12 haemophilia A patients having FVIII antibodies have 
been characterized in the current study. Since the FVIII light chain contributes 
to the FVIII binding to VWF (Saenko et al., 1999b; Saenko and Scandella, 
1997; Saenko et al., 1994) only those samples were selected, which contained 
antibodies targeted at the FVIII light chain and the A2 domain as detected by 
using the immunoblotting assay. Anti-FVIII antibodies had developed in all 12 
tested patients (samples from 6 patients from the Department for Coagulation 
Disorders of Malmö University Central Hospital, Malmö, Sweden, and 6 
patients from Children’s Hospital of Tartu University Clinicum, Tartu, Estonia) 
in response to the on-demand treatment with plasma-derived FVIII preparations. 
The Bethesda titer of antibodies ranged from 1 to 300 BU/ml. Plasma samples 
were taken in a stable clinical situation before any immune tolerance induction.
The study protocols were approved by the Ethics Committee of the 
University of Tartu, Estonia.
4.1.2. Patient undergoing immune tolerance treatment (II, III)
High responder patient TK (FVIII antibodies > 5BU/ml) was tolerated to FVIII 
by the administration of the FVIII preparation that contains VWF (Haemoctin- 
SDH, Biotest, Dreieich, Germany) and the epitope specificity of FVIII anti­
bodies was investigated during treatment. A three-year-old severe haemophilia 
A patient carrying the intron 22 inversion (Type 1) developed FVIII antibodies 
as a response to the treatment with the plasma-derived FVIII preparation with 
the maximal antibody titer of 26 BU/ml. At the beginning of the immune 
tolerance treatment (ITT) the Bethesda titer was 17.5 BU/ml. Before the ITT the 
patient had had 23 exposure days to FVIII. Haemoctin SDH was used since it 
was the only available FVIII preparation in Estonia at that time. The immune 
tolerance therapy comprised continuous infusion (40 IU/kg/h for 8 days via 
vascular line) followed by bolus injections of 100 IU/kg/day for 
1 month and treatment was continued with a dose of 100 IU/kg twice a week for 
10 months. Treatment was temporarily interrupted after 3 months due to the 
problems with venous access. Therefore, the second continuous infusion was 
applied for 8 days with a dose 150 IU/kg/h. After that treatment was continued 
with a dose 100 IU/kg twice a week until in vivo recovery had normalized in 13
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months and prophylactic treatment was started (a dose of 100 IU/kg twice a 
week). During ITT the patient had no bleeding episodes.
4.2. Reagents
Recombinant FVIII (rFVIII, Recombinate™ and albumin-free rFVIII provided 
for laboratory use by Baxter, Glendale, CA, USA) was used throughout the 
study. Recombinate™ contains full-length FVIII produced by the recombinant 
DNA technology and a large amount of human albumin as a stabilizer, but it is 
free of VWF. As a source of the FVIII-VWF complex, a plasma-derived FVIII 
preparation Haemoctin SDH (Biotest, Dreieich, Germany) was used in in vitro 
and in vivo experiments. Recombinant FVIII heavy chain and light chain were 
kindly provided by Dr. Mirella Ezban. Bovine serum albumin (BSA), casein, 
p-nitrophenylphosphate (pNPP), thrombin, 5-bromo-4-chloro-3-indolyl-pho- 
sphate (BCIP), 4-nitro-blue-tetrazolium-chloride (NBT), L-(-phosphatidyl)- 
1-serine, ristocetin, and avidin-peroxidase were purchased from Sigma Chemi­
cals Co. (St. Louis, MO, USA). Biotin derivate (EZ Link sulfo-NHS-LC-Biotin) 
was purchased from the Pierce company (Rockford, IL, USA). Polyclonal anti- 
VWF antibody and its conjugate with HRP, rabbit anti-human IgG conjugated 
to alkaline phosphatase, and substrate o-phenylene-diaminedihydrochloride 
(OPD) were obtained from Dako (Glostrup, Denmark). Rabbit anti-human IgG 
and the anti-human IgG-peroxidase conjugate were purchased from Bio Rad 
(Hercules, California, USA). IgG subclass-specific antibodies (sheep anti­
human IgGl, IgG2, IgG3, IgG4) were obtained from CLB (Amsterdam, the 
Netherlands). Sheep anti-rabbit IgG-biotin conjugate, the donkey anti-sheep 
IgG-biotin conjugate, and the ECL™ kit were obtained from Amersham Phar­
macia Biotech (Piscataway, NJ, USA). Human monoclonal anti-human FVIII 
antibodies 2E9 and B02C11 as well as mouse monoclonal anti-human FVIII 
antibodies Mabl5, F29B10 and F7B4 (Figure 3) were kindly provided by 
Dr. J.-M. Saint-Remy from the University of Leuven (Leuven, Belgium). 
Mouse monoclonal FVIII antibody ESH4 was obtained from American Diag- 
nostica (Greenweich, CT, USA). The test kit for measuring the FVIILC activity 
(Coatest FVIII: C), purified bovine factor X, factor IXa with factor X (FIXa+FX 
reagent), phospholipid emulsion, Russell’s viper venom and substrates S-2288 
and S-2337 were purchased from the Chromogenix Instrumentation Laboratory 
SpA (Milano, Italy). International standards, the WHO 3rd standard for FVIII 
and VWF in plasma (code 91/666) and 4th international standard for the blood 
coagulation factor VIILC concentrate (code 88/804) were obtained from NIBSC 
(Potters Bar, UK). The in vitro assays were carried through in Tris-buffered 
saline (TBS, 0.02 M Tris, 0,15 M NaCl, pH 7.2), phosphate-buffered saline 
(PBS, 0.08 M, pH 7.2), carbonate buffer (0.015 M Na2C 03, 0.035 M NaHC03,
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pH 9.6) or glycine-buffered saline (GBS, 0.02 M glycine, 0.034 M NaCl, 
pH 9.2). All chemicals were of an analytical grade if not stated otherwise.
4.3. Assays for studying the functional activity 
of FVIII antibodies
4.3.1. Bethesda assay (I—III)
FVIII antibody level in a patient’s plasma samples was measured by the 
Bethesda method as described by Kasper et al. (Kasper et al., 1975), except that 
TBS buffer containing 1% of BSA was used instead of imidazole buffer for 
preparing the test plasma dilutions. The normal plasma pool (made from 22 
plasma samples of healthy persons) was used as a source of FVIII. The resulting 
residual FVIII:C was determined by the chromogenic method according to the 
manufacturer’s instructions (Coatest FVIILC) in 96-well microplates (Micro- 
Well™, Nunc, Denmark). The coefficient of variance between the assays was 
3.0% at FVIILC activity 1 IU/ml (6.4% at FVIILC activity 0.5 IU/ml and 11.2% 
at FVIILC activity 0.2 IU/ml). The local plasma pool of 22 donors’ plasmas 
calibrated against the WHO 3rd standard for FVIII and VWF in plasma (code 
91/666) was used as a standard throughout the study.
4.3.2. Inhibition of FVIII :C activity by antibodies 
in the presence and absence of VWF (I—III)
The standard Bethesda method was slightly modified in order to investigate the 
protective effect of VWF on the inhibition of FVIILC activity by FVIII anti­
bodies. Plasma-derived FVIII-VWF concentrate (Haemoctin SDH) and recom­
binant FVIII (Recombinate™) were diluted to 1 IU/ml of FVIILC in TBS buffer 
containing 1% of BSA (TBS-BSA) and incubated with an equal volume of a 
serially diluted (1:2 to 1:1000 in TBS-BSA) FVIII antibody plasma sample for
1 h at 37°C. The residual FVIILC was determined by the chromogenic method. 
Nearly the maximal inhibition of FVIILC coagulation activity was obtained 
already during 1st h of incubation with FVIII antibodies, while the prolongation 
of incubation to 2 h had a minimal supplementary effect (0.1-2%). Percentage 
of neutralization was calculated in relation to a control. The control contained a 
mixture where the test plasma sample was replaced by a buffer (TBS with 1 % 
of BSA) or by plasma from a haemophilia A patient without FVIII antibodies 
and a detectable level of FVIII:Ag (CRM negative). The test plasma sample
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dilution yielding 50% of the neutralization of FVIII:C activity was determined 
for both concentrates. The results were used to calculate the ratio between the 
dilutions resulting in 50% neutralization of FVIII:C with rFVIII and FVIII- 
VWF, respectively.
4.3.3. Purification of IgG from plasma samples (II)
IgG was purified from the plasma samples of patient TK in order to eliminate 
several proteins present in plasma, which could interfere with the detection of 
FVIII antibodies in various assays, e.g. VWF which is able to compete with 
FVIII antibodies in interfering with the FVIII binding to phospholipids. 
IgG was purified from plasma samples by affinity chromathography using 
Protein-G Sepharose (HiTrap™ Protein G, Pharmacia, Uppsala, Sweden) accor­
ding to the manufacturer’s instructions. The eluted IgG fraction was dialysed 
against PBS overnight at 4°C. The concentration of the obtained IgG was 
measured by the ELISA assay using the rabbit anti-human IgG antibody (Bio 
Rad, USA) coated onto microplates (2 (ig/ml in GBS) and the bound IgG from 
the investigated sample was detected by using the rabbit anti-human IgG anti­
body conjugated with peroxidase. The standard curve was built by using the 
human IgG standard with the known concentration. Antibodies specific of FVIII 
were detected by an analogous ELISA assay using rFVIII-coated (Recombi­
nate™) microplates.
4.3.4. Tagging of recombinant FVIII with biotin (II)
Recombinant full-length carrier-free FVIII (specific activity >4000 IU/mg of 
protein) was labelled with biotin under mild conditions by using EZ Link sulfo- 
NHS-LC-Biotin (Pierce, Rockford, IL, USA) according to the manufacturer’s 
instructions. Biotin can easily be attached to the free amino groups of protein, 
but a great care has to be taken to retain the functional activity of FVIII during 
biotinylation. The water-soluble biotin derivative was used in order to perform 
the biotinylation reaction in the absence of organic solvents such as dimethyl 
sulfoxide, which could cause the denaturation of protein. This biotin derivative 
has an approximately 22.4 Ä long spacer arm that facilitates biotin recognition 
by streptavidin and avidin. Briefly, rFVIII (100 |J.g/ml) was dialysed against 
HEPES buffer (0.01 M HEPES, 0.15 M NaCl, 0.01 M CaCl2, pH 8.5). The 
biotin derivative was dissolved in water to a concentration of 0.01 mg/ml. Nine 
volumes of rFVIII and 1 volume of the biotin solution were mixed and incu­
bated for 2 h at RT. The free residual biotin derivative was removed by dialysis
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against HEPES buffer (HEPES 0.01 M, NaCl 0.15 M, CaCl2 0.01 M, pH 7.2). 
Biotinylation in such conditions did not impair FVIII: C activity as estimated in 
the chromogenic assay, neither the binding to phosphatidylserine nor binding to 
VWF in the respective ELISA assays.
4.3.5. Inhibition of FVIII binding to phospholipids 
by the antibodies of the patient (II)
To study whether the FVIII antibodies of patient TK were able to interfere with 
the FVIII binding to phospholipids, the IgG fraction of plasma samples was 
incubated with the FVIII-biotin conjugate and added to phosphatidyl serine- 
coated microplates. Briefly, the wells of polystyrene microplates (MaxiSorp™, 
Nunc, Denmark) were coated with L-(-phosphatidyl)-l-serine (100 julI of 5 jig/ml 
solution in methanol), air-dried and blocked with 5% BSA in TBS for 1 h at 
room temperature (RT). The wells were rinsed with washing buffer TBS con­
taining 0.1% of Tween 20 (TBS-T) and a mixture containing an equal volume 
of biotin-labelled rFVIII 2 |Lig/ml in TBS-BSA (1% of BSA in TBS buffer), and 
a serially diluted IgG sample of the patient (from 500 jig/ml to 15 (ig/ml) was 
added and incubated for 2 h at RT. The amount of the bound FVIII-biotin was 
determined by using avidin-peroxidase (1 |Lig/ml in PBS with 1% of BSA). 
The reaction was visualized with the OPD substrate solution (o-pheny- 
lenediamine in 0.1 M citrate-phosphate buffer, pH 5.0, containing 0.03% H20 2). 
The reaction was stopped by adding 1M H2S04 to the wells. Absorbance was 
read at 492 nm on a microplate reader Labsystem Multiscan Plus (Labsystems 
Oy, Finland). A control was included in each test where buffer was used instead 
of the test plasma sample dilution. The human monoclonal C2-domain-specific 
antibody B02C11 was used as a positive control.
4.3.6. Inhibition of FVIII binding to the von Willebrand factor 
by the antibodies of the patient (II)
In order to study whether FVIII antibodies were able to interfere with the FVIII 
binding to VWF, the IgG fraction from plasma samples was incubated with the 
FVIII-biotin conjugate and added to VWF-immobilized microplates. First, the 
microplate wells (MaxiSorp™, Dako, Denmark) were coated with 100 |il of the 
mouse anti-human VWF polyclonal antibody (2 jug/ml) in GBS buffer by over­
night incubation at 2-8°C. The wells were blocked with 0.5% of casein in TBS 
(TBS-casein) for 30 minutes. The immobilized polyclonal antibody was satu­
rated with VWF in complex with FVIII by using the normal plasma pool
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(plasma pool of 22 plasmas of healthy persons) diluted to 1:20 in TBS-BSA by 
incubating for 1 h at RT. Factor VIII was dissociated from VWF by incubating 
with 0.4 M CaCl2 for 30 min at RT. After washing with TBS-T, a mixture was 
added containing the test IgG sample dilution and an equal volume of rFVIII- 
biotin conjugate diluted to 2 jig/ml in TBS-casein (preincubated for 30 min at 
37°C before adding). The reaction was carried through for 2 h at RT and the 
amount of the bound FVIII was determined as described above. Monoclonal 
antibody B02C11 was again used as a positive control.
4.3.7. Chromogenic method for measuring 
FXa generation (II)
In order to characterize the mechanism of the inhibition of FVIILC activity by 
the antibodies of patient TK, we used the FXa generation assay. The rate of the 
conversion of FX to FXa was monitored in a reconstituted system. Recombinant 
FVIII (2 IU/ml in TBS-BSA) was preincubated with various concentrations 
(500 to 4 fig/ml) of the tested IgG for 30 min at 37°C. Then the FVIII-antibody 
complex was reacted with purified bovine FIXa+FX (final concentration 2.4 
IU/ml according to labelled activity) in the presence of phospolipids for 10 min 
at 37°C. FXa generation was initiated by adding the CaCl2 solution to the mix­
ture (final concentration 6.25 mM). Aliquots were removed at appropriate times 
to assess the initial rates of product formation and were added to microplate 
wells containing the EDTA solution (final concentration 11 mM) to stop the 
reaction. The amount of the generated FXa was determined by the activity of 
cleaving chromogenic substrate S-2288 (final concentration 1.1 mg/ml) by rea­
ding absorbance at 405 nm. Each assay included 2 controls, namely, in the first 
mixture the tested IgG was replaced by the IgG prepared from the plasmas of 
healthy donors (a positive control), and in the second the tested IgG and FVIII 
were substituted by buffer (TBS-BSA, a negative control). The amount of the 
generated FXa in the sample was expressed as a percentage of the positive 
control. The IgG fractionated from healthy donors was checked for the absence 
of FVIII antibodies by the ELISA assay. In another experiment, rFVIII was 
substituted by the recombinant FVIII light chain diluted to 12 IU/ml in TBS- 
BSA. Preliminary experiments showed that in the presence of the FVIII light 
chain FXa generation was lower than in the presence of rFVIII. Using the 
recombinant FVIII heavy chain instead of rFVIII, led to the generation of a 
negligible amount of FXa.
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4.3.8. Inhibition of FX binding to FVIII by the antibodies 
of the patient (II)
In order to assess whether the antibodies of patient TK were able to inhibit the 
FIXa and FX binding to FVIII, we used the ELISA assay. The microplates were 
coated with PS (5 jig/ml in methanol) and air-dried. The wells were blocked 
with 5% of BSA in TBS for 1 h at RT. An equal amount of rFVIII (2 IU/ml in 
buffer A, 0.05 M Tris, 0.015 M NaCl, 0.015 M CaCl2 , BSA 1%) and the tested 
IgG at indicated concentrations (7 to 500 [Ig/ml) were preincubated for 30 min 
at 37°C and transferred to PS-coated wells of the microplate. After 2 h of 
incubation, the non-bound material was removed by washing the wells with 
buffer B (0.05 M Tris, 0.015 M NaCl, 0.05 M CaCl2, Tween-20 0.1%, pH 7.2). 
Purified bovine FX diluted to 0.1 U/ml in buffer A according to the labelled 
activity, was added to the wells and incubated for 15 min at RT. The wells were 
rapidly washed 3 times with buffer B. Subsequently substrate S-2337 (final 
concentration 0.6 mg/ml) was added to the wells and FX was activated by the 
FX-activating enzyme from Russell’s viper venom (21.5 jlg/ml) in the presence 
of CaCl2 (0.025 M). The inhibition of FX binding was calculated relative to the 
control, which contained the IgG preparation from healthy donors instead of the 
tested IgG sample (100% of binding). Control experiments confirmed that the 
RVV enzyme by itself did not hydrolyse the chromogenic substrate.
4.4. Assays for characterization 
of epitope specificity of FVIII antibodies
4.4.1. Immunoblotting analysis (I-III)
The immunoblotting assay was used for the estimation of the FVIII antibody 
binding to the FVIII light chain and heavy chain. Plasma-derived FVIII prepa­
ration Haemoctin SDH (Biotest, Germany) was separated on sodium dodecyl 
sulfate containing polyacrylamide gradient gel (6-15%). In addition to intact 
FVIII, the thrombin-digested FVIII and the recombinant FVIII light chain and 
heavy chain were separated on the respective lines of SDS-PAGE. The optimal 
thrombin concentration and suitable incubation time were chosen according to 
pilot experiments. FVIII was cleaved by thrombin (0.01 IU thrombin per 1 IU 
of FVIII) for 30 minutes at 37°C. After electrophoresis, the proteins were trans­
ferred to a nitrocellulose membrane (Amersham Pharmacia Biotech, Piscata- 
way, NJ, USA). The membrane was blocked with 3% (w/v) fat-free milk pow­
der in PBS and incubated with plasma samples diluted 1:4 in PBS. Antibody 
binding to FVIII fragments was detected with the rabbit anti-human IgG-AP
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conjugate and bands were developed by using BCIP/NBT as a substrate. After 
each incubation step, the membrane was extensively washed with TBS-T. If the 
sample contained a low amount of FVIII antibodies, antibody binding was 
detected after subsequent incubations with the sheep anti-rabbit IgG-biotin con­
jugate and the streptavidin-HRP solution by using more sensitive chemilumi- 
nescence-based Western blotting detection reagents, the ECL™ kit.
4.4.2. ELISA for the quantification of antibodies recognizing 
the light chain or heavy chain of FVIII (I—III)
In order to estimate a relative amount of FVIII antibodies that bind to the FVIII 
light chain or heavy chain, respectively, the tested plasma samples were incu­
bated with increasing concentrations of the respective recombinant FVIII frag­
ments, and the amount of remaining FVIII antibodies was determined by the 
ELISA assay. Microplates (PolySorp™, Nunc, Denmark) were coated with 
8 lU/ml rFVIII (Recombinate™) in carbonate buffer overnight at 2-8 °C. The 
sites of non-specific binding in the wells of the microplate were blocked with 
3% of BS A in TBS for 1 hour at room temperature and the unbound BSA was 
washed off with TBS-T. Plasma samples with FVIII antibodies were diluted to
4 BU/ml, except the plasma samples with the FVIII antibody titer <4 BU/ml, 
which were used undiluted. In order to neutralize FVIII antibodies, the plasma 
samples were incubated for 1 h at 37°C with an equal volume of the recombi­
nant FVIII heavy chain or light chain, serial dilutions ranging from 0.2 to 
12.6 IU/ml according to the labelled activity. After incubation, aliquots of the 
incubation mixture were transferred to the wells of the microplate precoated 
with rFVIII and incubated for 2 h at 37°C. The amount of bound FVIII anti­
bodies was determined by using the rabbit anti-human IgG conjugated with 
alkaline phosphatase (1:1000, Dako, Glostrup, Denmark) and visualised with 
AP-substrate pNPP (p-nitrophenyl phosphate), recording absorbance at 405 nm 
after stopping the reaction with 2M NaOH. Two controls were included in each 
assay: a mixture that contained buffer instead of the antibody plasma sample 
(minimal binding), and the other where buffer instead of recombinant FVIII 
fragments was used (maximal binding). The percentage of neutralization was 
calculated as follows: 100 — [(binding after incubation with fragment — 
minimal binding) / (maximal binding — minimal binding)] x 100. The plateau 
concentration was defined as the minimal concentration of the FVIII fragment, 
which yielded the maximum optical density (OD), and all OD values within the 
plateau region were averaged.
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4.4.3. Chromogenic method for the quantification 
of antibodies recognizing the light chain 
or heavy chain of FVIII (I-III)
To estimate a relative amount of FVIII inhibitory antibodies neutralized by the 
FVIII light chain or heavy chain, the tested plasma samples were incubated with 
increasing concentrations of the respective recombinant FVIII fragments and 
the amount of remaining FVIII antibodies was estimated as the ability to inhibit 
FVIILC activity by the chromogenic method. Plasma samples were diluted to 
obtain neutralization activity of 4 BU/ml, except the plasma samples containing 
<4 BU/ml of FVIII antibodies, which were used undiluted. The resulting samp­
les were incubated with an equal volume of serially diluted recombinant FVIII 
fragments as described above, and an aliquot was removed for the estimation of 
the amount of antibodies by an ELISA assay. To the remaining solution an 
equal volume of rFVIII (2 IU/ml in TBS containing 2% of BSA) was added and 
incubated for 1 h at 37°C. Residual FVIII coagulation activity (FVIILC) was 
measured by using the chromogenic method. Percentage of neutralization was 
calculated as above using FVIILC activity instead of binding capacity. Maxi­
mum FVIILC activity was measured in the mixture of the respective recombi­
nant fragment and rFVIII without any antibody sample. If the tested plasma 
contained FVIII antibodies less than 10 BU/ml, a plasma sample taken from a 
haemophilia A patient (CRM-negative, without FVIII antibodies) instead of 
buffer was used in order to measure the maximal FVIILC activity. Minimal 
FVIILC activity was measured for each test sample by incubating rFVIII wit­
hout any competitive FVIII fragments. The plateau value was calculated ana­
logously to the previous assay.
In order to obtain comparable results, all neutralisation experiments for the 
testing each particular sample were carried out simultaneously under identical 
conditions. In principle, the total amount of the FVIII light chain and FVIII 
heavy chain recognizing antibodies has to be approximately 100%, but also 
slightly higher or lower values were obtained analogously to previous studies, 
where a similar methodology had been used (Scandella et al., 1995b).
4.4.4. Recombinant FVIII fragments (II)
The respective FVIII DNA fragments for cloning were generated by PCR using 
primers with the restriction enzyme sites. The fragments were cloned into the 
pGEX4T-2 expression vector (Pharmacia, Uppsala, Sweden) and controlled by 
sequencing in both directions with the T7 sequencing kit. Glutathione S-trans- 
ferase (GST) fusion proteins were expressed in the DH5 a  Escherichia coli
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strain. Fusion protein aggregates were dissolved by using 1.5% Sarkosyl 
(Sigma) and 2% Triton X-100 and purified on the glutathione column.
The FVIII domains were expressed so that each domain contained an additional 
8 to 97 amino-acid residues of the neighbouring domains at both ends in order 
to ensure the intactness of cleavage sites for thrombin, FXa and activated 
protein C (Lenting et al., 1998).
The recombinant FVIII fragments were produced and purified by Abdellah 
Benhida at the Centre for Molecular & Vascular Biology, University of Leuven, 
Leuven, Belgium.
4.4.5. Binding of FVIII antibodies 
to recombinant FVIII fragments (II)
In order to more precisely characterize the epitope specificity of patient TK’s 
antibodies, we studied the antibody binding to the following recombinant FVIII 
fragments: A l, al, A2, a3, A3, C l, C2 by using an ELISA assay (Figure 3). 
Microplates were coated with the respective recombinant FVIII fragments 
(2 (Xg/ml in GBS buffer) for 2 h at RT. The wells were blocked with TBS-casein 
(0.5% of casein) for 30 min. Investigated IgG fractions with concentrations 
from 15 (Jig/ml to 500 Jig/ml in TBS-casein were added to the wells of the 
microplate and incubated for 2 h at RT. The fraction of bound FVIII antibodies 
was determined by using the rabbit anti-human IgG peroxidase conjugate. After 
washing the reaction was visualized with the OPD substrate solution. Absor­
bance was read at 492 nm after stopping the reaction with 1M H2S 04. As a 
positive control, the monoclonal antibody specific of a particular recombinant 
FVIII fragment was included in each experiment. The results were expressed as 
OD values corrected by the subtraction of the background value (non-specific 
binding to GST fusion with irrelevant protein).
This assay was performed in the Centre for Molecular & Vascular Biology, 
University of Leuven, Leuven, Belgium.
Al B A2
HCh
.I C1 1 C2l
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a) Recombinant fragments 
1 rHCh
b) Fusion proteins
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Figure 3. FVIII recombinant fragments (a) used in neutralization experiments and 
GST-fusion proteins (b) used for characterization of epitope specificity in ELISA 
assays. Binding sites of monoclonal FVIII antibodies used in a competitive binding 
assay (c).
4.4.6. Competitive binding to FVIII between the antibodies 
of the patient and monoclonal antibodies with 
the known epitope (II)
Monoclonal FVIII antibodies with the known epitope were used in the compe­
titive binding assay to characterize the specificity of FVIII antibodies of patient 
TK (Figure 3). Human monoclonal C2-domain-specific antibody B02C11, Cl- 
domain-specific antibody 2E9, and mouse monoclonal antibodies F29B10 
(amino-acids 2170-2195), and ESH4 (aa 2303-2332) were applied to characte­
rize the FVIII-light-chain-specific antibodies of the patient. Mouse monoclonal 
antibodies F7B4 (aa 356-360) and mAb 15 (A2 -domain-specific) were selected 
to characterize the epitopes of the patient’s antibodies targeted at the FVIII 
heavy chain. Microplates were coated with different human or mouse mono­
clonal antibodies to human FVIII (diluted to 2 |ig/ml in GBS buffer) for 2 h and 
blocked with TBS-casein for 30 min at RT. A mixture containing an equal vo­
lume of the tested IgG sample (concentrations from 15 |ag/ml to 500 |ig/ml) and 
the recombinant FVIII-biotin conjugate (2 (ig/ml) was applied and incubated for
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2 h at RT. The amount of the bound rFVIII-biotin was determined by using 
avidin-peroxidase as described above. The validity of the assay was confirmed 
by using the same monoclonal antibody that was used to coat microplates 
instead of the tested antibody. The background value (no antigen in the coating 
solution) was subtracted from the respective OD values. The degree of compe­
tition was calculated relative to the maximal binding obtained when no 
competitor (buffer instead of the test IgG sample) was used.
4.5. Characterization of IgG subclasses 
of FVIII antibodies
4.5.1. IgG 1-4 subclasses of FVIII antibodies (III)
In order to characterize the IgG subclassess of FVIII antibodies, the antibody 
binding to the recombinant FVIII (Recombinate™) that was immobilized onto 
microplates was detected by using the IgG-subclass-specific antibodies. 
Immunoplates (PolySorp™, Nunc, Roskilde, Denmark) were coated with rFVIII 
(8 IU/ml in carbonate buffer) overnight at 2-8°C and blocked with 5% of BSA 
in TBS for 1 h at RT. Plasma samples containing FVIII antibodies were diluted 
from 1:10 to 1:5000 in TBS and reacted with immobilized FVIII for 2 h at 
37°C. After washing with TBS-T, the bound FVIII antibodies were detected by 
incubating with the respective sheep anti-human IgGl, IgG2, IgG3 or IgG4 
antibodies (1:1000 dilution in TBS) for 1 h at 37°C followed by the donkey 
anti-sheep IgG-biotin conjugate (diluted 1:1000) and incubated for 1 h at RT. 
The wells were washed thoroughly and streptavidin-AP conjugate (1:1000) was 
added to the wells and incubated for 30 min at RT. After washing, the substrate 
pNPP solution was added and absorbance was read at 405 nm after stopping the 
reaction with 2M NaOH (maximum absorbance was achieved in 30 min). FVIII 
antibody-free plasma from a severe haemophilia A patient was used instead of 
the investigated plasma sample as a negative control. The cut-off value was 
defined as a mean value plus 3 standard deviations of optical densities measured 
for controls. The ELISA titer was defined as a maximal dilution of the sample 
yielding OD exceeding the cut-off value. The estimated cut-off values of opti­
cal density for IgGl, IgG2, IgG3, and IgG4 FVIII antibodies were 0.113, 0.103, 
0.089 and 0.089, respectively.
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4.5.2. IgGl-4 subclasses 
of FVIII-light-chain-specific antibodies (III)
Immunoplates (PolySorp™, Nunc, Roskilde, Denmark) were coated with the 
recombinant FVIII light chain diluted in TBS at 6 IU/ml and incubated over 
night at 2-8°C. The next steps of the assay were identical to those described in 
the previous section. However, the cut-off values were higher for the FVIII light 
chain than for the full-length FVIII. The cut-off values for IgGl, IgG2, IgG3 
and IgG4 were 0.222, 0.217, 0.167 and 0.166, respectively.
4.6. Characterization of VWF content 
in FVIII preparation (IV)
4.6.1. FVIII preparations (IV)
Four different FVIII preparations were characterized as follows, Haemoctin 
SDH 250 IU (Biotest, Dreieich, Germany), Koate-HP 310 IU (Bayer Miles, 
Elkhart, IN, USA), lyophilized cryoprecipitate KRYO-AHG 400 IU (North 
Estonian Blood Centre, Tallinn, Estonia) and Haemate 1000 IU (Aventis Beh­
ring, Bridgewater, NJ, USA). FVIII preparations were diluted according to the 
manufacturer’s instructions, and stored at -70°C until assayed.
4.6.2. ELISA for the quantification 
of the VWF antigen (IV)
The concentration of the VWF antigen in FVIII preparations was determined by 
using an ELISA. The microplates (MaxiSorp™, Nunc, Roskilde, Denmark) 
were coated with the rabbit polyclonal anti-human VWF antibody (1:1000 in 
carbonate buffer) overnight at 2-8°C. The samples were diluted to yield 
FVni:C activity from 0.02 to 0.05 IU/ml in PBS, transferred to the wells and 
incubated for 2 h at RT. The bound VWF was quantified by using the rabbit 
polyclonal anti-human VWF antibody conjugated with peroxidase (1:1000 dilu­
tion, incubation for 1 h at RT), by using OPD as a substrate, and reading absor­
bance with the ELISA reader after stopping the reaction with 1M H2S 04. The 
standard graph was constructed by using the normal plasma standard (made 
from plasmas obtained from 22 healthy persons) that was calibrated against the 
international standard (the 3rd standard for FVIII and VWF in plasma, code 
91/666) in an analogous ELISA assay. The coefficient of variance between the 
days was 4.2 % at the VWF:Ag level of 1 IU/ml.
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4.6.3. Estimation of FVIII coagulation activity (IV)
The FVIILC activity in FVIII preparations was measured by the chromogenic 
method in microplates using the test kit Coatest FVIILC according to the 
manufacturer’s instructions. FVIII preparations were pre-diluted to yield the 
FVIILC activity of 1 IU/ml in TBS-BSA (1% BSA). The 4th International stan­
dard for blood coagulation factor VIILC preparation (88/804) was used for buil­
ding a standard graph. The coefficient of variance between the days was 3.5% 
for FVIILC activity 1 IU/ml.
4.6.4. Ristocetin cofactor assay (IV)
Ristocetin cofactor activity of VWF (RCof) was determined by using the 
formaldehyde-fixed washed platelets for the aggregation test (Macfarlane et al., 
1975). The assay is based on the ability of antibiotic ristocetin to dimerize and 
initiate the aggregation of platelets, which is dependent on the presence of 
VWF. The formaldehyde-fixed platelets from a healthy donor were prepared as 
described previously (Evans and Austen, 1977). Briefly, the platelets were fixed 
by incubating 1 part of platelet-rich plasma with an equal volume of formal­
dehyde in PBS buffer (4% formaldehyde) overnight at 2-8°C. The platelets 
were washed and resuspended in TBS. The investigated samples were diluted to 
yield FVIILC activity from 0.2 to 0.5 IU/ml in TBS containing 1% of BSA and 
incubated with an equal volume of formaldehyde-fixed platelets for 10 min at 
37°C in an aggregometer (Jelena Laboratories) under continuous agitation. The 
aggregation of platelets was initiated by adding ristocetin (1.6 mg/ml final 
concentration) and recording the slope of the aggregation curve. The normal 
plasma standard (made from plasmas obtained from 22 healthy persons) calib­
rated against the international standard (the WHO 3rd standard for FVIII and 
VWF in plasma, code 91/666) was used to construct the standard curve. The 
coefficient of variance between the days was 19%.
4.6.5. Characterization of VWF multimers (IV)
The VWF multimerization status was analysed by the SDS-agarose gel 
electrophoresis in 1.9% agarose gel according to the method of Metzner et al., 
by applying the discontinuous submarine technique (Metzner et al., 1998). 
VWF multimers were detected after the transfer to a nitrocellulose membrane 
by using the rabbit polyclonal anti-human VWF antibody and the goat anti­
rabbit IgG-alkaline-phosphatase conjugate. The bands were developed by using 
BCIP/NBT as a substrate.
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4.6.6. ELISA for the quantification 
of VWF binding to collagen (IV)
Acid soluble collagen type III from the human placenta was dissolved in 3% 
acetic acid. The collagen solution was rapidly diluted in PBS buffer, pH 7.2 to 
reach the concentration of 10 jig/ml and then immobilized onto a microplate for 
1 h at room temperature. The plate was blocked with 5% of BSA in PBS 
containing Tween 20 (0.05%) for 1 h at RT and washed with PBS-containing 
Tween 20 (0.05%). The tested FVIII preparations diluted from 0.1 to 
0.01 IU/ml of FVIII:C activity were transferred to collagen-coated wells and 
incubated for 1 h at RT. After washing with PBS-T, the bound VWF was 
detected by using the rabbit anti-human VWF antibody conjugated with 
peroxidase (1:2000 in PBS). After 1 h of incubation, the wells were thoroughly 
washed and the bound VWF was quantified by using OPD and stopping the 
reaction with 1M H2S 0 4 after 5 min, and with absorbancies being read at 
492 nm. Normal plasma pool of 22-donor plasmas was calibrated against 
ristocetin cofactor activity which was the only accepted characteristic of the 
functional activity of VWF in the 3rd international standard for FVIII and VWF 
in plasma (91/666) and was used as a local standard for building the standard 
curve. The coefficient of variance of this assay was 4.8% at the VWF:CB level 
of 1 IU/ml.
4.7. Statistical analyses (I-IV)
All the calculations were done by using the GraphPad Prizm Program Package 
(GraphPad Software Inc., USA) Correlation was calculated according to the 
Spearman rank order correlation coefficient and the coefficient of p  0.05 
was considered to be significant. The values were analysed by using the paired 
t-test or one-way analysis of variance (ANOVA). The data are expressed as 
means ± SD.
5. RESULTS
5.1. Inhibition of FVIII:C activity by FVIII antibodies 
in the presence of VWF (Paper I)
In order to assess whether the presence of VWF in the FVIII preparation 
decreases the inhibition of FVIILC activity by FVIII-specific antibodies, we 
used a neutralization assay where the plasma samples of haemophilia A patients 
were incubated either with the rFVIII or FVIII-VWF preparation. All 12 
investigated plasma samples contained antibodies which recognised the FVIII 
light chain and the A2 domain as detected by immunoblotting. To estimate the 
proportion of antibodies recognizing epitopes within the FVIII light chain or 
heavy chain, the investigated samples were incubated with the respective 
recombinant FVIII fragment. After incubation, the residual amount of FVIII 
antibodies was measured by the ELISA assay or by their ability to inhibit 
FVIILC activity by using the chromogenic method. Two groups of plasma 
samples were identified on the basis of the relative amount of FVIII light chain 
antibodies and on the neutralization of FVIII in the presence and the absence of 
VWF (Table 5). The first group, consisting of 9 plasma samples, had a signi­
ficantly lower neutralization activity when exposed to the FVIII-VWF complex 
compared to rFVIII. The ratio between the dilutions yielding 50% neutralization 
with rFVIII and with FVIII-VWF ranged from 1.5 to 18.3 (mean 6.8). The 
samples classified to Group 1 contained a significantly higher amount of anti­
bodies directed towards the FVIII light chain (53-96%) than the amount of 
antibodies directed towards the FVIII heavy chain (3-58%). The proportion of 
FVIII-light-chain-specific antibodies was calculated relative to FVIII heavy 
chain antibodies (ratio rLCh/rHCh) ranged from 1.6 to 30 as estimated by the 
ELISA assay and from 1.9 to 26.6 by the chromogenic method. Three samples 
classified to Group 2 showed no difference in the inhibition of FVIILC activity 
when exposed to rFVIII or FVIII-VWF (the mean ratio 1.0). These plasma 
samples contained an equal or a lower amount of FVIII-light-chain-specific 
antibodies than FVIII-heavy-chain-specific antibodies. The ratio between the 
amounts of FVIII-light-chain-specific antibodies and FVIII-heavy-chain- 
specific antibodies ranged from 0.2 to 1. When the results of all 12 investigated 
samples were included, the ratio between the sample dilutions resulting in 50% 
of the inhibition of FVIILC acti vity with rFVIII and with FVIII-VWF correlated 
with the ratio between the amounts of FVIII light chain antibodies and FVIII 
heavy chain antibodies as estimated by the chromogenic assay (Spearman rank 
order correlation coefficient r=0.59, p=0.04, Figure 4).
55
Table 5. Characterization of investigated FVIII antibodies.
Plasma
sample
FVIII
anti­
bodies
BU/ml
Epitope
specificity
Neutralization of rFVIII and 
FVIII-VWF
Antibodies targeted to the recombinant light chain (rLCh) and 
the heavy chain (rHCh) of FVIII
rFVIII
1050%
FVIII-
VWF
ID50%
Ratio
rFVIII
FVIII-VWF
ELISA FVIII:C
rLCh
%
rHCh Ratio 
% rLCh/rHCh
rLCh rHCh
% %
Ratio
rLCh/rHCh
Group 1
1 140 A2, LCh 750 150 5 96 7 13.7 53 8 6.6
2 9 A2, LCh 9 2 4.5 100 7 14.3 78 30 2.6
3 5 A2, LCh 27.5 1.5 18.3 97 25 3.9 82 42 1.9
4 7 A2, LCh 25 1.5 16.7 92 20 4.6 93 3.5 26.6
5 8 A2, LCh 5 2 2.5 62 20 3.1 75 27 2.8
6 37 A2, LCh 30 8 3.7 93 58 1.6 82 21 3.9
7 300 A2, LCh 265 110 2.5 90 7 12.8 95 7 13.6
8 280 A2, LCh 350 50 7 95 6 15.8 96 6 16
9 4 A2, LCh 3 2 1.5 90 3 30 83 15 5.5
Group 2
10 1 A2, LCh 0.7 0.7 1 n.d. n.d. n.d. 21 21 1
11 5 A2, LCh 2 2 1 70 74 0.9 64 65 1
12 150 A2, LCh 28 23 1.2 18 94 0.2 26 74 0.4
n.d. -  not determined; ID50% - dilution of plasma sample neutralizing 50% of FVIII.C activity
Figure 4. Correlation between the ratio of plasma dilutions yielding 50% of inhibition 
of FVIII:C activity when incubated with rFVIII or FVIII-VWF (ratio of rFVIII to 
FVIII-VWF) and the proportion of FVIII-light-chain-specific antibodies relative to 
FVIII-heavy-chain-specific antibodies as estimated by the chromogenic method (ratio of 
rLCh to rHCh).
5.2. Characterization of the patient’s 
FVIII antibodies during immune tolerance treatment 
with VWF containing FVIII preparation (II, III)
5.2.1. The amount of FVIII-light-chain- and 
FVIII-heavy-chain-specific antibodies (II, III)
Further we characterized the epitope specificity of FVIII antibodies and the 
changes in epitope specificity during treatment with FVIII-VWF concentrate 
administered for the immune tolerance treatment (ITT) to a high responder 
patient TK. The investigated patient’s plasma sample taken several months 
before ITT belonged to Group 1 (Table 4, patient No 2) based on the properties 
of FVIII antibodies. This sample contained a significantly higher amount of 
FVIII light chain antibodies than FVIII heavy chain antibodies and the inhi­
bition of FVIII:C activity by FVIII antibodies was lower in the presence of 
VWF. The results of in vitro experiments suggest that the administration of the 
FVIII-VWF preparation could be more efficient in achieving haemostasis in 
patient TK. However, FVIII preparation Haemoctin SDH which contains VWF
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was actually used for ITT because the choice of concentrates was limited to this 
one as the only available product at that time in Estonia. Plasma samples for 
measuring the amount of FVIII antibodies and for characterizing epitope 
specificity were taken at the beginning and during the immune tolerance 
treatment. FVIII antibodies in plasma samples were detected by using the 
Bethesda method (Figure 6D). The relative amount of antibodies targeted at the 
FVIII light chain or the heavy chain was measured by using both the ELISA 
and the chromogenic method. At the beginning of treatment (zero point on 
Figure 6), a significantly higher amount of antibodies were targeted at the FVIII 
light chain than to the FVIII heavy chain as measured by both, the ELISA assay 
or the chromogenic method (Figure 5). The neutralization of FVIII inhibitory 
antibodies by the recombinant FVIII light chain followed Type 2 kinetics as 
defined by Biggs et al. (Biggs et al., 1972a; Biggs et al., 1972b). In all samples 
taken during treatment, the FVIII-light-chain-specific antibodies were 
predominant, ranging from 50 to 100% of FVIII antibodies. A low amount (2- 
30%) of FVIII-heavy-chain-specific antibodies were detected during 10 months, 
after which the concentration of FVIII heavy chain antibodies dropped below 
the level of detection (Figure 6C).
Figure 5. Neutralization of patient TK’s anti-FVIII antibodies by the recombinant light 
chain and heavy chain of FVIII as measured by the chromogenic method (rLCh 
FVIILC, rHCh FVIILC) or the ELISA assay (rLCh ELISA, rHCh ELISA). Tested 
plasma sample was taken at the beginning of ITT.
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IgG binding to recombinant FVIII light chain fragments
IgG binding to recombinant FVIII heavy chain fragments
FVIII antibodies neutralized by rLCh or rHCh, %
rLCh
rHCh
- rLCh ELISA c  
■ rHCh ELISA
Bethesda titer and administered FVIII
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Figure 6. Changes of properties of patient TK’s anti-FVIII antibodies during treatment. 
Binding of patient TK’s antibodies to recombinant fragments of FVIII light chain (A) 
and recombinant fragments of FVIII heavy chain (B) at 100 fig/ml IgG concentration 
(mean ± SD). Neutralization of the patient’s anti-FVIII antibodies by the recombinant 
FVIII light chain and the heavy chain as estimated by using the chromogenic method 
(LCh, HCh) or an ELISA assay (LCh ELISA, HCh ELISA) (C). The Bethesda titer and 
administration scheme of FVIII preparation Haemoctin SDH (Biotest, Germany) (D).
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5.2.2. Epitope specificity 
of FVIII-light-chain-specific antibodies (II)
A more detailed characterization of patient TK’s antibody epitopes in the FVIII 
light chain was achieved by using the fragments of the FVIII light chain. We 
studied the antibody binding to the following recombinant FVIII light chain 
fragments: a3, A3, C l, C2 by using an ELISA assay. The respective fragments 
expressed as fusion proteins with glutathione S-transferase (GST) were 
immobilized onto microplates and incubated with various concentrations of IgG 
fractions purified from patient TK’s plasma samples. At the beginning of 
treatment of the patient we were able to detect the FVIII-light-chain-specific 
antibodies directed towards the C l, C2 and a3 domain of FVIII. The amount of 
antibodies recognizing the Cl domain was significantly higher than the amount 
of antibodies recognizing the C2 domain of FVIII (p<0.01, paired t-test, Figure 
6A). The binding of patient TK’s antibodies to the recombinant Cl domain 
immobilized to polystyrene surface was linearly dependent on antibody con­
centration (Figure 7). A negligible amount of antibodies bound to the a3 domain 
but no antibody binding to the A3 domain was detected. On the second day of 
treatment, the amount of C l- and a3- specific antibodies decreased. However, 
the Bethesda titer also decreased from 17.5 BU/ml to 10.5 BU/ml. Probably, 
some of FVIII antibodies were neutralized by the administered FVIII. During 
the following treatment a linear decrease in the concentration of Cl-domain- 
and a3-domain-specific antibodies was detected. The amount of antibodies 
recognizing different FVIII-light-chain fragments remained rather unchanged, 
except an observed significant rise in the C2-domain-specific antibody level in 
the sample taken in 5th month soon after the interruption of treatment (p<0.05, 
ANOVA). The decreases in C2-domain antibody concentration until the inter­
ruption of treatment and during the following period were similar.
Since the patient’s antibodies were able to bind to the recombinant Cl 
domain and C2 domain, we studied further whether the antibodies were able to 
recognize the common region in both these recombinant fragments (amino acids 
2125-2222). In a competitive binding assay we used the mouse monoclonal 
FVIII antibody F29B10, which binds to an epitope within amino acids 2170- 
2195, present in both, the recombinant Cl and C2 domain. Surprisingly, anti­
body F29B10 bound to the recombinant C2 domain only, but no binding to the 
C l domain was detected. At the beginning of treatment the patient’s antibodies 
inhibited the F29B10 binding to FVIII by 12% (Figure 8A), indicating the 
presence of antibodies directed also towards this epitope in the C2 domain. 
During treatment all the tested IgG fractions contained a small amount of anti­
bodies, which interfered with the FVIII binding to mAb F29B10. No correlation 
was found between the concentration of the C2-domain-specific antibodies and 
the concentration of antibodies able to compete with mAb F29B10.
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Figure 7. Concentration dependence of the binding of patient TK’s antibodies to recom­
binant Cl domain in the ELISA assay. Monoclonal Cl-domain-specific antibody 2E9 
was used as a control (insert).
Next we studied whether the tested antibodies could compete with monoclonal 
antibodies 2E9 and B02C11 for their binding sites within the Cl domain (Jac­
quemin et al., 2000) or the C2 domain (Spiegel et al., 2001), respectively. These 
monoclonal antibodies are known to abolish the interaction of FVIII with VWF. 
The tested patient’s antibodies were mainly targeted at the Cl domain of the 
FVIII light chain. However, no inhibition of the FVIII-biotin binding to mAb 
2E9 was detected in the presence of the patient’s IgG fraction in a competitive 
binding assay. Moreover, no inhibition was detected even when FVIII was pre­
incubated with the tested IgG fraction for 30 min before adding it to mAb-2E9- 
coated microplates. Probably the patient’s antibodies and mAb 2E9 were 
directed to different epitopes of the Cl domain of the FVIII light chain. The 
patient’s antibodies were not able to interfere with the FVIII binding to mAb 
B02C11 even when added directly to the wells of the microplate or later, after 
30 min of pre-incubation with the FVIII-biotin conjugate.
We used monoclonal antibody ESH4 in a competitive binding assay to study 
whether the patient’s antibodies could bind to the C-terminus of the C2-domain. 
At the beginning of the treatment of patient TK, antibodies completely 
abolished the FVIII binding to ESH4 (Figure 8A). The concentration of anti­
bodies capable of interfering with the FVIII binding to ESH4 decreased during 
treatment. Thus, the tested antibodies were probably targeted at the N-terminus 
(2170-2190) and C-terminus of the C2-domain, since both ends of the C2 
domain are connected close to each other with a disulphide bridge. Obviously, 
the binding of FVIII to ESH4 was inhibited by the FVIII-light-chain-specific 
antibodies targeted at the C2 domain and the Cl domain, which could interfere
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with this interaction by steric hindrance or by inducing a conformational change
of the FVIII light chain so that the ESH4 binding to FVIII was abolished.
5.2.3. Epitope specificity 
of FVIII-heavy-chain-specific antibodies (II)
The epitope specificity of the FVIII-heavy-chain-specific antibodies was cha­
racterized in an ELISA assay by using the recombinant FVIII fragments 
corresponding to the al, A l, and A2 domains. At the beginning of treatment of 
patient TK we could detect antibodies, which bound to epitopes within the A2 
domain or Al domain, but no binding to the al domain was detected. The 
amount of antibodies recognizing the A2 or A l domains was lower compared to 
the amount of Cl-specific antibodies (Figure 6B). On the second day, the 
amount of A2- and A 1 -specific antibodies decreased analogously to the FVIII 
light chain antibodies. During treatment the concentration of the A l- and A2- 
domain-specific antibodies decreased.
More precise characterization of the targets of patient TK’s antibodies was 
achieved by the competitive binding assay using FVIII-heavy-chain-specific 
antibodies. As the first choice, monoclonal antibody F7B4, whose binding site 
contains amino acids 356-360 of the al domain, was used in a competitive 
binding assay. The result that antibody F7B4 bound with similar affinity to re­
combinant fragments al and A2 was expected, since the epitope of this antibody 
was present in both these recombinant FVIII fragments. At the beginning of 
treatment, patient TK’s antibodies inhibited mAb F7B4 binding to FVIII by 
25% (Figure 8A). All other IgG samples taken during treatment also contained 
antibodies, which were able to compete with F7B4 for its binding site on FVIII. 
The inhibition of FVIII interaction with mAb F7B4 correlated with the con­
centration of antibodies bound to the recombinant A2 domain (Spearman rank 
order correlation coefficient r=0.881, p=0.007). Contrary to mAb F7B4, the tes­
ted patient’s antibodies themselves were not able to bind to the al recombinant 
fragment, thus obviously the epitopes of the patient’s FVIII-heavy-chain- 
specific antibodies located within the C-terminus of Al domain or the N-termi- 
nus of the A2 domain and interfered with the antibody F7B4 binding to FVIII 
indirectly.
In the competitive binding assay, we also used FVIII-heavy-chain-specific 
monoclonal antibody, mAb 15, which binds to a conformational epitope in the 
C-terminus of the A2 domain resulting in a complete inhibition of the FVIII 
coagulation activity (Gilles et al., 1996; Gilles et al., 1997). The FVIII binding 
to mAb 15 was interfered with by some of the tested antibody samples, showing 
that the patient’s antibodies were also targeted at this region of the C-terminus 
of the A2 domain (Figure 8A).
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Inhibition of FVIII binding to mAb, % o f control
FVIII antibodies in IgG and inhibitory activity in FXa generation assay
Be the s da titer and adm inistered FVIII
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Figure 8. Inhibition of monoclonal anti-FVIII antibody binding to FVIII by patient 
TK’s IgG (mean ± SD) (A). The concentration of FVIII antibodies in purified IgG (jag 
per 10 mg of IgG) and the ELISA titer estimated in plasma. The inhibitory activity of 
FVIII antibodies in the FXa generation assay is shown as IgG concentration yielding 
50% of the inhibition of FXa generation induced by rFVIII (IC 50% FVIII) or the 
recombinant light chain of FVIII (IC 50% rLCh) (B). The Bethesda titer and the 
administration scheme of FVIII preparation Haemoctin SDH (Biotest, Germany ) (C).
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5.2.4. IgG subclasses of FVIII antibodies (III)
5.2.4.I. IgG subclasses of FVIII antibodies 
in patients with persistent FVIII antibodies (III)
Antibodies to FVIII are generally of the IgG type immunoglobulins with the 
prevalence of the IgG4 subclass (Algiman et al., 1992; Fulcher et al., 1987), or 
according to others, the normal physiological distribution of IgG subclasses is 
detected as reported by different research groups (Gilles and Saint-Remy, 
1994). Since only a negligible amount of FVIII antibodies of the IgM type has 
been found, we focused on the IgG type antibodies. In order to assess whether 
the IgG subclass distribution of FVIII antibodies in haemophilia A patients with 
persistent FVIII antibodies differs from that detected during the immune tole­
rance treatment, we first investigated the plasma samples of 12 haemophilia A 
patients. The samples were divided into 2 groups according to the properties of 
FVIII antibodies as described in section 5.1, except that the first group was 
represented with 8 samples, because there was not enough plasma of patient 
No. 9 to perform respective analyses. We used a sensitive ELISA assay for the 
detection of IgG subclasses of FVIII antibodies directly from the plasma 
sample. The distribution of IgG subclasses of FVIII antibodies is shown in 
Table 6. The most abundant in both groups was the IgG4 subclass of FVIII 
antibodies (p<0.01, paired t-test). Results of the Bethesda assay correlated fairly 
well with the ELISA titers of all four IgG subclasses of FVIII antibodies.
The relative distribution of the IgG subclasses of FVIII-light-chain-specific 
antibodies was compared to a relative subclass distribution of antibodies against 
the whole FVIII molecule. The FVIII-light-chain-specific antibodies of Group 1 
samples were mainly of the IgG4 subclass. The samples classified into Group 1 
showed a similar subclass distribution of antibodies against the FVIII light 
chain and the whole-FVIII molecule. IgGl subclass FVIII light chain antibodies 
and IgG4 subclass FVIII antibodies dominated in the samples classified into 
Group 2. The difference between the subclass distribution of the FVIII-light- 
chain-specific and FVIII antibodies could be explained by a higher amount of 
FVIII-heavy-chain-specific antibodies in these 3 samples. A good correlation 
was found between the results of the Bethesda assay and the amount of the 
FVIII light chain antibodies of all IgG subclasses (p<0.01).
Further we evaluated the putative changes in the IgG subclass distribution of 
FVIII antibodies and the FVIH light chain antibodies of patient TK in the course 
of ITT. At the beginning of the immune tolerance treatment the patient had 35% 
of IgG4, 23% of IgGl, 29% of IgG2 and 13% of IgG3 subclass FVIII anti­
bodies. Factor VUI-light-chain-specific IgG antibodies were present in the 
following percentages: 34% of IgG4, 28% of IgGl, 23% of IgG3 and 15% of 
IgG2 subclasses. Results of the IgG 1-4 subclass distribution are shown in 
Figure 9 (A, B). At the beginning of treatment the concentration of the IgG4 
subclass FVIII and the FVIII light chain antibodies was slightly higher than that 
of other IgG subclasses. During the first continuous infusion the decrease in the 
concentration of all IgG subclasses except that of IgGl of FVIH antibodies was 
identical. During treatment, the distribution of FVIII antibodies between IgG 
subclasses remained unchanged, retaining a significantly higher level of IgG4 
subclass antibodies (p<0.05, paired t-test). The curves possessed identical slo­
pes, but significantly different intercepts (pcO.OOl). Antibodies specific of the 
FVIII light chain had a different IgG subclass distribution. During ITT, factor 
VIII light chain antibodies of subclasses IgGl, IgG4, IgG3 were almost 
identically expressed and at a significantly higher level than IgG2 antibodies 
(p<0.05, paired t-test). At the beginning of treatment a fluctuation in the FVIII 
light chain antibody subclass distribution was found to be analogous to that of 
FVIII antibodies.
There were two pronounced increases in IgGl subclass antibody levels 
(p<0.05, ANOVA). The first rise was observed after a one-month treatment 
with the dose 100 IU/kg per day and the other after 5 months, probably being 
caused by the second continuous infusion. One of these increased levels was 
accompanied by an increase of the concentration of FVIII light chain antibodies 
of the IgGl subclass and an increase in the Bethesda titer. The other one was 
associated with a rise in antibodies against the epitopes within the FVIII heavy 
chain.
5.2A.2. Changes in the IgG subclass distribution
of FVIII antibodies during immune tolerance treatment (III)
Distribution of IgG subclasses of the FVIII light chain antibodies, % a
Distribution of IgG subclasses of FVIII antibodies, % B
— lgG1 % lgG2%
-  lgG3 % —X — lgG4 %
Figure 9. Distribution of IgG subclasses of antibodies targeted at FVIII (B) or the FVIII 
light chain (A).
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Table 6. Distribution o f FVIII antibodies and FVIII light chain antibodies between IgG subclasses.
Plasma
sample BU/ml
Distribution of FVIII antibodies Distribution of FVIII light chain antibodies Inversion in
IgGl
%
IgG2
%
IgG3
%
IgG4
%
IgGl
%
IgG2
%
IgG3
%
IgG4
%
intron 22 of 
FVIII gene
Group 1
1 140 22 25.2 21 31.6 29.5 23.2 17 33.5 Type 1
2 9 25.5 25 19.6 29.8 24 17 21 38 Type 1
3 5 25 25 23 26 29.8 10.7 1.8 41.7 Rare inversion
4 7 30 14.5 21 33.9 74 7.4 0 18.5 n.d.
5 8 10.6 19 19 51 17 17 22 43.5 Type 1
6 37 32 17 21 32 12.5 12.5 25 50 Type 2
7 300 32.8 20.4 19.8 26.9 22.6 19.3 30.4 27.6 Type 1
8 280 16.2 34.2 17 32.4 3.4 13.7 31 51.7 n.d.
9 4 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Mean 23 22.5 20.1 32.9 26.6 15.1 18.9 38
SD 7.5 6.2 1.8 7.8 21.1 5 11.2 11.2
Group 2
10 1 27.8 12.8 11 27.8 27.4 39.6 17.8 14.8 Type 2
11 5 26 24.6 24.6 24.6 55 22 11 11 n.d.
12 150 30 7 28.9 33.3 24 20 28 28 n.d.
Mean 27.9 14.8 21.5 28.5 35.5 27.2 18.9 17.9
SD 2 8.9 9.3 4.4 17 10.8 6.9 8.9
M ean,11=1' 25.3 20.4 20.5 31.8 29.0 18.4 20.1 32.6
SD 6.8 7.5 4.5 7.1 19.7 8.5 9.1 13.8
n.d. - not determined
5.3. Inhibition of FVIII:C activity by the patient’s 
antibodies, the putative mechanism (II)
After the characterization of the specificity of FVIII antibodies during the ITT 
of patient TK, we attempted to explore the mechanism of FVIII antibodies in 
the inhibition of FVIILC activity in relation to epitope specificity. Therefore, 
we studied whether patient TK’s antibodies interfered with the FVIII interaction 
with VWF and/or the binding of FVIII to PS, since these interactions are most 
commonly impaired by the FVIII-light-chain-specific antibodies. No influence 
on the FVIII interaction with VWF or the FVIII binding to PS was detected 
when FVIII was pre-incubated with the patient’s IgG before adding it to either 
VWF- or PS-coated microplates, as observed in the respective ELISA assays. 
Monoclonal antibody B02C11, which interfered with both of these interactions 
in a concentration dependent manner, was used as a control in each assay.
Since the FVIII antibodies of patient TK were not able to interfere with the 
FVIII-PS interaction, we assessed whether the antibodies impair the FVIII 
interaction with FIXa and/or FX and hinder the formation of the FXase 
complex. We used a factor Xa generation assay, which was dependent on the 
presence of phospholipids, FVIII as well as Ca2+ and if one of these was not 
added to the reaction mixture, FXa generation was abolished.
Preliminary experiments showed that in the presence of the light chain of 
FVIII, FXa generation was lower than in the presence of rFVIII. The recombi­
nant FVni heavy chain led to the generation of a negligible amount of FXa 
only. Due to a limited amount of plasma available for IgG purification, we 
investigated only four samples in this assay. At the beginning of treatment the 
patient’s antibodies at the IgG concentration of 500 jig/ml completely abolished 
the generation of FXa induced by rFVIII or the FVIII light chain (Figure 10). 
The concentration-dependence of the inhibition of FXa generation by patient 
TK’s antibodies is shown in Figure 11.
Figure 10. Inhibition of FXa generation induced by rFVIII (rFVIII) or the recombinant 
light chain of FVIII (rLCh) with patient TK’s FVIII antibodies (0.5 mg/ml IgG) taken at 
the beginning of ITT. Each data point represents the mean of at least two individual 
experiments.
Figure 11. Inhibition of FXa generation induced by rFVIII or the recombinant light 
chain of FVIII (rLCh) with patient TK’s FVIII antibodies. The amount of FXa was esti­
mated after 5 min of induction. Each data point represents the mean of at least two indi­
vidual experiments.
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Patient TK’s antibodies also inhibited the generation of FXa induced by the 
FVIII light chain, although a slightly lower concentration of IgG was needed for 
that, as compared to the rFVIII-induced FXa generation (Figure 10). Probably, 
FVIII light chain antibodies were mainly responsible for the inhibition of 
FVIHiC activity by interfering with the FVIII interaction with FIXa and FX. 
The IgG concentrations that caused 50% of the inhibition of FXa generation 
induced by rFVIII or the light chain of FVIII are shown in Figure 8B.
Since the tested FVIII antibodies hindered the formation of the FXase 
complex, we assessed whether or not the interaction of FVIII with FX takes 
place in the presence of patient TK’s antibodies. The microplates coated with 
phosphatidylserine were used to ensure the specific orientation of FVIII on the 
surface allowing of an efficient binding of FX. This strategy for FVIII immo­
bilization was chosen, because the tested antibodies did not interfere with the 
binding of FVIII to phosphatidylserine, and the orientation of FVIII was known 
to be highly important for the interaction with FX. The amount of FX bound to 
FVIII was estimated by a subsequent activation of FX with Russell’s viper 
venom and the ability of the formed FXa to cleave a specific substrate. All four 
tested IgG samples characterized by the FXa generation assay, were able to 
inhibit the FX binding to FVIII immobilized to PS (Figure 12). The progressi­
vely higher concentrations of IgG obtained from the subsequent plasma samples 
during treatment were needed for the inhibition of the FX binding to FVIII 
analogously to the FXa generation assay. Since the light chain of FVIII has 
been reported to participate in the FX binding to FVIII (Nogami et al., 1999), 
we assessed the ability of the FVIII light chain to interact with FX in a 
respective experimental set-up. The binding of FX to the light chain of FVIII 
was also inhibited in the presence of patient TK’s antibodies. IgG fractionated 
from the plasma of healthy donors did not impair the interaction of FX with 
FVIII or its light chain and was therefore used as a control.
FX itself could also bind to PS in a FVIII-independent manner and give rise 
to high background values. Consequently, in parallel with an oriented immo­
bilization of FVIII onto a phosphatidylserine layer, we also attempted the FVIII 
binding to surface-attached antibodies. The antibodies which are known to be 
targeted at the regions of FVIII, which do not participate in the interaction with 
FX (e.g. B02C11, ESH4) bound efficiently to FVIII. Unfortunately, the ability 
of FVIII to interact with FX was completely lost upon binding to these 
monoclonal antibodies (data not shown).
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Figure 12. Interaction of FX with rFVIII and its recombinant light chain bound to pho­
sphatidyl serine in the presence of patient TK’s antibodies. Each data point represents 
the mean of at least two individual experiments.
5.4. Characterization of VWF 
in FVIII preparations (IV)
We characterized the composition and the amount of VWF in various FVIII 
preparations registered in Estonia. Due to different protocols for isolating the 
FVIII-VWF complex from plasma dissimilar FVIII preparations are produced in 
which VWF serves as a biological carrier and stabilizer of FVIII (Vlot et al.,
1998). However, the degradation of VWF by protelytic cleavage can occur 
during different manufacturing procedures resulting in the cleavage of VWF 
high-molecular-weight multimers. We used various assays to characterize the 
VWF content in FVIII preparations. Compared to other investigated prepa­
rations, Haemoctin SDH showed a higher ratio between the results of VWF 
antigen and collagen binding, and high-molecular-weight multimers were not 
detected, which facts both indicate that some proteolytic cleavage of VWF had 
occurred (Table 7). The highest VWF content was in product Koate-HP, 
showing a good correlation between the results of FVIIFC activity and 
VWF:Ag (r=0.94, p<0.05) and also between the results of VWF antigen and 
collagen binding assays (r=0.96, p<0.05). Factor VIII preparation Haemoctin 
SDH (Biotest) showed correlation only between the results of VWF:Ag and
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RCof activity (r=0.94, p<0.05). Factor VIII preparation Haemate had the ratio 
VWF:Ag/CBA 1.1, while for the lyophilized cryoprecipitate (Kryo-AHG) the 
ratio 1.4 ± 0.4 was found, which shows the presence of functional VWF in both 
products.
Table 6. Properties of the von Willebrand factor in different FVIII preparations. Multi­
merization is shown as the total number of multimers.
FVIII
preparation
FVIII :C 
IU/ml
VWF:Ag
IU/ml
VWFrRCo
IU/ml
VWF:CB
IU/ml
Ratio
VWF:Ag/
VWF:CB
Multi­
meri­
zation
Haemoctin 
SDH (Bio­
test) n=6
58.4 + 3.5 31.8 ±4.6 13.3 ±3.2 8.5 ± 1.9 4.0 ± 1.6 14
Koate-HP
(Bayer)
n=6
114.4 ±39.2 251.4 ±79.5 118.8 ±1.7 96.5 ±42.0 2.4 ± 0.4 16
Kryo-AHG 
(North Esto­
nian Blood 
Centre) n=6
8.5+ 2.2 12.2 + 3.1 8.4 ±1.7 10.2 + 3.1 1.4 ±0.4 16
Haemate
(Aventis)
n=l
47.6 89.1 85.5 81.8 1.1 17
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6. DISCUSSION
6.1. Inactivation of FVIII by antibodies, 
the protective effect of VWF
The results of our study indicate that the protective effect of the von Willebrand 
factor on the inhibition of the FVIILC activity by FVIII antibodies depends 
primarily on the concentration of antibodies specific of the light chain of FVIII. 
All 12 investigated samples contained antibodies targeted at both the light chain 
and the heavy chain of FVIII. We found that the samples with a higher amount 
of the FVIII-light-chain-specific antibodies caused a significantly lower 
inhibition of FVIIIrC activity in the presence than in the absence of VWF. 
Similar inhibition pattern of FVHLC by FVIII antibodies developed in haemo­
philia A patients using FVIII preparations of different purity has been observed 
in in vitro experiments also by several other investigators (Amano et al., 1995; 
Bemtorp et al., 1996; Gensana et al., 2001; Littlewood et al., 1991). The results 
of our study are well in line with the report by Suzuki et al. who has shown a 
lower inhibition of FVIII complexed with VWF by antibody samples that 
contained only C2-domain antibodies compared to the antibody sample 
containing C2- and A2-domain antibodies (Suzuki et al., 1996).
The VWF binding sites are located within the a3 and C2 domains of FVIII 
(Saenko and Scandella, 1997). The proper conformation of these regions and an 
intact thrombin cleavage site at the amino-acid position 1689-1690 of FVIII 
contribute to a high affinity binding to VWF (Saenko et al., 1999c). Recently it 
has been reported that the recombinant C1-C2 fragment binds to VWF at least 
2 orders of magnitude more strongly than the C2 domain alone (Liu and 
Thomson, 2000). The Cl-domain-specific antibodies are reported to interfere 
with the FVIII binding to VWF (Jacquemin et al., 2000). Several regions of the 
FVIII light chain participate in the interaction of FVIII with VWF, therefore we 
used the recombinant FVIII light chain in order to characterize a panel of FVIII 
antibodies, which could influence the binding of FVIII to VWF. On the other 
hand, VWF could hinder the binding of antibodies to FVIII by binding to their 
epitopes, by steric hindrance or by inducing such conformational changes as a 
result of which the respective epitopes are buried or are not recognized by 
antibodies any more.
Whether the presence of VWF in FVIII preparations is necessary or not has 
been under discussion since immuno-affinity chromatography was applied for 
the production of plasma-derived FVIII preparations of very high purity. 
Haemophilia A patients have a normal level of VWF and half of the adminis­
tered FVIII could bind to VWF in 10 seconds (Vlot et al., 1996). In order to 
mimic the in vivo situation, plasma samples containing FVIII antibodies were 
used in neutralization experiments allowing the complex formation between
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rFVIII and VWF of the patient’s plasma. Still, the FVIILC activity of the rFVIII 
preparation was more strongly inhibited by the patient’s antibodies than the 
activity of the FVIII-VWF concentrate. This could be caused by a looser 
complexing of VWF with rFVIII or easier dissociation of the formed complex 
compared to FVIII-VWF complexes present in respective concentrates. On the 
other hand, FVIII antibodies could have a higher affinity to FVIII than to VWF 
or may have complexed with FVIII faster than with VWF.
Although a small number of plasma samples was investigated, two samples 
out of 12 contained almost an equal amount of FVIII light chain and heavy 
chain antibodies and one plasma sample containing predominantly FVIII heavy 
chain antibodies. Our data are in good agreement with the results by Scandella 
and the co-workers who found that 2 out of the 10 investigated plasma samples 
had almost an equal amount of antibodies recognizing the A2 domain and the 
light chain of FVIII as judged by immuno-precipitation (Scandella et al., 
1995b). Apparently, the development of antibodies with an almost equal relative 
contribution to binding activity and neutralization activity towards both the light 
and the heavy chains of FVIII is not typical.
Comparison of the neutralization activity of FVIII antibodies towards the 
FVIII or FVIII-VWF complex and the estimation of the amount of FVIII 
antibodies targeted at the light chain of FVIII might be useful in order to select 
the most suitable FVIII preparation for the treatment of the patient and thereby 
contribute to the lowering of treatment costs. Characterization of the antibody 
response to the FVIII-VWF concentrate administered for the immune tolerance 
treatment was another aim of this study.
6.2. Characterization of the patient’s FVIII antibodies 
during immune tolerance treatment with FVIII 
preparation containing VWF
6.2.1. Epitope specificity of FVIII antibodies
Immune tolerance induction with the FVIII-VWF concentrate into a high 
responder patient TK (the Bethesda titer >5 BU/ml) resulted in a persistent 
production of antibodies targeted mainly at the light chain of FVIII analogously 
to the situation observed at the beginning of treatment. The concentration of 
inhibitory and non-inhibitory antibodies decreased significantly and in vivo 
recovery normalized at the end of treatment. The FVIII-light-chain-specific 
antibodies recognised mainly the Cl domain, but also the C2 domain, and a 
negligible amount of antibodies was targeted at the a3 domain. A significantly 
lower amount of antibodies recognized the FVIII heavy chain. Antibodies were
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targeted at the C-terminal parts of the Al domain and A2 domain (Figure 13). 
The heterogeneous antibody response like the one observed in the tested patient 
is generally characteristic of haemophilia A patients, while in the case of 
acquired haemophilia the antibodies are targeted at a smaller number of epi­
topes (Prescott et a l ., 1997). Antibody epitopes often localise within the C2 do­
main of the light chain or the A2 domain of the heavy chain of FVIII, which are 
believed to be the most immunogenic regions on FVIII (Fulcher et al., 1985; 
Scandella et al., 1989; Scandella et al., 2001).
To our knowledge, this is the first time when clinically significant 
Cl-domain specific antibodies have been detected in a severe haemophilia 
A patient. Rare presence of antibodies of such specificity has been demonstrated 
by using synthetic peptide arrays (Palmer et al., 1997). Recently a monoclonal 
Cl-domain-specific antibody 2E9, which interferes with the FVIII binding to 
VWF, has been obtained by the immortalization of B-lymphocytes of a patient 
with mild haemophilia A (Jacquemin et al., 2000). In order to compare the 
epitope specificity of the Cl domain antibodies developed in our patient with 
mAb 2E9, we used a competitive binding assay. The tested antibodies were not 
able to compete with mAb 2E9 for binding to FVIII, hence these antibodies 
probably possess a different specificity. On the other hand, mAb 2E9 was 
capable of inhibiting the interaction of FVIII with VWF, but patient TK’s anti- 
FVIII antibodies did not interfere with FVIII-VWF interaction. This corro­
borates the suggestion that the epitopes of these antibodies were not over­
lapping.
Epitope mapping of FVIII C2-domain antibodies showed that patient TK’s 
antibodies were targeted at both the N-terminus and C-terminus of the C2 
domain, since the patient’s antibodies were able to compete with monoclonal 
antibodies F29B10 (aa 2170-2195) and ESH4 (aa 2303-2332) for their binding 
sites on FVIII respectively. The binding of ESH4 (aa 2303-2332) to FVIII was 
abolished by the tested antibodies. Several reasons allow us to assume, that the 
Cl-domain-specific antibodies could also inhibit the ESH4 binding to FVIII. 
The disulphide bonds in the C2 domain (Cys2174-Cys2326) and in Cl domain 
(Cys2021-Cys2169) connect the N-terminal and C-terminal ends of domains in 
close proximity (Pratt et al., 1999; Stoilova-McPie et al., 2002) (Figure 13). 
Therefore, antibodies which were able to interfere with the mAb F29B10 
binding to FVIII could in principle also interfere with the binding of ESH4 to 
FVIII. Factor VIII fragment 2303-2332, the putative binding site of ESH4, 
contains (3 strands 18 and 19 of the C2 domain, which localize opposite the Cl 
domain. This part of the C2 domain participates in the FVIII binding to PL, 
being one of the four different loops of the C2 domain (aa 2222-2227, 2196— 
2201, 2313--2315, and 2249-2255) that are shown to be involved in interaction 
with the negatively charged phospholipids’ head groups (Barrow et a l ,  2001; 
Spiegel et al., 2001). Unfortunately, the epitope of ESH4 is not precisely map­
ped. Probably ESH4 could induce conformational changes of the C2 domain 
and abolish further interactions of FVIII with VWF or PL. The patient’s
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antibodies, particularly the Cl-domain-specific antibodies, however, interfered 
with the FVIII binding to ESH4 probably by steric hindrance or by inducing 
conformational changes, but had no inhibitory effect on FVIII-VWF and FVIII- 
PS interactions.
Although we could detect antibodies recognizing the C-terminus of the 
C2 domain and a3 domain, the tested antibodies were neither able to interfere 
with the FVIII binding to VWF nor to compete with monoclonal antibodies 
B02C11 and 2E9, which are both able to interfere with this interaction 
(Jacquemin et al., 2000; Spiegel et al., 2001). This suggests that VWF present 
in the FVIII preparation used for the immune tolerance treatment could bury the 
respective immunogenic regions on the FVIII surface and thereby prevent the 
development of antibodies towards those epitopes (Figure 14). This result is in 
accordance with the observation reported by Prescott, who characterized the 
differences in antibody epitope specificity in patients treated with pdFVIII or 
rFVIII preparations (Prescott et al., 1997). Antibodies against the a3-A3-Cl 
fragment were three-fold more common in the group of patients treated with 
pdFVIII than the patients treated with the rFVIII preparation, while the 
development of antibodies recognizing the A2 domain and/or the C2 domain 
was a characteristic response to the rFVIII treatment (Prescott et al., 1997).
Some of patient TK’s antibodies were targeted at the Al and A2 domains of 
the FVIII heavy chain. Monoclonal antibody mAbl5 (aa 720-740) binding site 
on FVIII is often a target of A2 domain antibodies developed in haemophilia A 
patients (Gilles et al., 1993; Gilles, et a l ,  1996). The A1-domain-specific anti­
bodies are rare, although by using synthetic peptide arrays a small fraction of 
antibodies recognizing region 20-349 has also been found in haemophilia A 
patients (Palmer et al., 1997). Patient TK antibodies were able to interfere with 
the binding of mAb F7B4 (aa 356-360) to FVIII. Region 337-372 is exposed 
on the surface of both the FVIII activated and inactivated form (Amano et al., 
1998a; Pemberton et al., 1997; Stoylova et al., 1999), which could explain why 
this region was also a target for antibodies developed in the tested patient.
It has been shown earlier that during the immune tolerance treatment the 
epitope specificity of anti-FVIII antibodies is changing. Immunoblotting of 
FVIII and its thrombin-cleaved fragments that was used for the characterization 
of the specificity of FVIII antibodies demonstrated the changes in the epitope 
specificity in five haemophilia A patients out of 13 (Fulcher et al., 1988). The 
changes in the concentration of antibodies recognizing the A2 domain of FVIII 
were observed in most of these patients. In our study we used recombinant 
FVIII fragments, which enabled us a more exact characterization of the changes 
in antibody specificity. In our patient antibody epitope specificity remained 
rather unchanged throughout the immune tolerance treatment, except an 
increase in C2-domain-specific antibodies caused by the interruption of 
treatment. However, the concentration of inhibitory and non-inhibitory FVIII 
antibodies decreased significantly. This result is in agreement with a previous 
study by Gilles and co-workers, where no changes in the profile of antibody
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Figure 13. Model o f membrane-bound FVIII and putative binding sites and the relative 
amount of patient TK's FVIII antibodies. Antibodies targeted at different domains o f FVIII 
are coloured respectively. Putative location of the a3 domain and VWF bound to FVIII are 
indicated. Adapted from Stoilova etal., 2001, courtesy of Geoffrey Kemball-Cook.
Figure 14. Model for the membrane-bound FVIII-FIXa complex and the putative location 
of binding sites of patient TK's FVIII antibodies. Adapted from Stoilova-McPhie et a l, 
2002, courtesy of Geoffrey Kemball-Cook.
specificity were observed in the course of the immune tolerance treatment in 2 
patients, except the changes in FVIII antibody concentration (Gilles et al.,
1996). They observed that successful desensitization led to the production of 
anti-idiotypic antibodies in both patients. A fair relationship was reported 
between FVIII administration and the following increase in the concentration of 
anti-idiotypic antibodies (Gilles et a l ,  1996). We observed a significant dec­
rease in the Bethesda titer after 2 weeks of treatment, while no change in anti- 
FVIII antibody concentration was detected, which could also be due to the 
development of anti-idiotypic antibodies. Unfortunately, we could not study the 
presence of anti-idiotypic antibodies in our patient because of the limited 
volume of the investigated plasma samples collected for our investigation.
To our knowledge, this is the first detailed characterization of the antibody 
response during the immune tolerance treatment although the antibody response 
has been described only in a single patient treated according to an uncommon 
treatment protocol. Usually, the amount of antibodies is determined by the 
Bethesda assay and in some studies the samples taken during treatment have 
also been characterized by immunoblotting with FVIII (Fulcher et al., 1985; 
Fulcher et al., 1987) or by the immunoprecipitation assay with recombinant 
FVIII fragments (Klinge et al., 2001; Scandella et al., 1988; Scandella et al., 
2000). Interruption of the treatment and a subsequent increase and decrease in 
FVIII antibody production allowed us to compare the situation with the one at 
the beginning of treatment. Although the titer of inhibitory and non-inhibitory 
antibodies increased after the second continuous infusion, no significant 
changes in epitope specificity were observed, except a slightly elevated level of 
the C2-domain-specific antibodies and antibodies that were able to compete 
with mAb ESH4 for binding to FVIII. However, the FVIII binding to VWF or 
PL was not interfered by these FVIII antibodies. An increase in the C2 domain 
antibody level suggests that the patient had a tendency to produce antibodies of 
such specificity, but their production was suppressed by the administration of 
the FVIII-VWF concentrate. The sample taken several months before the 
immune tolerance treatment from the same patient contained predominantly the 
FVin light chain antibodies. Their inhibitory activity towards FVIII complexed 
to VWF was 14.5-fold lower than towards FVIII itself (Table 5, Patient 2). It is 
generally believed, that C2-domain antibodies capable of interfering with the 
FVIII-VWF binding are responsible for a lower neutralization ability in the 
presence of VWF (Shima et al., 1995b; Suzuki et al., 1996). We were unable to 
characterize antibodies in a this particular sample in a more detailed manner, 
but apparently the concentration of the C2-domain-specific antibodies was 
significantly higher and the epitope specificity differed from FVIII antibodies 
produced during the immune tolerance treatment. Therefore, minor changes in 
antibody epitope specificity during treatment were probably caused by the 
administration of this particular FVIII-VWF concentrate.
Our patient has an inversion in intron 22 of the FVIII gene, which is the 
most common gene defect in a severe form of haemophilia A. This gene defect
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abolishing the synthesis of FVIII protein, is usually accompanied by a higher 
prevalence of the FVIII antibody development (Schwaab et al., 1995b; 
Tuddenham and McVey, 1998; Antonarakis et al., 1995; Tuddenham et al., 
1991). Characterization of antibodies developed in these patients has shown a 
wide variety of epitopes with no prevalence of any binding site either on the 
heavy or the light chain of F VIII (Scandella et al., 2001).
6.2.2. The IgG subclass distribution of FVIII antibodies
Inhibitory and non-inhibitory FVIII antibodies of the IgG4 subclass dominated 
during the whole immune tolerance treatment of patient TK, but the FVIII light 
chain antibodies of all IgG subclasses were expressed at an almost equal level, 
except the IgG2 subclass. The subclass distribution of FVIII light-chain anti­
bodies during ITT differed from that of the patients with persistent inhibitory 
antibodies possessing mainly the IgG4 subclass FVIII-light-chain-specific anti­
bodies (Table 6). However, the results of our study are in good agreement with 
the data published earlier, which report that the on-demand treatment of 
haemophilia A patients causes the development of the IgGl or IgG4 subclass 
FVIII antibodies mainly (Algiman et al., 1992; Fulcher et al., 1987).
We detected the elevated IgGl subclass levels of FVIII antibodies at two 
different time points during treatment. Both increased levels of IgGl subclass 
antibodies were observed after the administration of a higher dosage of the 
FVIII preparation, indicating the presence of a novel clone that produces FVIII 
antibodies with a different epitope specificity or affinity. The level of IgGl 
subclass antibodies rises quickly after antigen administration, while the pro­
duction of the IgG4 subclass probably needs more support on the part of 
cytokines produced by Th2 cells (Mosmann et al., 1986).
This observation was supported by the results of the epitope mapping of 
FVIII antibodies. The first rise in the IgGl subclass FVIII antibodies was 
accompanied by elevated levels of the Cl domain antibodies and antibodies that 
were able to compete with mAb F29B10 for their binding sites on the C2 
domain. The second rise in the IgGl subclass level of FVIII antibodies was 
obviously caused by the interruption and resumption of treatment and reflected 
probably the increased concentration of the A2-domain-specific antibodies, 
which were able to compete with mAb 15 for the binding site on FVIII. 
Although an increase in the C2-domain-specific antibody level was also 
observed at the same time point, we found no significant increase in FVIII light 
chain antibodies of the IgGl subclass. It might be that the C2-domain-specific 
antibodies belonged to the IgG4 subclass. Unfortunately, we were unable to 
detect the IgG distribution of C2-domain-specific antibodies due to a limited 
plasma volume.
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The results of our study are in agreement with the results obtained in the 
mouse haemophilia A models, where the IgGl subclass (corresponds to human 
IgG4) FVIII antibodies dominate (Rossi et al., 2001; Sasgary et al., 2002; Wu et 
al., 2001). Rossi with the co-workers found that the distribution of FVIII 
antibodies into IgG subclasses correlated well with the results of cytokine 
assays indicating that the antibody response is very complex and might involve 
both Thl and Th2 type cells and is especially dependent on the production of 
IL-10 (Rossi et al., 2001). A recent report by Sasgary et al suggested that the 
IFN-y producing cells were most prominent, but decreased along with the 
increase in number of IL-10 producing FVIII-specific T cells (Sasgary et al., 
2002). They also observed the presence of two types of IL-10-positive cells; the 
first produced only IL-10 and the second produced, in addition to IL-10 also 
IFN-y (Sasgary et al., 2002). IFN-y is known to support the production of the 
IgG2a subclass and inhibit the production of IgGl subclass antibodies in mice. 
Based on that we assume that the antibody response in the tested haemophilia 
A patient was determined by the dominance of IFN-y producing cells or IL-10 
producing cells at different time points during the immune tolerance treatment, 
which was also reflected in the changes in IgG subclass levels.
A very recent study reported that the concentration of FVIII antibodies in 
haemophilia A patients may poorly correlate with a proliferative response to 
FVIII of their CD4+ blood lymphocytes (Reding et al., 2002). A response to 
FVIII by CD4+ lymphocytes of healthy donors was somewhat lower and tran­
sient as compared to haemophilia A patients with and without FVIII antibodies. 
But CD4+ lymphocytes of the patient who was tolerated to FVIII did not 
respond to FVIII at all (Reding et al., 2002). The normal level of FVIII in 
healthy persons may induce anergy or apoptosis of FVIII-specific CD4+ cells, 
when FVIII epitopes are presented without co-stimulatory signals (Johnson and 
Jenkins, 1994; Schwartz, 1996). We were unable to study the proliferation of 
FVIII-specific CD4+ cells of our patient during treatment, although we could 
suppose that the activated FVIII-specific CD4+cells persisted rather long, 
especially when the level of FVIII in plasma was low and transient and not 
sufficient to sustain the persistent toleration of CD4+ cells. Probably, in 
haemophilia A patients such FVIII-specific CD4+ cells have not been 
eliminated during ontogenesis of the immune system due to the absence of 
FVIII and, therefore, a higher level of FVIII is needed for successful toleration. 
However, information about the role of different cytokines producing CD4+ 
cells in a FVIII antibody response and in the toleration of haemophilia A 
patients is rather limited and further studies are needed.
6.3. Inhibition of FVIII: C activity by the patient’s 
antibodies, the putative mechanism
The antibodies of patient TK recognized mainly the FVIII light chain and were 
unable to interfere with the FVIII binding to PS or to VWF, but on the other 
hand they inhibited FXa generation and the FX binding to FVIII. These results 
are rather different from a well-characterized inhibitory effect of FVIII anti­
bodies developed in most patients, since FVIII-light-chain-specific antibodies in 
general are able to block the binding of FVIII to VWF or to PS (Saenko and 
Scandella, 1995; Shima et al., 1995b; Shima etal., 1993).
Patient TK’s antibodies inhibited FXa generation induced by FVIII or by its 
light chain. The generation of FXa involves successive processes starting with 
the FVIII binding to PS and the FlXa binding to FVIII, followed by the 
interaction of FX with the formed complex. FlXa binding to FVIII takes place 
at three sites: two within the A2 domain (aa 558-565 and aa 698-710) that have 
been found to be responsible for the binding to the FlXa heavy chain (Fay et al., 
1994; Lenting, et al., 1998) and the third region within the A3 domain 
(aa 1811-1818) that binds to the FlXa light chain (Lenting et al., 1996). The 
tested antibodies recognised the C-terminus of the A2 domain, which obviously 
contributes to the FVIII binding to FlXa. Unfortunately, we were not able to test 
the effect of the patient’s antibodies on the FlXa binding to FVIII because of 
our limited sample volume. The concentration of A2-domain-specific antibodies 
as well as the inhibitory activity of FVIII heavy chain antibodies were 
significantly lower than that of the FVIII light chain antibodies, therefore the 
hindrance of the FlXa binding to FVIII was probably not the main mechanism 
of the inhibition of FXa generation. In addition, FX generation induced by the 
FVIII light chain was also inhibited by the patient’s antibodies indicating that 
FVIII light chain antibodies were mainly responsible for interfering with FXa 
formation, pointing to a novel, yet unknown mechanism of the inhibition of 
FVIILC activity by FVIII light chain antibodies specific of the Cl domain.
The patient’s antibodies were capable of interfering with the FX interaction 
with FVIII on the phosphatidylserine layer. FVIII-light-chain-specific anti­
bodies were responsible for that effect as the FX binding to the FVIII light 
chain on PS was also impaired by the patient’s antibodies. We found that 
C2-domain-specific antibodies ESH4 and B02C11 were also able to inhibit the 
FVIII interaction with FX. However, since both of these antibodies interfere 
with the FVIII binding to PS, we used another strategy, coupling first FVIII to 
an antibody on the microplates, but unfortunately, FX was unable to bind to the 
formed complex. Obviously, ESH4 is able to induce such a conformation 
change in the FVIII C2 domain that FVIII was not able any more to bind to 
VWF or to PS and the interaction with FX was also abolished. Surprisingly, we 
encountered an analogous inhibition of the FVIII binding to FX by using mAb 
B02C11, which is shown to interact with the PS binding site of the C2 domain
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(aa 2251-2252, 2199-2200). The C2-domain-specific antibodies (ESH4, 
B02C11) and Cl-domain-specific antibodies of the tested patient were able to 
interfere v/ith the FVIII binding to FX, confirming that the conformation of the 
FVIII light chain as well as the distance between the binding sites of FVIII and 
FX are extremely important for efficient interaction. Nogami with the co­
workers has studied the role of the FVIII C2 domain in the FVIII interaction 
with FXa (Nogami, 2002; Nogami, et al., 1999). They showed that monoclonal 
antibody ESH8 (aa 2248-2285, non-competitive with ESH4 used in our 
experiments) abolished proteolytic cleavage at Argl689 and Argl721 of the 
light chain of FVIII by FXa and partially inhibited cleavage at Arg372 of the 
heavy chain of FVIII both in the presence and absence of PL. Another mAb 
NMC-VIII/5 (aa 2170-2337) had no protective effect and on the contrary, even 
tended to promote cleavage by FXa. VWF was also able to protect FVIII against 
proteolytic activation by FXa. It was demonstrated with synthetic peptides that 
amino acids 2253-2270 within the C2 domain are essential for FXa binding. 
Since ESH8 did not interfere with the FVIII binding to PL, they suggested that 
the FXa binding site should be within the N-terminal of the C2 domain 
(Nogami, 2002; Nogami et a l ., 1999). Probably the FX and FXa binding sites 
on FVIII are not completely overlapping. The tested patient’s antibodies were 
targeted at the N-terminus of the C2 domain and were able to hinder the FVIII 
binding to FX but were not interfering with the FVIII binding to PL. Therefore 
the patient’s antibodies could also interfere with the FXa binding to FVIII. 
Since the tested antibodies were a mixture of C2 domain antibodies and 
antibodies against other epitopes within the light chain and heavy chain of 
FVIII, the mechanism of inhibiting FVIII coagulation activity by every antibody 
in this mixture has in principle to be investigated by using monoclonal 
antibodies against the same epitope as the patient’s antibodies. However, the 
properties of FVIII antibodies in haemophilia A patients vary in the course of 
therapy in their affinity, concentration, epitope specificity, neutralization 
mechanism, etc. and often only the major traits can be characterized.
So far little is known about the function of the Cl domain in FVIII. Liu and 
Thompson have reported that compared to the C2 domain alone, C1-C2 
fragment has a higher binding affinity to VWF, FX/FXai and FIX/IXai (Liu and 
Thomson, 2000). They also reported that the VWF binding site was different 
from and not overlapping with the binding sites for FX/Xai and FIX/IXai, 
however, FX and FIX were competing for the binding site within C1-C2 
fragment (Liu and Thomson, 2000). The patient’s antibodies were unable to 
interfere with the FVIII binding to a Cl-domain-specific monoclonal antibody 
2E9, which interferes with the FVIII binding to VWF. However, the patient’s 
antibodies were capable of impairing the FVIII binding to FX. These findings 
are in good accordance with the results obtained by Liu and Thompson, 
showing that different regions of the Cl domain are involved in FVIII-VWF 
and FVIII-FX interactions.
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The patient’s antibodies recognized the Al domain and were able to compete 
for the binding site on FVIII with mAb F7B4 (aa 356-360), therefore the 
Al domain antibodies were obviously also able to interfere with the FX binding 
to FVIII. It has been shown that, human antibodies directed to the epitope of 
amino-acids 338-362 (Ware et al., 1988) or to the epitope of amino-acids 
351-361 within the Al domain interfere with the FVIII binding to FX (Foster et 
a l ,  1990a). On the other hand, amino-acids 337-372 of the al domain are 
suggested to participate in the interaction of FVIII with FX (Lapan and Fay,
1997). Therefore, A1-domain-specific antibodies of the tested patient could 
inhibit the interaction FVIII-FX by covering FX binding site on the al domains. 
The IgG concentrations needed for the inhibition of the FVIII binding to FX or 
the FVIII light chain binding to FX were slightly different, thus indicating that 
A1-domain-specific antibodies were also involved in the inhibition of this 
interaction. However, the inhibitory effect of FVIII light chain antibodies 
dominated.
Two types of antibodies can be distinguished by the inhibitory character of 
FVIILC activity in haemophilia A patients (Biggs et al., 1972a; Biggs et al., 
1972b; Gawryl and Hoyer, 1982; Ling et al., 2001). Patient TK’s antibodies 
inhibited FVIILC activity incompletely even at very high antibody concentra­
tions, and we observed a non-linear relationship between FVIII: C activity and 
antibody concentration. Analogous inactivation pattern was observed when the 
patient’s antibodies were pre-incubated with the recombinant FVIII light chain 
and the ability of the remaining antibodies to neutralize FVIILC activity was 
measured by the chromogenic method (Figure 5) and also by the FXa gene­
ration assay. Therefore, we can conclude that FVIII light chain antibodies were 
mainly responsible for Type 2 inhibition pattern of FVIILC, which has also 
been reported by other investigators (Peerlinck et al., 1997). However, 
FVIII-light-chain inhibitory antibodies with the Type 2 inactivation pattern are 
usually targeted at the C2 domain and interfere with the FVIII binding to VWF 
and to PS (Peerlinck et al., 1997; Sawamoto et al., 1998).
6.4. Characterization of the von Willebrand factor 
content in FVIII preparations
The amount and the functional activity of VWF was characterized in various 
FVIII preparations including Haemoctin SDH, which was used in in vitro 
neutralization experiments as a source of the FVIII-VWF complex and also for 
the immune tolerance treatment. Haemoctin SDH had a higher ratio between the 
results of the VWF antigen and collagen binding compared to other investigated 
preparations, and high-molecular-weight multimers were absent in Haemoctin 
SDH. This indicates that the proteolytic degradation of VWF occurred in the
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course of the manufacturing process. Our data are in good agreement with the 
results obtained by Kotitchke and his co-workers: VWF collagen binding of 
about 12 IU/ml and the ratio of VWF:Ag to VWF:CB being 4.1 (Kotitschke 
et al., 1999).
Despite the lack of high- molecular-weight multimers and the increased level 
of intermediate- and low-molecular weight multimers, VWF in this particular 
preparation was able to protect FVIII:C inactivation caused by FVIII antibodies 
in in vitro experiments. Presumably, the multimerization of VWF is necessary 
for an efficient binding of VWF to the platelet Gp Ib-IX-V receptor complex 
and integrin a ubP3 for the induction of platelet adhesion and aggregation, 
respectively. On the other hand, the multimerization of VWF is not obligatory 
for the complexing with FVIII, its protection and stabilization, since each VWF 
monomer has a FVIII binding site and can therefore bind to FVIII (Vlot et al., 
1996). By using the platelet function analyzer, PFA-100, platelet adhesion to 
the collagen surface was studied, and the authors concluded that FVIII 
preparations of high purity and intermediate purity lacking high-molecular- 
weight multimers were also able to promote platelet adhesion in a dose- 
dependent manner upon the flow at high shear stress (Siekmann et al., 2002). 
These results can explain why these concentrates are effective in treating 
haemorrhages in VWD Type 3 patients, although without correcting the 
prolonged bleeding time (Rodeghiero et al., 1992).
We investigated the VWF binding to collagen by an ELISA assay, which 
measures the ability of VWF to bind to collagen in static conditions. As repor­
ted by us and other investigators, the source and the concentration of collagen, 
and some more parameters are critical for an effective VWF binding to collagen 
(Favaloro 2000; Favaloro et al., 2000; Siekmann et al., 1998). The measuring of 
ristocetin cofactor activity of VWF (VWF:RCo) enables researchers the cha­
racterization of VWF-mediated platelet-platelet interaction and quantifies the 
level of intermediate- and high-molecular-weight multimers (Favaloro, 1999; 
Favaloro, 2001). An optimised VWF collagen binding (VWF:CB) assay esti­
mates the amount of the largest VWF multimers, which have the highest 
functional activity. Although the VWF:CB assay is recommended for use by 
European Pharmacopoeia (European Pharmacopoeia, 2001), a potential official 
European Pharmacopoeia assay for the characterization of VWF in factor VIII 
preparations is still under development (Neugebauer et al., 2001). Therefore, we 
designed a respective ELISA for the characterization of VWF composition in 
FVIII preparations. The optimal collagen III concentration (10 (Ig/ml) in the 
assay enabled us to lower of the variation coefficient (4.8% for normal values), 
to discriminate well between different types of VWD and fairly correlate 
between the values of VWF:CB and VWF multimers in the VWD patients’ 
plasmas as well as in FVIII preparations. Ramasamy with the co-workers 
showed the applicability of the VWF:CB assay for the characterization of VWF 
in the course of a small-scale manufacturing process of the preparation. They 
used collagen Type I in the assay and the assay had the coefficient of variance
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12.5% for normal values (Ramasamy et al., 1998). Results of the multi­
laboratory characterization of VWF in different FVIII preparations including 
Haemate P (Aventis Behring, USA), showed results similar to our findings 
(Favaloro et al., 2002).
Analogously to other investigators, we used a local plasma standard, which 
was calibrated against the VWF:RCo activity of the WHO plasma standard, 
because the VWF:CB values were not available at that time and the VWF:RCo 
activity was the only well-characterized functional activity of VWF (Casonato 
et al., 2001; Favaloro et al., 2000; Siekmann et al., 1998). Recently the National 
Institute of Biological Standards and Controls (NIBSC, UK) has completed an 
international study on the measuring of VWF:CB in one of its international 
plasma standards and in the proposed WHO 1st International Standard for FVIII 
preparations containing VWF (Montgomery, 2001). Both these standards will 
be available in the near future and improve the standardization of the VWFrCB 
assay.
In principle, the FVIII preparation containing VWF, is of a lower price as 
compared to the FVIII preparations of a very high purity obtained by immuno- 
affinity chromatography. The cost of treatment is always considered to be 
important, especially that of the immune tolerance treatment. The cost of FVIII 
preparations accounts for 80-90% of the total ITT costs (Colowick et al., 2000). 
After a change of the FVIII preparation of a very high purity to the FVIII-VWF 
concentrate used for achieving tolerance in haemophilia A patients with FVIII 
antibodies, resulted in successful immune tolerance in several patients as repor­
ted by Kreuz and co-authors (Kreuz et al., 1995b). According to the results 
obtained in our study, the screening of FVIII antibodies for their neutralization 
activity against FVIII and FVIII-VWF, the estimation of the amount of the 
FVIII light chain antibodies and the information about the functional activity of 
VWF in a particular preparation helps with the in optimization of treatment and 
especially with choosing the most appropriate FVIII preparation in order to 
achieve a better outcome.
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7. CONCLUSIONS
The results of the present study allow us to conclude the following:
1. The von Willebrand factor complexed with FVIII is able to counteract the 
inhibition of the FVIII coagulation activity by antibodies that are targeted at 
the light chain of FVIII. The concentration of the FVIII-light-chain-specific 
antibodies determines to which extent the inhibition of the FVIII coagulation 
activity by these antibodies is reduced in the presence of VWF (FVIII-VWF 
complex) compared to FVIII itself.
2. Proteolytic degradation of VWF high-molecular-weight multimers in the 
FVffl preparation does not affect the protective effect on the FVIILC activity 
by masking the epitopes on FVIII antibodies.
3. The administration of the FVIII-VWF concentrate for immune tolerance 
treatment led to the development of a unique pattern of FVIII antibody 
specificity: antibodies were targeted mainly at epitopes exposed on the 
surface of the FVIII-VWF complex. Factor VIII light chain antibodies 
(Cl-domain-, C2-domain-specific) dominated during the whole treatment 
period, and these antibodies were unable to interfere with the FVIII binding 
to VWF.
4. The immune tolerance treatment caused no significant changes in epitope 
specificity, although the concentration of inhibitory and non-inhibitory 
antibodies decreased significantly in the course of treatment. The interrup­
tion of treatment resulted in an increased FVIII antibody production with 
different epitope specificity.
5. FVIII-specific IgG antibodies with inhibitory and non-inhibitory activity 
were mainly of the IgG4 subclass. A change in the IgG subclass distribution 
of FVIII antibodies, particularly an increase in the IgGl subclass antibody 
levels was accompanied by a change in the production of FVIII antibodies 
with different epitope specificity or affinity.
6. The patient’s antibodies that were targeted mainly at the light chain of FVIII 
were unable to interfere with the FVIII binding to PL or to VWF. However, 
these antibodies interfered with FXa generation by inhibiting the FX binding 
to FVIII, which is a novel so far undescribed mechanism of FVIII antibodies 
in inhibiting the FVIILC activity.
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7. The binding sites of FVIII for VWF and for FX within the Cl domain of the 
light chain are different, hence the patient’s antibodies targeted mainly at the 
Cl domain of FVIII were able to interfere with the FVIII binding to FX, but 
unable to inhibit the FVIII binding to VWF. Therefore, the patient’s anti­
bodies were unable to compete for binding to FVIII with the Cl-domain- 
specific monoclonal antibody 2E9 (University of Leuven, Belgium), which 
inhibits the FVIII binding to VWF.
8. The well-characterized monoclonal C2-domain-specific antibodies ESH4 
(American Diagnostica, USA) and B02C11 (University of Leuven, 
Belgium) in addition to their ability to interfere with the FVIII binding to 
PL and VWF, can also block the binding of FX to FVIII. This suggests that 
the FVIII-light-chain-specific antibodies can inhibit the FVIII coagulation 
activity by different mechanisms, and that the light chain of FVIII parti­
cipates in several different interactions of FVIII with other components of 
the coagulation cascade.
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VIII HÜÜBIMISFAKTORI VASTASED 
ANTIKEHAD HEMOFIILIA A HAIGETEL
Kokkuvõte
Hemofiilia A on pärilik kaasasündinud vere hüübimishäire, mis on tingitud VIII 
hüübimisfaktori geeni mutatsioonist, põhjustades mittefunktsionaalse hüübimis- 
faktori sünteesi või täieliku puudumise. VIII hüübimisfaktori geen asub 
X kromosoomi pikas õlas ning seetõttu on haigus peamiselt meestel sagedusega 
1:5000 (Larsson, 1984). Sõltuvalt VIII hüübimisfaktori koagulantsest aktiivsu­
sest ja kliinilistest sümptomitest eristatakse rasket (FVIII koagulantne aktiivsus, 
FVIII:C 1 IU/dl), keskmist (FVIII:C 1-5 IU/dl) või kerget (5-40 IU/dl) hemo­
fiilia A vormi. 35% raske hemofiilia A juhtumitest on põhjustatud inversioonist 
FVIII geeni 22 intronis, mis on kõige sagedasem geenidefekt (Antonarakis 
et al., 1995). Spontaansete ja traumajärgsete veristuste ravi seisneb puuduva
VIII hüübimisfaktori asendamises eksogeensega. Tänapäeval on kasutada nii 
plasmast fraktsioneeritud kui rekombinantse DNA meetodil valmistatud FVIII 
kontsentraadid, mille õigeaegne manustamine peatab verejooksu ja parandab 
tunduvalt haige elu kvaliteeti. Siiani on raskeimaks komplikatsiooniks VIII 
hüübimisfaktori manustamisel tema aktiivsust inhibeerivate antikehade teke ligi 
25% hemofiilia A haigetest (Scharrer and Neutzling, 1993). Vastavate anti­
kehade tekke põhjused on siiani teadmata, kuid nende olemasolul on veritsuse 
peatamine komplitseeritud. Antikehad VIII hüübimisfaktori vastu tekivad 
sagedamini just raske hemofiilia A korral (kuni 60%-l haigetest (Kemball-Cook 
and Tuddenham, 1997)), tavaliselt esimese 5 eluaasta jooksul ning 9-15 
manustamispäeva järel (Scharrer and Neutzling, 1993). Faktor VIII antikehade 
tekke sageduse ja asendusteraapias kasutatava preparaadi puhtusastme vahel 
seni seost leitud ei ole (Scharrer and Neutzling, 1993), välja arvatud kahe 
kontsentraadi korral, mille tootmisprotsessis kasutati pastöriseerimist viiruste 
inaktiveerimiseks, mis seetõttu põhjustasid FVIII antikehade tekke ka eelnevalt 
ravitud haigetel (Laub, et al., 1999; Peerlinck, et al., 1997; Peerlinck et al., 
1993b). Tootmisprotsess võib mõjutada FVIII omadusi ja aktiivsust ning 
seetõttu on tähelepanu pööratud FVIII füsioloogilisele stabiliseerijale, von 
Willebrandi faktorile (VWF). Vereplasmas moodustab von Willebrandi faktor 
kompleksi VIII hüübimisfaktoriga, kaitstes teda enneaegse aktivatsiooni ja 
sellele järgneva inaktivatsiooni eest. VWF juuresolekul ei seondu FVIII memb­
raani fosfolipiididega (veresoone vigastuskohal), samuti on inhibeeritud inter­
aktsioon aktiveeritud IX hüübimisfaktoriga ning aktiveeritud X faktor ei saa 
lõhustada ega aktiveerida VIII hüübimisfaktorit. Samal ajal VWF aga ei takista 
FVIII aktiveerimist trombiiniga, millele järgnevad FVIII molekuli konfor- 
matsioonilised muutused võimaldavad mitmesuguseid interaktsioone, mis 
omakorda kiirendavad trombiini teket ja stabiilse fibriinivõrgustiku moodus­
tumist vigastuskohale. Faktor VIII juuresolekul on FX generatsioon 500 korda
1 1 0
efektiivsem kui selle puudumisel (Mertens et al., 1985). Aminohapete homo- 
loogia põhjal saab VIII hüübimisfaktoris eristada järgmisi domeene: Al-al-A2- 
a2-B-a3-A3-Cl-C2. FVIII antikehad tekivad kõige sagedamini A2 domeeni 
vastu raskes ahelas (A1-A2-B) ja C2 domeeni vastu kerges ahelas (A3-C1-C2) 
(Scandella, et al., 2001). Antikehi, mis seonduvad FVIII molekuli Al domeeni 
või A3-C1 domeeniga on kirjeldatud harva (Palmer et al., 1997; Prescott et al., 
1997; Shibata et al., 2000). Von Willebrandi faktori seondumiskoht asub FVIII 
kerges ahelas, C2 domeenis ja a3 domeenis (Saenko and Scandella, 1997; 
Saenko et al., 1994). Seetõttu inhibeerivad vastavad antikehad FVIILC aktiiv­
sust, takistades FVIII seondumist VWF-ga ja/või fosfolipiididega (Saenko and 
Scandella, 1995; Shima et al., 1993). Võiks arvata, et FVIII kontsentraadis olev 
VWF on võimeline neutraliseerima FVIII antikehade inhibeerivat toimet ning 
madala antikehade tiitri korral oleks hea kasutada veritsuse peatamiseks haigel 
eelkõige FVIII-VWF kompleksi sisaldavaid kontsentraate. Immuuntolerantsuse 
kujundamisel on selliseid kontsentraate edukalt rakendatud (Scharrer et al.,
1999), samal ajal on olnud tulemuslik ka rekombinantsete preparaatide kasuta­
mine, mis ei sisalda VWF (Batlle et al., 1999; Rothschild et al., 1998). On 
oluline märkida, et seni ebaefektiivse immuuntolerantsuse ravi jätkamine neljal 
hemofiilia A haigel VWF-i sisaldava kontsentraadiga andis hea tulemuse 
(Kreuz et al., 1995b). Sellest võib järeldada, et ravi efektiivsus sõltub oluliselt 
kasutatavast FVIII preparaadist ja sellest, millise FVIII piirkonna vastu on haige 
antikehad tekkinud.
Uurimuse eesmärgid
Lähtuvalt eespool toodust olid uurimuse esmärgid järgmised.
• Uurida, kas VWF on võimeline kaitsma VIII hüübimisfaktori aktiivsust 
antikehade inhibeeriva toime eest in vitro.
• Iseloomustada VIII hüübimisfaktori vastaste antikehade epitoobispetsiifi- 
lisust ja IgG subklasse ning muutusi immuuntolerantsuse ravi käigus hemo­
fiilia A haigel, keda raviti FVIII-VWF kontsentraaadiga.
• Uurida FVIII antikehade toimemehhanismi FVIII koagulantse aktiivsuse 
inhibeerimisel.
• Iseloomustada VWF funktsionaalset aktiivsust FVIII kontsentraatides, mida 
kasutati in vitro ja in vivo uurimustes.
Uuritavad ja meetodid
FVIII antikehade inhibeerivat toimet VWF juuresolekul uuriti hemofiilia
A haigete plasmaproovides (n=12), mis sisaldasid FVIII kerge ja raske ahela
vastaseid antikehi. Antikehade epitoobispetsiifilisust ja selle võimalikke
muutusi uuriti plasmaproovides, mis olid võetud hemofiilia A haigelt immuun- 
tolerantsuse ravi jooksul. FVIII antikehade sisalduse ja omaduste iseloomusta­
miseks plasmaproovides kasutati Bethesda meetodit ja immunoloogilisi meeto­
deid. Antikehade epitoobispetsiifilisuse määramiseks tarvitati rekombinantseid 
FVIII raske ja kerge ahela fragmente ning GST-liitvalke FVIII erinevate 
domeenidega (Al, A2, al, a3, A3, Cl, C2) ja meetodina konkureerivat seondu­
mist monoklonaalsete FVIII antikehadega, mille seondumiskoht FVIII mole­
kulis oli teada. Antikehade toimemehhanismi uurimisel rakendati ELISA 
meetodit (FVIII seondumine VWF-le või fosfolipiididele) ja kromogeenset 
meetodit FXa hulga määramiseks. Von Willebrandi faktori iseloomustamiseks 
FVIII kontsentraatides määrati von Willebrandi faktori antigeeni sisaldus 
(ELISA), kollageeniga seondumise võime (ELISA), multimeersuse aste (Wes­
tern blot) ja võime indutseerida trombotsüütide agregatsiooni antibiootikum 
ristotsetiini juuresolekul (agregomeetriline meetod).
Uurimuse tulemused
Uurimuse tulemusel ilmnes, et VWF juuresolekul inhibeerisid antikehad 
FVIILC aktiivsust vähem kui VWF puudumisel. Eriti märgatav erinevus ilmnes 
siis, kui plasmaproovis olid peamiselt antikehad, mis seondusid FVIII kerge 
ahelaga. Kui plasmaproov sisaldas aga peamiselt FVIII raske ahelaga 
seonduvaid antikehi, siis oli erinevus minimaalne või puudus. Seega võis in 
vitro tulemuste põhjal eeldada, et haigel, kellel on dominantsed FVIII kerge 
ahela spetsiifilised antikehad, saab kasutada veritsuse peatamiseks FVIII-VWF 
kompleksi sisaldavat kontsentraati.
In vitro katses kasutatud FVIII kontsentraadis VWF funktsionaalse aktiiv­
suse iseloomustamisel ilmnes, et selles puudusid VWF kõrge molekulmassiga 
multimeerid ning VWF antigeeni sisaldus oli tunduvalt suurem kui von 
Willebrandi faktori funktsionaalne aktiivsus. Samal ajal olid ka keskmise ja 
madala molekulmassiga VWF-i multimeerid võimelised stabiliseerima VIII 
hüübimisfaktorit ja vähendama antikehade inhibeerivat toimet FVIII koagulant- 
sele aktiivsusele.
Sama preparaadi manustamisel hemofiilia A haigele immuuntolerantsuse 
kujundamiseks ilmnes, et kogu ravi jooksul domineerisid vastupidiselt oodatule 
FVIII kerge ahela spetsiifilised antikehad. Põhimõtteliselt oleks VWF pidanud 
katma ja kaitsma epitoobid FVIII kerges ahelas ning seega ka reguleerima FVIII 
kerge ahela vastaste antikehade produktsiooni B-rakkude poolt, kuna need 
epitoobid ei ole FVIII-VWF kompleksis eksponeeritud. Täpsemal uurimisel 
selgus, et FVIII antikehad olid Cl, C2, A2, Al domeenide spetsiifilised, kus­
juures Cl-spetsiifiliste antikehade kontsentratsioon oli tunduvalt kõrgem kui 
teiste domeenide vastastel antikehadel. Ravi käigus vähenes nii FVIILC aktiiv­
sust inhibeerivate kui ka mitteinhibeerivate omadustega FVIII antikehade 
kontsentratsioon, kuigi ei ilmnenud olulisi muutusi epitoobispetsiifilisuses. Ravi
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katkestamisel ja uuesti jätkamisel aga suurenes FVIII antikehade produktsioon, 
sealhulgas ka C2-domeeni spetsiifiliste antikehade kontsentratsioon, kuid vaata­
mata sellele jäi Cl-domeeni spetsiifiliste antikehade kontsentratsioon kõrge­
maks. Kuigi haige antikehad olid suunatud peamiselt FVIII kerge ahela vastu, ei 
olnud ühegi antikeha seondumiskoht niisuguses piirkonnas, mis oleks takis­
tanud VWF seondumist FVIII-ga, või oli selliste antikehade kontsentratsioon 
märgatava mõju avaldamiseks liiga madal. Seega olid epitoobid peamiselt 
FVIII-VWF kompleksi pinnal. Uurides FVIII antikehade IgG jaotust sub- 
klasside järgi, selgus, et enamus nii FVIII kui ka FVIII kerge ahela 
spetsiifilistest antikehadest oli IgG4 klassi. Ravi jooksul detekteeriti IgGl klassi 
antikehade kontsentratsiooni suurenemine kahel ajahetkel ning samades proovi­
des ilmes ka FVIII antikehade produktsiooni muutus.
Immuuntolererantsuse ravi käigus tekkinud antikehade inhibeeriva toime 
uurimisel selgus, et kuigi enamus antikehi olid FVIII kerge ahela spetsiifilised, 
ei blokeerinud need FVIII seondumist von Willebrandi faktoriga ega fosfoli- 
piididega. Samal ajal olid haige antikehad võimelised inhibeerima FXa gene­
ratsiooni, takistades FX seondumist FVIII-ga. Sellist antikehade toimemehha­
nismi FVIII:C aktiivsuse inhibeerimisel ei ole eelnevalt kirjeldatud.
Antud mehhanismi edasisel uurimisel leidsime, et FVIII C2-domeeni- 
spetsiifilised monoklonaalsed antikehad B02C11 ja ESH4 on samuti võime­
lised seonduma FVIII-ga nii, et selle interaktsioon FX-ga on välistatud. Mõle­
mad ülalnimetatud monoklonaalsed antikehad inhibeerivad ka FVIII inter­
aktsiooni VWF-ga ja fosfolipiididega (Scandella et al., 1995a; Spiegel et al., 
2001).
Cl-domeeni tähtsusest FVIII aktiivsusele on praeguseks vähe teada. Antud 
uurimuse tulemused näitavad, et FX seondumiskoht Cl-domeenis erineb VWF 
seondumiskohast, sest haige Cl-spetsiifilised antikehad ei konkureerinud mo- 
noklonaalse Cl-domeeni-spetsiifilise antikehaga, mis on võimeline blokeerima 
FVIII seondumist VWF-ga (Jacquemin et al., 2000).
Kokkuvõttes võib järeldada, et FVIII kerge ahela antikehad on võimelised 
inhibeerima FVIII koagulantset aktiivsust erinevalt, kusjuures von Willebrandi 
faktoriga seondumise takistamine on mitmetest võimalustest ainult üks. FVIII 
antikehade inhibeeriva toime erinevuse määramine FVIII ja FVIII-VWF 
kompleksi suhtes ning FVIII kerge ahela vastaste antikehade kontsentratsiooni 
hindamine võimaldab valida sobivaima ja efektiivseima FVIII kontsentraadi 
haige veritsuste raviks või immuuntolerantsuse kujundamiseks, võimaldades 
suurendada ravi efektiivsust ja vähendada ravi kulusid.
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Summary. We investigated the neutralization 
activity of factor VIII (FVIII) antibodies of 12 
haemophilia A patients, acquired during treatment 
with plasma-derived FVIII concentrates. All plasma 
samples, drawn in a clinically stable situation before 
any immunotolerance treatment, contained anti-A2 
domain and anti-light-chain FVIII antibodies. In nine 
patients’ plasmas, containing relatively high amounts 
of FVIII light-chain antibodies (53-96% ), a higher 
neutralization activity was found against recombin­
ant FVIII concentrate (Recombinate) than against 
plasma-derived von Willebrand factor (vWF)-con- 
taining concentrate (Haemoctin SDH). N o difference
in neutralization of the two concentrates was found 
in two patients’ plasmas with almost equal content 
of FVIII light- and heavy-chain antibodies, or one 
plasma with predominantly heavy-chain antibodies. 
These results suggest that haemophilia A patients 
with relatively high amounts of FVIII light-chain 
antibodies in plasma might benefit by infusion of 
FVIII concentrates containing vWF because vWF 
appears to have some protective effect on FVIII. This 
hypothesis should be tested by a clinical study.
Keywords: factor VIII antibody, factor VIII, haemo­
philia A, von Willebrand factor.
Introduction
Factor VIII (FVIII) circulates in plasma as a hetero­
dimer composed of a heavy chain (the domains 
A1-A2-B) and a light chain (domains A3-C1-C2) 
[1]. Non-covalent complexing with vWF protects 
FVIII from dissociation and from interaction with 
phospholipids and thrombin-activated platelets [2]. 
The half-life of infused FVIII depends on the circu­
lating level of vWF [3]. Haemophilia A patients with 
blood group O have lower vWF antigen and activity 
levels and a shorter half-life of administered FVIII 
[4]. Plasma-derived FVIII concentrates, which are 
used for replacement therapy of haemophilia A 
patients, differ in purity and vWF content. Develop­
ment of FVIII antibodies (inhibitors) in 5-25%  of 
haemophilia A patients is the most serious conse­
quence of replacement therapy [5]. Patients treated
Corrcspondcncc: Adc Kalias, D epartm ent o f Pharmacy, University 
of Tartu, Jakobi 2, Tartu, 51014, Estonia.
Fax: +• 372 7375 289; e-mail: ade.kallas@kliinikum.ee 
Accepted 22 M arch 2001
© 2001 Blackwell Science Ltd
with plasma-derived FVIII concentrates (pdFVIII) are 
more prone to develop antibodies against the heavy- 
chain A2 domain and the light chain domains, A3, 
C l and C2, while patients treated with recombinant 
FVIII are more likely to produce antibodies against 
the A2 and C2 domains [6], The vWF binding site is 
located within the light chain of FVIII [1] therefore 
vWF may protect FVIII from neutralization by 
antibodies recognizing the epitopes in the light chain. 
The aim of our study was to investigate the protect­
ive effect of vWF on FVIII binding and neutralization 
by the plasmas of 12 haemophilia A patients with 
inhibitors, in relation to the distribution of antibod­
ies against the most common epitopes of FVIII.
Materials and methods
Investigated FVIII antibodies
Plasma samples from 12 haemophilia A patients with 
FVIII antibodies were included to the study. Anti- 
FVIII antibodies had developed in all the patients in 
response to on-demand treatment with plasma- 
derived FVIII concentrates. Plasma samples were
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drawn in a clinically stable situation before any 
immunotolerance treatment. The study protocol was 
approved by the Ethics Committee of the University of 
Tartu, Estonia. Plasma samples contained 1-300 
Bethesda units (BU) mL-1 of FVIII antibodies. All 
investigated FVIII antibodies reacted with the A2 
domain of the FVIII heavy chain cleaved by thrombin 
(Sigma Chemical Co., St Louis, MO, USA) and the 
FVIII light chain, detected by Western blotting using 
plasma-derived FVIII concentrate (Haemoctin SDH; 
Biotest, Dreieich, Germany) and recombinant FVIII 
fragments (FVIII light chain, 6318 IU mL-1, and heavy 
chain, 7366 IU mL-1; kindly provided by Dr Mirella 
Ezban from Novo Nordisk, Bagsuaerd, Denmark). All 
plasma samples contained antibodies preventing FVIII 
interactions with vWF and phosphatidylserine as 
measured by ELISA assays previously described by 
Shima and coworkers [7], FVIII antibodies of all plasma 
samples competed with murine monoclonal antibody 
ESH4 (American Diagnostica, Greenwich, CT, USA) 
for the phospholipid binding site of the C-terminus 
of the light chain of FVIII, as detected by ELISA.
N eutraliza tion  assay in the presence and absence 
o fv W F
Recombinant FVIII concentrate (Recombinate; Bax­
ter, USA; specific activity > 4000 IU m g'3 of pro­
tein) and plasma-derived concentrate (Haemoctin; 
specific activity 100 IU mL-1 of protein) were used 
in the neutralization experiments. Haemoctin SDH 
vials with labelled potency of S00 IU contained 
58.3 ± 3.9 IU mL”1 of FVIII:C, 31.8 ± 4.6 IU mL“‘ 
of vWF:Ag, 12.9 ± 2.9 IU mL-1 of RCof, 8.5 ± 
1.9 IU mL-1 of CBA, after dissolving.
Both concentrates were diluted to 1 IU mL~J of 
FVIII:C with Tris-buffered saline (TBS; 20 mraoL"1 
Tris-HCl, 150 mmoL'1 NaCl; pH 7.2) containing
1 % bovine serum albumin (BSA) and incubated with 
an equal volume of serially diluted (1 : 2 to 1 : 1000 
in TBS containing 1% BSA) FVIII antibody plasma 
sample for 1 h at 37 °C. The maximum neutraliza­
tion of FVIIIrC activity was achieved after 1 h. 
Residual FVIII:C was measured by a chromogenic 
test according to the manufacturer’s instructions 
(Coatest FVIII; Chromogenix Instrumentation 
Laboratory, SpA, Milan, Italy) on a 96-well micro­
plate (Micro-Well™; Nunc, Roskilde, Denmark). 
Percentage neutralization was calculated relative to a 
control. The control had the test plasma sample 
replaced by plasma from a CRM-negative haemo­
philia A patient without FVIII antibodies. The test 
plasma sample dilution that gave 50% neutralization 
of FVIII-.C activity was found using both FVIII
concentrates. The results were used to calculate a 
ratio of 50% neutralization of FVIII:C with rFVIII to 
that with FVIII-vWF.
D istribu tion  o f  FVIII light-chain and heavy-chain  
neutralizing antibodies m easured by an ELISA assay
Microplates (PolySorp1M; Nunc) were coated with 
rFVIII (Recombinate) diluted to 8 IU mL-1 in carbon­
ate buffer (50 mmoL’ 1 sodium carbonate-bicarbon­
ate buffer; pH 9.6)andincubatedovernightat2-8 °C. 
Prior to using, the wells of microplate were blocked 
with TBS containing 3% BSA for 1 h at room 
temperature and washed with TBS-Tween (0.05% 
Tween 20). Plasma samples with FVIII antibodies 
were diluted to 4 BU mL-1, except plasma samples 
no. 9 and 10, which were used undiluted. The samples 
were incubated with an equal volume of serially 
diluted recombinant FVIII fragments, from 0.2 to 
12.6 IU mL"5 according to labelled activity, for 1 h at 
37 °C. After incubation, aliquots were removed and 
added to the wells of the microplate and incubated for
2 h at 37 °C. Bound FVIII antibodies were detected 
using rabbit antihuman IgG conjugated with alkaline 
phosphatase (AP) diluted 1 : 1000 (Dako, Glostrup, 
Denmark). The reaction was visualized with the AP 
substrate p-nitrophenyl phosphate (pNPP; Sigma) and 
the colour change was read at 405 nm. Two controls 
were included with each test: one mixture that had the 
antibody plasma sample replaced by buffer and a 
second mixture that used buffer instead of the recom­
binant FVIII fragments. The percentage neutralization 
was calculated as follows:
100 -  [(binding with fragment -  minimum binding)/ 
(maximum binding -  minimum binding)] x 100.
The maximum binding measurement was obtained 
from the incubation in the microplate of the antibody 
sample and buffer without recombinant fragments. 
Minimum binding was measured from the incuba­
tion of buffer alone. The plateau was defined as the 
point beyond which increasing the FVIII fragment 
concentrations did not lead to a greater neutraliza­
tion of FVIII antibodies. When FVIII antibodies were 
partially neutralized by recombinant fragments, all 
values within the plateau region were averaged.
D istribution o f  FVIII ligbt-cbain an d  heavy-chain  
neutralizing antibodies m easured b y  a chrom ogenic 
m ethod
Factor VIII antibody plasma samples were diluted 
to a neutralization activity of 4 BU mL'1, except
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plasma samples no. 9 and 10, which were used 
undiluted, and incubated with an equal volume of 
serially diluted recombinant FVIII fragments as 
described in the previous assay. An aliquot was 
removed for measuring residual FVIII antibodies 
using an ELISA assay. To the remaining mixture, an 
equal volume of rFVIII (Recombinate), diluted to 
2 IU mL-1 was added and incubated for 1 h at 
37 °C. Residual FVIILC activity was measured by 
the chromogenic method. Percentage neutralization 
was calculated using the above-mentioned formula, 
but binding capacity was substituted with FVIII:C 
activity. Maximum FVIII:C activity was measured 
from the mixture of recombinant fragments and 
rFVIII without antibody sample, incubated in the 
same conditions. If the tested plasma contained an 
FVIII antibody level < 10 BU mL-1, the plasma 
sample from the CRM-negative haemophilia A 
patient without FVIII antibodies was used in the 
mixture to obtain the maximum FVIILC activity. 
Minimum FVIILC activity was found for each test 
sample incubated with rFVIII without any compet­
itive FVIII fragments. The plateau value was simi­
larly measured as in the previous assay.
Statistical analysis
Calculation of correlation was based on the Spear­
man rank order correlation coefficient, with P < 0.05 
considered significant.
Results
Two groups were identified with respect to the 
relative amount of FVIII light-chain antibodies 
among the heterogeneous mixture of antibodies in 
the patients’ plasmas, and to the neutralization of 
FVIII in the presence and the absence of vWF. The 
first group, consisting of nine plasma samples (sam­
ples no. 1-9 in Table 1), had significantly lower 
neutralization activity when exposed to FVIII con­
taining vWF (FVIII-vWF; Fig. 1A). The ratios of 
50% neutralization with rFVIII over that with FVIII- 
vWF ranged from 1.5 to 18.3 (mean 6.8). The group 
1 samples contained higher amounts of recombinant 
FVIII light-chain neutralizing antibodies (53-96%; 
Fig. 2A). Three samples (nos. 10-12) belonged to the 
second group with no difference in neutralization of 
FVIILC exposed to FVIII or FVIII-vWF (mean ratio 
1.0; Fig. IB). Two plasma samples contained equal 
amounts of antibodies neutralized by rLCh and 
rHCh (Fig. 2B) and one sample (no. 12) contained 
a higher amount of recombinant FVIII heavy-chain 
neutralizing antibodies. Figure 3 illustrates the
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Dilution, 13
Dilution,
Fig. 1. Neutralization of FVIILC activity by FVIII antibodies from 
plasma sample no. 1 (A) and plasma sample 11 (B) in the presence 
and  absence o f vWF. Plasma dilutions were incubated with 
recom binant FVIII concentrate (rFVIII; Recombinate, Baxter) 
and FVIII concentrate containing vWF (FVIII-vWF; Haemoctin 
SDH, Biotest). The residual FVIII:C activity was measured by 
chromogenic method. Each datapoint represents the mean of two 
individual experiments.
Recombinant F VIII fragment, IU/ml
Rocombinant F VIII fragment, IU/ml
Fig. 2. Neutralization of FVIII antibodies from plasma sample no. 
1 (A) and plasma sample 11 (B) by recom binant FVIII light chain 
(rLCh) and heavy chain (rHCh). Plasma sample was diluted to 
4 BU mL”1 and incubatcd w ith increasing concentrations of rLCh 
and rHCh. The neutralization of antibodies was measured by an 
ELISA assay (ELISA) and a chromogenic test (FVIILC) as 
described in ‘M aterials and m ethods’. Each datapoint represents 
the mean of a t least two individual experiments.
correlation between the distribution of rLCh-neut- 
ralizing antibodies relative to rHCh antibodies 
measured by the chromogenic method (ratio rLCh 
to rHCh) and FVIII neutralization in the absence or 
presence of vWF (ratio rFVIII to FVIII-vWF) for all 
investigated samples (Spearman analysis r — 0.59; 
F =  0.04).
Discussion
We studied the effect of vWF on neutralization of 
FVIII by plasma antibodies. All studied plasma 
samples, collected from haemophilia A patients, 
contained FVIII antibodies with reactivity against 
the light chain and the A2 heavy chain domain of 
FVIII. Plasma-derived FVIII concentrate with vWF 
was significantly less neutralized by most plasma 
samples than recombinant FVIII concentrate. The
extent of neutralization correlated with the relative 
amount of FVIII light-chain antibodies in a 
patient’s plasma. A lower neutralization of FVIII 
coagulation activity in the presence of vWF was 
associated with a higher amount of FVIII light- 
chain antibodies compared to FVIII heavy-chain 
antibodies (Fig. 3).
The interaction between FVIII and vWF has been 
studied extensively. vWF binds to different domains 
of the FVIII molecule. Antibodies reacting with 
epitopes within the C l [8] and C2 [7] domains, or 
the acidic region A3 in the light chain of FVIII, 
inhibit the binding of FVIII to vWF. As only the 
intact light chain has the maximum vWF binding 
affinity |2], we used the recombinant full-length 
FVIII light chain in neutralization experiments to 
cover the whole panel of plasma antibodies interfer­
ing with FVIII-vWF interaction.
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Fig. 3. The relationship between neutralization activity of FVIII 
antibodies in the absence and in the presence of vWF (ratio rFVIII 
to  FVIII-vWF) and the distribution of recom binant FVIII light- 
chain (rLCh) neutralizing antibodies compared to  recom binant 
heavy-chain (rHCh) neutralizing antibodies m easured by a 
chromogcnic test (ratio rLCh to  rHCh).
The different reactivity of FVIII antibodies against 
a panel of FVIII concentrates with varying levels of 
purity has been described [9,10]. Plasma antibodies 
with FVIII C2 domain specificity from haemophilia 
A patients possess a lower ability to neutralize FVIII, 
if it is in complex with vWF [11]. FVIII antibodies 
investigated in our study developed as a response to 
treatment with pdFVIII concentrates, varying in their 
content of functional vWF. Compared to rFVIII and 
recombinant fragments, factor VIII, when complexed 
with vWF, expresses a significantly different number 
of epitopes, especially conformational epitopes. The 
epitope specificity of FVIII antibodies was detected in 
reduced and unreduced conditions by Western blot­
ting. The same antibody-binding pattern was 
observed using plasma-derived FVIII concentrate or 
recombinant light- and heavy-chain fragments. 
Antibody binding was not altered because of the 
linear structure of epitopes. As epitopes are presented 
in pdFVIII and in recombinant fragments, von 
Willebrand factor, having occupied the binding sites 
in the light chain of FVIII, can block epitopes on the 
light chain of FVIII or interfere with antibody 
binding by steric hindrance.
The limitation of our study is the small number of 
investigated plasma samples. Only two samples out 
of 12 contained an almost equal amount of FVIII 
antibodies against the light and heavy chains and one 
plasma sample contained predominantly FVIII heavy- 
chain antibodies. However, these results agree 
with those reported by Scandella and coworkers, 
who found that two out of 10 plasma samples
© 2001 Blackwell Scicncc Ltd
investigated by an immunoprecipitation method [12] 
had an almost equal amount of antibodies neutral­
izing the A2 heavy chain domain and the light chain 
of FVIII. Apparently, antibodies with almost equal 
relative contribution to binding activity and neutral­
ization activity are uncommon.
The data presented here represent a situation at 
one timepoint. However, the composition of anti­
bodies can vary over time and the epitope specificity 
of antibodies can change due to treatment or 
independently [13].
The results of our in v itro  study suggest that a 
screening of the neutralizing activity of plasma 
antibodies before treatment might be useful in 
determining the selection of FVIII concentrate for 
treatment. These findings might have implications 
for the prediction of a better response of FVIII-vWF 
concentrate and thus contribute to lower treatment 
costs. Further experiments and clinical studies should 
establish the correlation between in v itro  and in vivo  
observations.
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Summary
The study aimed at characterizing the putative changes in the epitope specificity 
of anti-FVIII antibodies during a successful immune tolerance treatment of the 
haemophilia A patient with the factor VIII (FVIII) preparation containing the 
von Willebrand factor (VWF). At the beginning of treatment, anti-FVIII inhi­
bitory antibodies recognizing predominantly the light chain of FVIII were 
prevalent and persisted throughout treatment. More detailed characterization of 
the FVm antibody epitope specificity by using GST-fusion proteins correspon­
ding to different FVIII domains revealed the prevalence of Cl-domain-specific 
antibodies, while a remarkably lower amount of antibodies were targeted at the 
C2 and the a3 domains of the FVIII light chain and towards the A2 and the Al 
domain of the FVIII heavy chain. The epitope specificity of antibodies 
remained rather unchanged throughout treatment except the elevated level of 
C2-domain-specific FVIII antibodies after a temporary interruption of treat­
ment. The patient’s antibodies were unable to interfere with the FVIII binding 
to VWF or to phospholipids, but inhibited FXa generation and the binding of 
FX to FVIII on the phospholipid monolayer. Thus, a unique pattern of the 
epitope specificity of FVIII antibodies and the mechanism to inhibit FVIILC 
activity by FVIII-light-chain-specific antibodies were characterized. The un­
common epitope distribution of FVIII antibodies of this patient was probably 
caused by the administration of the FVIII preparation containing VWF.
Keywords: Factor VIII antibody, Factor VIII, haemophilia A, immune tole­
rance
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Introduction
Defects or malproduction of factor VIII (FVIII) in haemophilia A patients 
causes bleedings, which are treated by the administration of functional FVIII. 
The most common serious complication of substitution therapy is the develop­
ment of antibodies against exogenous FVIII in up to 20% of haemophilia 
A patients (Hoyer, 1995). It is generally accepted that patients with a certain 
defect in the FVIII gene have a higher risk of the FVIII antibody response to 
occur (Schwaab et a l ,  1995). According to the updated database, up to 60% of 
haemophilia A patients carrying an inversion in intron 22 and 38% of patients 
with large deletions in the FVIII gene have an elevated FVIII antibody response 
(Kemball-Cook et a l ,  1998). Different point mutations usually yield a moderate 
or mild form of the disease and are accompanied by a lower incidence of FVIII 
antibodies.
A large number of studies have been focused on the FVIII antibody develop­
ment in patients treated with FVIII preparations of different purity. However, a 
higher purity of plasma-derived preparations and the application of the recombi­
nant DNA technology for FVIII production have not been accompanied by any 
significant change in the incidence of FVIII antibody formation (Scharrer et al., 
1999). Two preparations produced by using treatment with a solvent-detergent 
and heat pasteurization for virus inactivation have been exceptions causing a 
remarkably higher antibody response, however, neither of these is in use any 
more (Laub et al., 1999; Peerlinck et al., 1997).
The FVIII molecule consists of a series of domains Al-al-A2-a2-B-a3-A3- 
C1-C2 serving as a basis for internal sequence homology (Lenting et al., 1998). 
Normal processing yields the FVIII heterodimer, comprising the heavy chain 
(Al-al-A2-a2-B) and the light chain (a3-A3-Cl-C2), circulating as a non- 
covalent complex with the von Willebrand factor (VWF). FVIII survival 
depends largely on the presence of VWF. The von Willebrand factor protects 
FVIII from premature activation and also from inactivation by proteolytic 
degradation. The VWF binding sites are located within the a3 domain and the 
C2 domain of the light chain of FVIII (Saenko and Scandella, 1997). Up to 68% 
of FVIII antibodies developed in the patients treated with plasma-derived FVIII 
preparations recognize epitopes within the A2 domain and the light chain of 
FVIII (Prescott et al., 1997; Scandella et al., 2001). The FVIII-light-chain- 
specific antibodies possess a lower inhibitory activity towards FVIII in the 
complex with VWF than towards FVIII itself as shown by in vitro experiments 
(Gensana et a l ,  2001; Kallas and Talpsep, 2001; Suzuki et a l ,  1996). The 
change of the FVIII preparation to the one containing VWF has resulted in a 
beneficial suppression of FVIII antibodies in the immune tolerance treatment 
(ITT) of the patients (Kreuz et a l ,  1995). Among various immune tolerance 
therapy protocols the administration of high doses of FVIII preparations is one 
of the strategies to reduce the FVIII antibody level (Berntorp et a l ,  1996). Here 
we present a case, where the FVIII preparation containing VWF was used for
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the treatment of a patient with high titer antibodies targeted at the FVIII light 
chain and the heavy chain. The FVIII light chain antibodies in the studied 
patient were mainly Cl-domain-specific. The patient’s antibodies were unable 
to interfere with the FVIII binding to VWF or with the FVIII binding to 
phosphatidylserine (PS), but they were able to inhibit FXa generation by 
interfering the FX binding to FVIII.
Materials and methods
Reagents
Recombinant FVIII (rFVIII, Recombinate™ and albumin-free rFVIII, provided 
by Baxter, Glendale, CA, for laboratory use only) was used throughout the 
study. Recombinant FVIII fragments (the recombinant heavy chain, rHCh, and 
the light chain, rLCh) were kindly provided by Dr. Mirella Ezban (Novo 
Nordisk, Denmark). Bovine serum albumin (BSA), casein, L-(-phosphatidyl)- 
1-serine, p-nitrophenylphosphate (pNPP), and avidin-peroxidase were purchased 
from Sigma (Sigma Chemicals, St. Louis, MO, USA), biotin derivate (EZ Link 
sulfo-NHS-LC-biotin) from Pierce company (Rockford, IL, USA), and substrate 
o-phenyldiaminedihydrochloride (OPD) from Dako (Glostrup, Denmark). The 
test kit for measuring FVIILC activity (Coatest FVIILC), purified bovine FX, 
factor IXa with factor X (FIXa+FX reagent), phospholipid emulsion, Russel’s 
viper venom and substrates S-2288 and S-2337 were purchased from the 
Chromogenix Instrumentation Laboratory SpA (Milano, Italy). The in vitro 
assays were carried out in Tris-buffered saline (TBS, 0.02 M Tris, 0,15 M NaCl, 
pH 7.2), phosphate-buffered saline (PBS, 0.08 M, pH 7.2), carbonate buffer 
(0.015 M Na2C 03, 0.035 M NaHC03, pH 9.6) or glycine-buffered saline (GBS, 
0.02 M glycine, 0.034 M NaCl, pH 9.2). All chemicals were of an analytical 
grade.
Patient description
A 3-year-old severe haemophilia A patient carrying intron 22 inversion in the 
FVm gene (Type 1) had developed FVIII inhibitors under therapy with various 
plasma-derived (pd) FVIII preparations, reaching a maximal historical titer of 
26 BU/ml. The immune tolerance (IT) therapy was started after 23 exposure 
days to FVIII (Bethesda titer 17,5 BU/ml), using the FVIII preparation 
Haemoctin SDH (Biotest, Dreieich, Germany). The immune tolerance protocol 
comprised continuous infusion (40 IU/kg/h for 8 days), followed by bolus 
injections of 100 IU/kg/day for 1 month, after which treatment was continued 
with a dose of 100 IU/kg twice a week for 10 months (Figure 1 E). After 2
3
months of therapy, the antibody titer was reduced to 0.7 BU/ml (Figure 1 D). 
During treatment with 100 IU/kg twice a week, difficulties in venous access 
were encountered, causing the interruption of treatment. The antibody titer 
increased then to 1.2 BU/ml. The second continuous infusion was therefore 
administered for 8 days with a dose of 150 IU/kg/h. The antibody titer peaked to
3.5 BU/ml and then dropped again to 0.8 BU/ml after 8 months of ITT. The 
three last plasma samples taken at the end of treatment showed the Bethesda 
titers of 0.8 BU/ml. The in vivo recovery had normalized by month 13, and 
prophylactic treatment (dose of 100 IU/kg twice a week) was started on the 
patient. No bleeding episodes occurred during immune tolerance treatment.
Functional activity o f  FVIII antibodies
The FVIII antibody levels were measured by the Bethesda method, as described 
by Kasper et al. (Kasper and Pool, 1975). The local plasma pool (made from 22 
plasma samples of healthy donors) was used as a source of FVIII. The residual 
FVIII:C was determined by the chromogenic method according to the 
manufacturer’s instructions (Coatest Factor VIII, Chromogenix AB, Italy) in a 
96-well microplate (Micro-Well™, Nunc, Denmark). FVIILC activity was cal­
culated relative to a control in which the test sample was replaced by a buffer 
solution (TBS containing 1% of BSA).
Purification o f IgG from  plasma samples
IgG was purified from plasma samples by using affinity chromatography on 
Protein-G Sepharose (HiTrap™ Protein G, Pharmacia, Uppsala, Sweden) accor­
ding to the manufacturer’s instructions and IgG-containing fractions were dia­
lysed against PBS at 4°C overnight. The concentration of total IgG was 
measured by a sandwich-type ELISA using the rabbit anti-human IgG antibody 
(Bio Rad, Hercules, CA). A human IgG reference sample (Bio Rad, Hercules, 
CA) was used for constructing a standard curve. Antibodies specific of FVIII 
were detected by a direct-binding ELISA using rFVIII-coated (Recombinate™) 
microplates.
Biotin labelling o f recombinant FVIII
Recombinant carrier-free FVIII (specific activity >4000 IU/mg of protein) was 
labelled with biotin by using EZ Link sulfo-NHS-LC-biotin under mild 
conditions according to the manufacturer’s instructions. Briefly, rFVIII 
(100 |oig/ml) was dialysed against the HEPES buffer (0.01 M HEPES, 0.15 M
NaCl, 0.01 M CaCl2, pH 8.5). The biotin derivative was dissolved in water to a 
final concentration of 0.01 mg/ml. Nine volumes of rFVIII and 1 volume of 
biotin solution were reacted for 2 h at RT. The free residual biotin derivative 
was removed by dialysis against the HEPES buffer (HEPES 0.01 M, NaCl 0.15 
M, CaCl2 0.01 M, pH 7.2). Biotinylation did not alter FVIII:C activity, the bin­
ding to phosphatidylserine or the binding to VWF as analysed by the respective 
assays.
Inhibition o f  FVIII binding to phospholipids
The wells of polystyrene microplates (MaxiSorp™, Nunc, Roskilde, Denmark) 
were coated with L-(-phosphatidyl)-l-serine (PS, 100 (il of 5 M-g/ml solution in 
methanol) and were allowed to dry up at room temperature (RT). The wells 
were blocked with 3% of BSA in TBS for 1 h at RT. The wells were rinsed with 
washing buffer (TBS containing 0.1% of Tween 20) and a mixture containing 
an equal volume of biotin-labelled rFVIII 2 fxg/ml in TBS-BSA (1% of BSA in 
TBS buffer), as well as the serially diluted (1:2 to 1:1000) purified IgG of test 
plasma samples were added and further incubated for 2 h at RT. The amount of 
FVIII-biotin bound to the wells was determined with avidin-peroxidase 
(1 |ig/ml in PBS with 1% of BSA) by using OPD as a substrate. For each series 
of tests, a control was included in which buffer was used instead of the test 
plasma sample dilution.
Inhibition o f  FVIII binding to the von Willebrand factor
Microplate wells (MaxiSorp™, Nunc, Roskilde, Denmark) were coated with 
100 jal of the mouse anti-human VWF polyclonal antibody (2 jig/ml, Dako, 
Denmark) in GBS buffer and incubated overnight at 4°C. The wells were 
blocked with 0.5% of casein in TBS for 30 minutes. A normal plasma pool at a 
dilution of 1:20 in TBS-BSA was used to saturate the wells of the microplate 
with VWF (plasma pool of 22 plasmas of healthy persons) for 1 h at RT. Factor 
V m  was dissociated from VWF by incubation with 0.4 M CaCl2 for 30 min at 
RT. A mixture containing a tested IgG sample dilution and an equal volume of 
the rFVIII-biotin conjugate diluted at 2 )Lig/ml in TBS-casein were preincubated 
for 30 min at 37°C before adding it to the microplates. The amount of the bound 
rFVIII was determined as described in the previous assay after a further 2h of 
incubation at RT.
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Factor Xa generation, the chromogenic assay
Recombinant FVIII (Recombinate™, 2 IU/ml in TBS-BSA) was preincubated 
with various concentrations (4 to 2500 jug/ml) of the tested IgG for 30 min at 
37°C. The resulting FVIII-antibody complex mixture was reacted with purified 
bovine FIXa+FX (final concentration 2.4 IU/ml according to labelled activity) 
in the presence of phospolipids for 10 min at 37°C. Factor Xa generation was 
initiated by adding the CaCl2 solution to the mixture (final concentration 
6.25 mM ). Aliquots were removed at appropriate times to assess the initial 
rates of product formation and the reaction was stopped with the EDTA 
solution (final concentration 11 mM). The amount of generated FXa was 
determined by the activity of cleaving chromogenic substrate S-2288 (final 
concentration 1.1 m g/m l) reading absorbance at 405 nm. Each assay included
2 controls, namely, in the first mixture the tested IgG was replaced by the 
IgG prepared from the plasmas of healthy donors (a positive control), and in the 
other, the tested IgG and FVIII were substituted by buffer TBS-BSA (a negative 
contol). The amount of generated FXa in the sample was expressed as a 
percentage of FXa generated in the positive control. The concentration of the 
tested IgG yielding 50% inhibition of FXa generation was calculated for each 
tested IgG sample. In an analogous assay, rFVIII was substituted by the 
recombinant FVIII light chain diluted to 12 IU/ml in TBS-BSA in order to 
estimate the effect of the patient’s antibodies on FXa generation induced by the 
FVIII light chain.
Inhibition o f  FX binding to FVIII
The microplates (PolySorp™) were coated with PS (5 jig/ml in methanol) and 
air-dried. The wells were blocked with 5% of BSA in TBS for 1 h at RT. 
An equal amount of rFVIII (2 IU/ml in buffer A, 0.05 M Tris, 0.015 M NaCl, 
0.015 M CaCl2, BSA 1%) and the tested IgG at indicated concentrations (7 to 
2500 jiig/ml) were preincubated for 30 min at 37°C and transferred to PS-coated 
wells of the microplate. After 2h of incubation, the non-bound material was 
removed by washing the wells with buffer B (0.05 M Tris, 0.015 M NaCl, 
0.05 M CaCl2, Tween-20 0.1%, pH 7.2). Purified bovine FX diluted to 0.1 U/ml 
in buffer A (according to the labelled activity) was added to the wells and 
incubated for 15 min at RT. The wells were rapidly washed with 3 changes of 
buffer B. Subsequently, substrate S-2337 (final concentration 0.6 mg/m) was 
added to the wells and FX was activated by the FX-activating enzyme from 
Russel’s viper venom (RVV, 21.5 |lg/ml) in the presence of CaCI2 (0.025 M). 
The inhibition of the FX binding was calculated relative to the control, which 
contained the IgG preparation from heathly donors instead of the tested IgG
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sample (100% of binding). Control experiments confirmed that the RVV 
enzyme by itself did not hydrolyse the chromogenic substrate.
Assays fo r  studying the epitope specificity o f  FVIII antibodies
FVIII heavy and light chain specificity o f  FVIII antibodies, ELISA assay
Microplates (PolySorp™, Nunc, Denmark) were coated with 8 IU/ml FVIII 
(Recombinate™) in a carbonate buffer overnight at 2-8°C. Non-specific binding 
sites were blocked with 3% of BSA in TBS for 1 hour at RT, and BSA was 
washed off with washing buffer. Plasma samples with FVIII antibodies were 
diluted to 4 BU/ml or used undiluted if the antibody titer was <4 BU/ml. Plasma 
samples were incubated for 1 h at 37°C with an equal volume of recombinant 
FVIII fragments (the recombinant heavy chain or the light chain of FVIII) by 
using concentrations ranging from 0.2 to 12.6 IU/ml according to the labelled 
activity. Aliquots were then transferred to rFVIII-coated microplates for an 
incubation of 2 h at 37°C. The amount of bound FVIII antibodies was 
determined by using the rabbit anti-human IgG conjugated with alkaline 
phosphatase (AP, Dako, Glostrup, Denmark) diluted to 1:1000 and visualized 
with AP-substrate pNPP (p-nitrophenyl phosphate). Two controls were included 
in each test: one mixture in which the plasma sample was replaced by buffer 
(minimal binding) and the other where buffer instead of recombinant FVIII 
fragments was used (maximal binding). The percentage of neutralization was 
calculated as follows: 100 -  [(binding after incubation with fragment -  minimal 
binding) / (maximal binding -  minimal binding)] x 100. The plateau concent­
ration was defined as a minimal concentration of the rFVIII fragment, which 
yielded a maximum optical density (OD), and all OD values within the plateau 
region were averaged.
FVIII heavy- and-light- chain specificity o f FVIII antibodies, 
chromogenic method
Plasma sample dilutions were prepared as above. An aliquot was taken for 
measuring the concentration of FVIII antibodies by the ELISA assay. To the 
remaining solution an equal volume of rFVIII (Recombinate™) 2 IU/ml in TBS 
containing 2% of BSA was added and incubated for 1 h at 37°C. Residual FVIII 
coagulation activity (FVIILC) was measured by the chromogenic method 
(Coatest Factor VIII, Chromogenix AB, Italy). The percentage of neutralization 
was calculated by using the above-mentioned formula using FVIII:C activity 
instead of binding capacity. Maximum FVIILC activity was measured in the 
mixture of a particular recombinant fragment and rFVIII in the absence of an
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antibody. When the tested plasma contained an FVIII antibody <10 BU/ml, a 
plasma sample from a haemophilia A patient (CRM-negative and without FVIII 
antibodies) instead of buffer was used in the mixture in order to obtain the 
maximal FVIILC activity. Minimal FVIILC activity was measured for each test 
sample incubated with rFVIII without any competitive FVIII fragments. The 
plateau value was calculated as described above.
Recombinant GST-fused FVIII fragments
The FVIII fragments for cloning were generated by PCR using primers with the 
added restriction cloning sites. The PCR products were cloned in frame into the 
pGEX4T-2 expression vector and controlled by sequencing in both directions 
with the T7 sequencing kit (Pharmacia, Uppsala, Sweden). The respective gluta­
thione S-transferase (GST) fusion proteins were expressed in the DH5 a  
Escherichia coli strain. Fusion protein aggregates were dissolved by using 1.5% 
Sarkosyl (Sigma, USA) and 2% Triton X-100 and purified by using a gluta­
thione column.
Binding o f  FVIII antibodies to recombinant FVIII fragments
MaxiSorp™ microplates were coated with the respective recombinant FVIII 
fragment (Figure 2) diluted to 2 |0g/ml in GBS buffer for 2 h at RT. The wells 
were blocked with TBS-casein for 30 min. IgG fractions obtained from the 
patient’s plasma samples were serially diluted from 15 jig/ml to 500 (ig/ml in 
TBS-casein before addition to the wells of the microplate for a further 
incubation for 2 h at RT. The bound FVIII antibodies were detected by using 
the peroxidase-conjugated rabbit anti-human IgG and OPD. As a positive cont­
rol, monoclonal antibodies specific of particular recombinant FVIII fragments 
were included in each experiment. Results were expressed as OD values 
corrected by subtracting background values (non-specific binding to GST-fused 
sham protein).
Competitive binding between FVIII-specific monoclonal and 
the patien t’s antibodies
Microplates were coated with different human or mouse monoclonal antibodies 
against human FVIII (hFVIII). The following FVIII-specific antibodies were 
used: human anti-hFVIII antibodies B02C11 and 2E9; and mouse anti-hFVIII 
antibodies F7B4, F29B10, mAb 15, and ESH4. All these antibodies had been 
produced in our laboratory (CMVB, Leuven), except ESH4 (American Diag-
nostica, Greenwich, CT, USA) and were used at the dilution of 2 |ig/ml in GBS 
buffer for 2 h at RT to coat the microplates. The wells of the microplate were 
then washed and blocked with TBS-casein for 30 min at RT. Mixtures 
containing an equal volume of the test IgG sample (15 }ig/ml to 100 jig/ml) and 
the rFVIII-biotin (2 |ig/ml) were then applied and incubated for 2 h at RT. The 
bound rFVIII-biotin was detected by using avidin-peroxidase as described 
above. The assay was validated by using the same monoclonal antibody than the 
one used to coat microplates instead of the tested antibody. Background values 
(no antigen in the coating solution) were subtracted from OD values. The 
degree of competition was calculated relative to the maximal binding obtained 
when no competitor (buffer instead of the test IgG sample) was used.
Statistical analysis
All the calculations were carried out by using the GraphPad Prizm Program 
Package. The Spearman rank order correlation test was used. The coefficient of 
p 0.05 was considered to be significant. The student paired t-test was used to 
confirm the difference in the concentration of antibodies bound to different 
FVIII fragments.
Results
Inhibition o f  FVIII:C activity by the pa tien t’s FVIII antibodies
The Bethesda assay was used to estimate the FVIII antibody content in samples 
taken during the immune tolerance treatment of the patient. The treatment 
resulted in two increases in the Bethesda titer. The first one was observed 
directly after the change from continuous infusion to bolus injection with an 
increased FVIII dosage (from 3.5 to 16.5 BU/ml, Figure ID). The other increase 
in the Bethesda titer was detected as a response to the second continuous 
infusion that was applied after a temporal interruption of treatment (from 1.2 to
3.5 BU/ml).
The relationship between the inhibition of FVIII:C activity and FVIII 
antibody concentration was not linear and reflected complex kinetics known as 
Type 2 kinetics according to Biggs et al. (Biggs et a l., 1972a; Biggs et al., 
1972b). This non-linear neutralization pattern was observed for all plasma 
samples containing more than 4 BU/ml of FVIII antibodies.
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We characterized the distribution of inhibitory and non-inhibitory FVIII anti­
bodies directed towards the light chain or the heavy chain of FVIII in plasma 
samples taken during treatment. At the beginning of treatment, the majority of 
the patient’s FVIII antibodies recognized epitopes within the light chain of 
FVIII and only about 10% of antibodies recognized epitopes within the heavy 
chain of FVIII as assayed by ELISA (Figure 3). Moreover, FVIII-light-chain- 
specific antibodies possessed higher inhibitory activity than FVIII-heavy-chain- 
specific antibodies as estimated by the chromogenic method. During treatment, 
the antibody specificity persisted; most of the antibodies with inhibitory and 
non-inhibitory activity were directed against the FVIII light chain (Figure 1C). 
However, at the beginning of treatment, the proportion of FVIII-heavy-chain 
antibodies rose and the maximum was detected in 1.5 months (30%). The 
amount of antibodies directed towards the FVIII heavy chain decreased below 
detection limit in month 10.
To characterize the epitope specificity of antibodies more precisely, we 
studied the antibody binding to the following recombinant FVIII fragments, 
namely the A l, al, A2, a3, A3, C l, C2 domains in an ELISA. The respective 
fragments were expressed as the fusion proteins with glutathione S-transferase 
(GST) in E. coli and were immobilized to the microplates. The relative amount 
of the bound antibodies was expressed as an OD value with the background 
value obtained with GST fusion with an irrelevant protein being subtracted. The 
patient’s antibody binding to recombinant fragments corresponding to the FVIII 
light chain (a3, A3, C l, C2) is shown in Figure 1A and binding to fragments of 
the FVIII heavy chain (Al, A l, A2) in Figure IB. At the beginning of treat­
ment, the concentration of antibodies recognizing the Cl domain significantly 
exceeded the concentration of the C2-domain-bound antibodies (p<0.01). No 
antibody binding to the A3 domain was detected, but a negligible amount of 
antibodies bound to the a3 domain. On the second day of treatment, the amount 
of antibodies bound to recombinant fragments decreased significantly. This was 
accompanied by a decrease in the Bethesda titer, which can probably be 
explained by the neutralization of FVIII antibodies by the administered FVIII. 
The decrease in the concentration of Cl domain antibodies and a3 domain anti­
bodies during treatment was linear (linear regression coefficient r=0,87,1-0.61, 
respectively). The binding of the patient’s antibodies to the recombinant Cl 
domain immobilized to the polystyrene surface is shown in Figure 4. The bin­
ding of the patient’s antibodies to the Cl domain was linearly dependent on 
antibody concentration.
During the following treatment period, the amount of antibodies recognizing 
the FVIII light chain fragments remained rather unchanged, except the signi­
ficantly elevated level of the C2-domain-specific antibodies (p=0.02, t-test) 
observed in samples taken in the 5th month of treatment.
Binding o f the patient’s antibodies to recombinant FVIII fragments
10
The amount of antibodies recognizing the recombinant FVIII heavy chain 
fragments was lower. We could detect antibodies, which bound to epitopes 
within the A2 domain or the Al domain. No binding to the al domain was 
detected. During the treatment the concentration of the Al and A2 domain 
specific antibodies decreased linearly (r=0.56, r=0.81, P<0.05 respectively).
Competitive binding assay using monoclonal FVIII antibodies
Further we characterized whether the tested FVIII antibodies were capable of 
competing with the monoclonal FVIII antibodies for the known binding sites in 
FVIII. In the competitive binding assay we used a mouse monoclonal FVIII 
antibody F29B10, which binds to the epitope within amino-acids 2170-2195, 
because both recombinant FVIII fragments, the Cl and C2 domain, contained 
this epitope (common region of amino-acids 2125-2222). Antibody F29B10 
bound to the recombinant C2 domain only, while no binding to the Cl domain 
was detected. At the beginning of treatment the patient’s antibodies inhibited 
the mAb F29B10 binding to FVIII by 12% (Figure 5A), and during the immune 
tolerance treatment we also found a small amount of antibodies able to interfere 
with the FVIII binding to mAb F29B10. No correlation was found between the 
extent of the inhibition of the mAb F29B10 interaction with FVIII by the 
patient’s antibodies and the concentration of C2-domain-specific FVIII anti­
bodies.
Another monoclonal antibody, F7B4, whose binding site locates within 
amino-acids 356-360 of the al domain, was used in the competitive binding 
assay. The result that antibody F7B4 bound with a similar affinity to the 
recombinant fragments al and A2 was expected, since the epitope of this 
antibody was present in both these recombinant FVIII fragments. At the 
beginning of treatment, the patient’s antibodies inhibited the mAb F7B4 binding 
to FVIII by 25% (Figure 5A), but the amount of such antibodies decreased 
concomitantly during treatment. The inhibition of FVIII interaction with this 
mAb correlated with the concentration of antibodies bound to the recombinant 
A2 domain (Spearman rank order correlation coefficient r=0.881, p<0.01). 
Contrary to mAb F7B4, the tested patient’s antibodies were unable to bind to 
the al recombinant fragment, thus the epitopes of the patient’s FVIII-heavy- 
chain-specific antibodies located obviously within the A2 domain or Al the 
domain and interfered with the mAb F7B4 binding to FVIII indirectly.
The proper conformation of the A2 domain of FVIII is critical for the 
interaction with FlXa (Fay et al., 1994; Fay et al., 1999). This interaction is 
probably abolished by the binding of mAb 15 to a conformational epitope in the 
C-terminus of the A2 domain of the FVIII heavy chain resulting in a complete 
inhibition of the FVIII coagulation activity (Gilles et a l ,  1996; Gilles et al., 
1997). The FVIII binding to mAb 15 was interfered with by some of the tested
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antibody samples, showing that the patient’s antibodies were targeted at this 
region of the C-terminus of the A2 domain (Figure 5A).
Interaction of FVIII with VWF is abolished by human monoclonal 
antibodies 2E9 and B02C11, which bind to the specific epitopes of the Cl 
(Jacquemin et al., 2000) and the C2 domain of the FVIII light chain (Jacquemin 
et al., 1998; Spiegel et al., 2001), respectively. Whether the patient’s FVIII- 
light-chain-specific antibodies recognized these specific epitopes was next 
assessed by the competitive binding assay. None of the investigated antibodies 
was able to interfere with the FVIII binding to mAb B02C11 or the FVIII 
binding to mAb 2E9, neither when added directly to the wells of the microplate 
nor later, after 30 min preincubation with the FVIII-biotin conjugate. The 
Cl domain was the main target for the FVIII antibodies of the patient, but the 
patient’s antibodies recognized different epitopes of the Cl domain of the FVIII 
light chain than the monoclonal antibody 2E9 binding site.
Surprisingly, the patient’s antibodies were able to compete with mAb ESH4 
for its binding site (2303-2332) within the C2 domain. At the beginning of 
treatment the binding of ESH4 to FVIII was abolished by the patient’s anti­
bodies (Figure 5A). During treatment the concentration of antibodies able to 
compete with ESH4 for the binding site on FVIII decreased.
Inhibition o f the FVIII binding to VWF and to PS by FVIII antibodies
In order to unravel the mechanism of the action of FVIII antibodies in the inhi­
biting FVIILC activity, we studied whether the patient’s antibodies interfered 
with the FVIII interaction with VWF and/or the binding of FVIII to PS, which 
are the most common interactions hindered by FVIII-light-chain-specific anti­
bodies. No interference with FVIII interaction with VWF or the FVIII binding 
to PS was detected when FVIII was preincubated with the patient’s IgG before 
adding to either VWF- or PS-coated microplates as observed in the respective 
ELISA assays. Monoclonal antibody B02C11, which interfered with both of 
these interactions in a concentration-dependent manner, was used as a control in 
each assay.
Inhibition o f FXa generation
Since FVIII antibodies were not able to interfere with the FVIII-PS interaction, 
we assessed whether the antibodies impair the FVIII interaction with FIXa 
and/or FX and abolish the formation of the FXase complex. We used a factor 
Xa generation assay, which was dependent on the presence of phospholipids, 
FVIII as well as Ca2+; when one of these was not added to the reaction mixture, 
the generation of FXa was abolished. Preliminary experiments showed that in 
the presence of the light chain of FVIII, FXa generation was lower than in the
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presence of rFVIII. Use of the recombinant FVIII heavy chain instead of rFVIII, 
led to the generation of a negligible amount of FXa only. Due to the limited 
amount of plasma available for IgG fractionation, we could investigate only 
four samples in this assay. At the beginning of treatment the patient’s antibodies 
completely abolished the generation of FXa at the IgG concentration 500 jug/ml 
in the presence of rFVIII or the FVIII light chain (Figure 6). The concentration- 
dependent inhibition of FXa generation by the patient’s antibodies is shown in 
Figure 7. The antibodies of the patient also inhibited the generation of FXa 
induced by the FVIII light chain, although a slightly higher concentration of 
IgG was needed than in the presence of rFVIII in an analogous assay (Figure 7). 
Obviously, the FVIII-light-chain-specific antibodies were responsible for the 
inhibition of FVIILC activity by interfering with FVIII interaction with FIXa 
and FX. The IgG concentrations that caused 50% inhibition of FXa generation 
induced by rFVIII or the light chain of FVIII are shown in Figure 5B.
Inhibition o f  the FX binding to FVIII
The tested FVIII antibodies hindered the formation of the FXase complex, 
therefore we assessed whether or not the interaction of FVIII with FX takes 
place in the presence of the patient’s antibodies. The microplates coated with 
phosphatidylserine were used to ensure a proper orientation of FVIII to the 
surface enabling an efficient binding of FX. This strategy for FVIII immo­
bilisation was chosen because the tested antibodies did not interfere with the 
binding of FVIII to phosphatidylserine, and the orientation of FVIII was known 
to be highly important for interaction with FX. The amount of FX bound to 
FVIII was estimated by a subsequent activation of FX with Russell’s viper 
venom and the ability to cleave a specific substrate. All four tested IgG samples, 
which were characterized by the FXa generation assay, were able to inhibit the 
FX binding to FVIII immobilized to PS (Figure 8). Since the light chain of 
FVIII has been reported to participate in the FX binding to FVIII (Liu and 
Thomson, 2000), we assessed the ability of the FVIII light chain to interact with 
FX in the respective experimental set-up. The binding of FX to the light chain 
of FVIII was also inhibited by the patient’s antibodies. IgG fractionated from 
plasmas of healthy donors did not impair the interaction of FX with FVIII or its 
light chain and was therefore used as a control.
FX itself could also bind to PS in an FVIII-independent manner and give rise 
to high background values. Therefore in parallel with the oriented 
immobilization of FVIII onto the phosphatidylserine layer, we also attempted 
the immobilization of FVIII via surface-attached antibodies. The antibodies 
which are known to be targeted at the regions of FVIII participating in the 
interaction with PS (e.g. B02C11, ESH4) bound efficiently to FVIII. 
Unfortunately, the ability of FVIII to interact with FX was completely lost upon 
binding to these monoclonal antibodies (data not shown).
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Discussion
A high responder haemophilia A patient having predominantly FVIII-light- 
chain-specific antibodies was tolerated to FVIII by the administration of the 
FVIII preparation containing VWF. During treatment the concentration of 
Cl-domain-specific antibodies was significantly higher than the concentration 
of antibodies targeted at the C2 domain, a3 domain of the light chain and the 
A l domain and A2 domain of the heavy chain of FVIII. The patient’s 
antibodies were not able to interfere with the FVIII binding to phospholipids 
and to VWF. We found that the antibodies of the tested patient were able to 
inhibit FXa generation and the binding of FX to FVIII.
The epitope specificity pattern of the patient’s antibodies was rather unique. 
Usually FVIII antibodies develop towards the C2 domain and A2 domain in 
both previously untreated patients (Scandella et al., 2001) as well as previously 
treated patients (Laub et al., 1999; Sawamoto et al., 1998). However, the results 
of our study are in agreement with the results described by Prescott et al 
(Prescott et al., 1997). They reported a higher prevalence of FVIII light chain 
antibodies targeted at the A3-C1 fragment in patients who were treated with the 
pdFVIII preparation, while A2- and C2-domain-specific antibodies were pre­
dominant in a group of patients treated with the rFVIII preparation (Prescott 
e t a l ,  1997).
We were unable to detect any significant changes in the antibody epitope 
specificity during immune tolerance treatment. However, the interruption of 
treatment caused a significant increase in antibody production and a rise in the 
level of C2-domain-specific antibodies. Still, the patient’s antibodies were 
unable to interfere with the FVIII binding to VWF or to PS. Obviously, the 
concentration of these antibodies was not sufficiently high to interfere with 
these bindings or the antibodies were targeted at another region of the 
C2 domain. This indicates that the development of C2-domain-specific anti­
bodies is a common response to the administration of FVIII, but the production 
of antibodies with such epitope specificity was probably suppressed, since VWF 
containing the FVIII preparation was used for treatment. In principle, VWF 
could have masked the respective epitopes on the C2 domain and lowered the 
response to the C2 domain.
The epitope specificity of the patient’s antibodies was characterized by using 
recombinant FVIII fragments and by the competitive binding assay with 
monoclonal antibodies whose binding sites on FVIII were defined. The latter 
strategy was chosen because the recombinant fragments may possess a different 
conformation as compared to these domains in the native FVIII. Therefore, a 
higher number of antibody binding sites could be detected on recombinant 
fragments. This could also explain why the amount of antibodies bound to the 
Al domain and A2 domain exceeded the amount of antibodies neutralising the 
FVIII heavy chain. This suggests that antibody binding sites on the recombinant 
Al domain and the A2 domain were more easily accessible than in the native
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FVIII. On the other hand, the recombinant FVIII heavy chain and light chain, 
which were expressed in CHO cells could have possessed a different glyco- 
sylation pattern compared to the recombinant fragments produced by E. coli. 
Using synthetic peptide arrays the FVIII antibody binding to a high number of 
epitopes has been shown (Palmer et al., 1997). However, the binding of 
antibodies to certain epitopes could impair the FVIII coagulation activity. 
Therefore, the monoclonal antibodies were chosen for the competitive binding 
assay according to the relevance of the binding site for the functional activity of 
FVIII focusing mainly on the interaction of FVIII with VWF.
We demonstrated that the antibodies of the patient were targeted at the 
epitopes that were exposed on the surface of the FVIII-VWF complex, except 
the a3 domain. One of the VWF binding sites locates within the a3 domain (aa 
1675-1684 (Shima et al., 1992), however, the antibodies of the patient were not 
able to hinder the FVIII binding to VWF. Presumably, the concentration of the 
a3-domain-specific antibodies was low or the binding sites of the patient’s 
antibodies were not overlapping with the VWF binding sites. The antibodies of 
the patient did not recognize the recombinant A3 domain, which shares a 
common region with the a3 domain (aa 1692-1700) and the Cl domain (aa 
1981-2043). This again could be explained by the presence of VWF in the 
administered FVIII preparation, which could have covered the respective 
immunogenic regions of FVIII or, on the other hand, by the different structure 
of the A3 domain in the recombinant fusion protein that was used in an ELISA. 
It could be expected that the A3 domain is also one of the targets of the 
antibodies of the patient, since several studies have shown the presence of 
antibodies against the A3-C1 fragment (Palmer et al., 1997; Prescott et al., 
1997; Scandella et al., 1995).
The antibodies of the patient were targeted at the C2 domain and were able 
to compete with monoclonal antibodies ESH4 and F29B10 for their binding 
sites on the C-terminus and the N-terminus of the C2 domain, respectively. No 
correlation between the amount of C2 domain antibodies and antibodies that 
compete with mAb ESH4 or mAb F29B10 was found. In spite of a low 
concentration of C2 domain antibodies, the binding of FVIII to ESH4 was 
abolished. Presumably, the antibodies of the patient were targeted at regions 
close to the ESH4 binding site on the FVIII light chain. Antibodies targeted at 
the N-terminus of the C2 domain as well as Cl-domain-specific antibodies 
could both be responsible for that, since the disulphide bonds position the 
C-terminus and N-terminus of the Cl domain and the C2 domain into close 
proximity as shown in the 3D model of FVIII (Liu et al., 2000; Stoilova- 
McPhie, 2002).
Studying the putative mechanism of the patient’s antibodies we discovered 
that these antibodies were able to inhibit FXa generation by interfering with the 
FX binding to FVIII. The formation of the FXa complex necessitates several 
subsequent interactions, namely the binding of FVIII to the PS monolayer, 
association of FIXa with the formed complex in the presence of Ca2+ and
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finally, the incorporation of FX into the complex. The FVIII binding to PS was 
not interfered by the tested patient’s antibodies. We were unable to study the 
interaction of FVIII with FIXa in the presence of the tested antibodies, since the 
volume of plasma samples available for the experiments was limited. The FIXa 
binding sites locate within the A2 domain (aa 558-565, 698-710, Fay et a l ,  
1994; Jorquera et al., 1992) and the A3 domain (aa 1811-1818, Lenting et al., 
1996) of FVIII and the tested antibodies recognized the A2 domain and 
interfered with the mAb 15 binding to FVIII, therefore we assume that the 
antibodies of the patient could inhibit the FIXa binding to FVIII.
The FX binding site locates within the Al domain (aa 337-372, Lapan and 
Fay, 1997) of FVIII, and a small amount of the patient’s antibodies was also 
able to interfere with the binding of mAb F7B4 (aa 356-360) to FVIII. These 
A 1-domain-specific antibodies were obviously able to inhibit the FX binding to 
FVIII, because in the presence of rFVIII a slightly lower amount of the patient’s 
antibodies was needed to abolish this interaction than in the presence of the 
FVIII light chain. Recently the FXa binding site on C2 domain amino acids 
2253-2270 has been mapped (Nogami e t al., 2000; Nogami et al., 1999). On 
the other hand, the presence of the FX and FXai binding sites within the C1-C2 
fragment has been reported (Liu and Thomson, 2000). However, these binding 
sites were different from that of VWF within the same fragment (Liu and 
Thomson, 2000). Most of the tested patient’s antibodies were targeted at the Cl 
domain, but the antibody binding sites were different from the epitopes of 
monoclonal antibody 2E9, which was able to interfere with the FVIII 
interaction with VWF. Our results are in agreement with the report by Liu et al. 
confirming that the binding site for FX is obviously within the Cl domain and 
differs from the binding site for VWF. Surprisingly, we discovered that 
C2-domain-specific antibodies ESH4 and B02C11, which were able to interfere 
with the FVIII binding to PS abolished the binding of FVIII to FX. This stresses 
the significance of a proper conformation of the C1-C2 domains in FVIII for 
binding to FX.
The antibody response was characterized in a single patient, who was treated 
according to an uncommon treatment protocol. The interruption of treatment 
caused the prolongation of the treatment period as described also in other 
studies (Kreuz et a i ,  1995; Oldenburg et al., 1999). Regardless of the elevated 
FVIII antibody level, the tolerance of the patient was achieved and the in vivo 
recovery normalized at the end of treatment. Although the Bethesda titer 
decreased to 0.8 BU/ml, we could still confirm the presence of FVIII antibodies 
by an ELISA at the end of treatment. A similar case proving that it was 
impossible to detect antibodies by the Bethesda assay during the immune 
tolerance treatment has been described in another study (Klinge et al., 2001). 
However, in that study an immuno-precipitation assay was used for detecting 
the respective antibodies (Klinge e ta l., 2001).
To our knowledge, this is the first detailed characterization of the FVIII 
antibody response during the immune tolerance treatment. Further studies are
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definitely needed in order to clarify the effect of VWF in the FVIII preparations 
on FVffl antibody production and epitope specificity. The exact determination 
of the Cl domain antibody binding sites of antibodies of the tested patient could 
lead to a better understanding of the structure as well as function of the Cl 
domain and could be of benefit to the development of FVIII pharmaceutical 
preparations in the future.
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Figure 1. Characterization of properties of the patient’s FVIII antibodies during ITT. 
The binding of the patient’s antibodies to the recombinant fragments of the FVIII light 
chain (A) and the recombinant fragments of the FVIII heavy chain (B) at 100 |Jg/ml IgG 
concentration (mean ± SD). Neutralization of the patient’s anti-FVIII antibodies by the 
recombinant FVIII light chain and the heavy chain as estimated by using the 
chromogenic method (LCh, HCh) or an ELISA assay (LCh ELISA, HCh ELISA) (C). 
The Bethesda titer and the administration scheme of FVIII preparation Haemoctin SDH 
(Biotest, Germany) (D).
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Figure 2. FVIII recombinant fragments used in the neutralization experiments (a) and 
GST-fusion proteins used for the characterization of the epitope specificity in ELISA 
assays (b ) .  The binding sites of monoclonal FVIII antibodies that were used in the 
competition assay (c).
Figure 3. Neutralization of the patient’s anti-FVIII antibodies by the recombinant light 
chain and the heavy chain of FVIII as measured by the chromogenic method (rLCh 
FVIII.C, rHCh FVIILC) or an ELISA assay (rLCh ELISA, rHCh ELISA). Tested 
plasma sample was taken at the beginning of ITT.
19
—*— 1st day 
2nd day 
—*— 1 month 
— 2 months 
5 months 
— 8 months 
— 10 months 
13 months
IgG concentration, [ig/ml
Figure 4. The binding of the patient’s antibodies to the recombinant Cl domain in an 
ELISA. Monoclonal antibody 2E9 specific to the Cl domain was used as a control 
(insert)
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Figure 5. Inhibition of the FVIII binding to different monoclonal FVIII antibodies by 
the patient’s IgG (mean ± SD) (A). Concentration of FVIII antibodies in purified IgG 
(jug per 10 mg of IgG) and the ELISA titer estimated in plasma. The inhibitory activity 
of FVIII antibodies in the FXa generation assay is shown as IgG concentration yielding 
50% of inhibition of FXa generation induced by rFVIII (IC 50% FVIII) or the 
recombinant light chain of FVIII (IC 50% rLCh) (B). The Bethesda titer and the 
administration scheme of FVIII preparation Haemoctin SDH (Biotest, Germany) (C).
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Figure 6. Inhibition of FXa generation induced by rFVIII (rFVIII) or the recombinant 
light chain of FVIII (rLCh) with the patient’s FVIII antibodies (0.5 mg/ml IgG) at the 
beginning of ITT. Each data point represents the mean of at least two individual 
experiments.
Figure 7. Inhibition of FXa generation induced by rFVIII (rFVIII) or the recombinant 
light chain of FVIII (rLCh) with the patient’s FVIII antibodies at different time point of 
ITT. The amount of FXa was estimated after 5 min of induction. Each data point 
represents the mean of at least two individual experiments.
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Figure 8. Interaction of FX with FVIII or its recombinant light chain bound to 
phosphatidylserine in the presence of the patient’s FVIII antibodies. Each data point 
represents the mean of at least two individual experiments.
References
Berntorp, E., Ekman, M., Gunnarsson, M., and Nilsson, I.-M. (1996). Variation in factor 
VIII inhibitor reactivity with different commercial factor VIII preparations. 
Haemophilia, 2, 95-99.
Biggs, R., Austen, D. E., Denson, K. W., Borrett, R., and Rizza, C. R. (1972a). The 
mode of action of antibodies which destroy factor VIII. II. Antibodies which give 
complex concentration graphs. British Journal o f Haematology, 23, 137-155.
Biggs, R., Austen, D. E., Denson, K. W., Rizza, C. R., and Borrett, R. (1972b). The 
mode of action of antibodies which destroy factor VIII. I. Antibodies which have 
second-order concentration graphs. Br J Haematol, 23, 125-35.
Fay, P. J., Beattie, T., Huggins, C. F., and Regan, L. M. (1994). Factor V illa A2 subunit 
residues 558-565 represent a factor IXa interactive site. J Biol Chem, 269, 20522-7.
Fay, P. J., Koshibu, K., and Mastri, M. (1999). The A l and A2 subunits of factor Villa  
synergistically stimulate factor IXa catalytic activity. J Biol Chem, 274, 15401-6.
Gensana, M., Altisent, C., Aznar, J. A., Casana, P., Hernandez, F., Jorquera, J. I., 
Magallon, M., Massot, M., and Puig, L. (2001). Influence of von Willebrand factor 
on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia, 7, 
369-74.
Gilles, J. G., Desqueper, B., Lenk, H., Vermylen, J., and Saint-Remy, J. M. (1996). 
Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in 
patients with hemophilia A. J Clin Invest, 97, 1382-8.
23
Gilles, J. G., Peerlinck, K., Arnout, J., Vermylen, J., and Saint-Remy, J. M. (1997). 
Restricted epitope specificity of anti-FVIII antibodies that appeared during a recent 
outbreak of inhibitors. Thromb Haemost, 77,938-43.
Hoyer, L. W. (1995). Factor VIII inhibitors. Curr Opin Hematol, 2, 365-71.
Jacquemin, M., Benhida, A., Peerlinck, K., Desqueper, B., Vander Elst, L., Lavend' 
homme, R., d'Oiron, R., Schwaab, R., Bakkus, M., Thielemans, K., Gilles, J. G., 
Vermylen, J., and Saint-Remy, J. M. (2000). A human antibody directed to the 
factor VIII Cl domain inhibits factor VIII cofactor activity and binding to von 
Willebrand factor. Blood, 95,156-63.
Jacquemin, M. G., Desqueper, B. G., Benhida, A., Vander Elst, L., Hoylaerts, M. F., 
Bakkus, M., Thielemans, K., Arnout, J., Peerlinck, K., Gilles, J. G., Vermylen, J., 
and Saint-Remy, J. M. (1998). Mechanism and kinetics of factor VIII inactivation: 
study with an IgG4 monoclonal antibody derived from a hemophilia A patient with 
inhibitor. Blood, 9 2 ,496-506.
Jorquera, J. I., McClintock, R. A., Roberts, J. R., MacDonald, M. J., Houghten, R. A., 
and Fulcher, C. A. (1992). Synthetic peptides derived from residues 698 to 710 of 
factor VIII inhibit factor IXa activity. Circulation, 86, 685a.
Kallas, A., and Talpsep, T. (2001). von Willebrand factor in factor VIII concentrates 
protects against neutralization by factor VIII antibodies of haemophilia A patients. 
Haemophilia, 7, 375-80.
Kasper, C. K., and Pool, J. G. (1975). Letter: Measurement of mild factor VIII inhi­
bitors in Bethesda units. Thromb Diath Haemorrh, 34, 875-6.
Kemball-Cook, G., Tuddenham, E. G., and Wacey, A. I. (1998). The factor VIII Struc­
ture and Mutation Resource Site: HAMSTeRS version 4. Nucleic Acids Res, 26, 
216-9.
Klinge, J., Auerswald, G., Budde, U., Klose, H., Kreuz, W., Lenk, H., and Scandella, D.
(2001). Detection of all anti-factor VIII antibodies in haemophilia A patients by the 
Bethesda assay and a more sensitive immunoprecipitation assay. Haemophilia, 7, 
26-32.
Kreuz, W., Ehrenforth, E., Funk, M., Auerswald, G., Mentzer, D., Joseph-Steiner, J., 
Beeg, T., Klarmann, D., Scharrer, I., and Kornhuber, B. (1995). Immune tolerance 
therapy on paediatric hemophiliacs with factor VIII inhibitors: 14 years follow-up. 
Haemophilia, 1, 24-32.
Lapan, K. A., and Fay, P. J. (1997). Localization of a factor X interactive site in the Al 
subunit of factor Villa. J Biol Chem, 272, 2082-8.
Laub, R., Di Giambattista, M., Fondu, P., Brackmann, H. H„ Lenk, H., Saenko, E. L., 
Felch, M., and Scandella, D. (1999). Inhibitors in German hemophilia A patients 
treated with a double virus inactivated factor VIII concentrate bind to the C2 domain 
of FVIII light chain. Thromb Haemost, 81, 39-44.
Lenting, P. J., van de Loo, J. W., Donath, M. J., van Mourik, J. A., and Mertens, K. 
(1996). The sequence Glul811-Lysl818 of human blood coagulation factor VIII 
comprises a binding site for activated factor IX. J Biol Chem, 271, 1935-40.
Lenting, P. J., van Mourik, J. A., and Mertens, K. (1998). The life cycle of coagulation 
factor VIII in view of its structure and function. Blood, 92, 3983-96.
Liu, M. L., Shen, B. W., Nakaya, S., Pratt, K. P., Fujikawa, K., Davie, E. W., Stod­
dard, B. L., and Thompson, A. R. (2000). Hemophilic factor VIII C l- and 
C2-domain missense mutations and their modeling to the 1.5-angstrom human 
C2-domain crystal structure. Blood, 96,979-87.
24
\Liu, M. L., and Thomson, A. R. (2000). Factor VIII’s Cl domain enhances C2 binding 
of factors IX/IXa, X/Xa and von Willebrand factor (VWF). Blood, SuppI, 2106.
Nogami, K., Shima, M., Hosokawa, K., Nagata, M., Koide, T., Saenko, E. L., Tana­
ka, I., Shibata, M., and Yoshioka, A. (2000). Factor VIII C2 domain contains the 
thrombin-binding site responsible for thrombin-catalyzed cleavage at Argl689. 
J Biol Chem, 275, 25774-80.
Nogami, K., Shima, M., Hosokawa, K., Suzuki, T., Koide, T., Saenko, E. L., Scan­
della, D., Shibata, M., Kamisue, S., Tanaka, I., and Yoshioka, A. (1999). Role 
of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem, 274, 
31000-7.
Oldenburg, J., Schwaab, R., and Brackmann, H. H. (1999). Induction of immune tole­
rance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive para­
meter for therapy duration and outcome. Vox Sang, 77,49-54.
Palmer, D. S., Dudani, A. K., Drouin, J., and Ganz, P. R. (1997). Identification of novel 
factor VIII inhibitor epitopes using synthetic peptide arrays. Vox Sang, 72, 148-61.
Peerlinck, K., Arnout, J., Di Giambattista, M., Gilles, J. G., Laub, R., Jacquemin, M., 
Saint-Remy, J. M., and Vermylen, J. (1997). Factor VIII inhibitors in previously 
treated haemophilia A patients with a double virus-inactivated plasma derived factor 
VIII concentrate. Thromb Haemost, 77, 80-6.
Prescott, R., Nakai, H., Saenko, E. L., Scharrer, I., Nilsson, I. M., Humphries, J. E., 
Hurst, D., Bray, G., and Scandella, D. (1997). The inhibitor antibody response is 
more complex in hemophilia A patients than in most nonhemophiliacs with factor 
VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood, 89, 3663-71.
Saenko, E. L., and Scandella, D. (1997). The acidic region of the factor VIII light chain 
and the C2 domain together form the high affinity-binding site for von Willebrand 
factor. J Biol Chem, 272, 18007-14.
Sawamoto, Y., Prescott, R., Zhong, D., Saenko, E. L., Mauser-Bunschoten, E., Peer­
linck, K., van den Berg, M., and Scandella, D. (1998). Dominant C2 domain epitope 
specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII 
CPS-P, in previously treated hemophilia A patients without inhibitors. Thromb 
Haemost, 19, 62-8.
Scandella, D., Kessler, C., Esmon, P., Hurst, D., Courter, S., Gomperts, E., Felch, M., 
and Prescott, R. (1995). Epitope specificity and functional characterization of factor 
VIII inhibitors. Adv Exp Med Biol, 386,47-63.
Scandella, D. H., Nakai, H., Felch, M., Mondorf, W., Scharrer, I., Hoyer, L. W., and 
Saenko, E. L. (2001). In hemophilia A and autoantibody inhibitor patients: the factor 
VIII A2 domain and light chain are most immunogenic. Thromb Res, 101, 377-85.
Scharrer, I., Bray, G. L., and Neutzling, O. (1999). Incidence of inhibitors in haemo­
philia A patients-a review of recent studies of recombinant and plasma-derived 
factor VIII concentrates. Haemophilia, 5, 145-54.
Schwaab, R„ Brackmann, H. H., Meyer, C., Seehafer, J., Kirchgesser, M., Haack, A., 
Olek, K., Tuddenham, E. G., and Oldenburg, J. (1995). Haemophilia A: mutation 
type determines risk of inhibitor formation. Thromb Haemost, 74, 1402-6.
Shima, M., Yoshioka, A., Nakajima, M., Nakai, H., and Fukui, H. (1992). A monoclo­
nal antibody (NMC-VIII/10) to factor VIII light chain recognizing Glul675- 
Glul684 inhibits factor VIII binding to endogenous von Willebrand factor in human 
umbilical vein endothelial cells. Br J Haematol, 81,533-8.
39 25
Spiegel, P. C., Jr., Jacquemin, M., Saint-Remy, J. M., Stoddard, B. L., and Pratt, K. P.
(2001). Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab 
complex: identification of an inhibitory antibody epitope on the surface of factor 
VIII. Blood, 98 ,13-9 .
Stoilova-McPhie, S., Villoutreix, BO, Mertens K, Kemball-Cook, G, Holzenburg, A.
(2002). 3-dimensional structure of membrane-bound coagulation factor VIII: 
modeling of the factor VIII heterodimer within a 3-dimensional density map derived 
by electron crystallography. Blood, 99, 1215-1223.
Suzuki, T., Arai, M., Amano, K , Kagawa, K , and Fukutake, K. (1996). Factor VIII 
inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII 
complexed with von Willebrand factor. Thromb Haemost, 76, 749-54.
26

Kallas A, Talpsep T, Everaus H. 
Changes in epitope specificity and in distribution of IgG subtypes 
of FVIII antibodies during immune tolerance therapy (ITT) 
in hemophilia A patients with FVIII antibodies -  a case report. 
In Scharrer I., Schramm W. (eds.) 31st Hemophilia Symposium.
Springer Verlag Berlin Heidelberg, 2001, 23-40
Changes in Epitope Specificity and in Distribution 
of IgG Subtypes of FVIII Antibodies during Immune 
Tolerance Therapy (ITT) in Hemophilia A Patients 
with FVIII Antibodies -  a Case Report
A. K a l l a s ,  T. T a lp s e p  and H. E v e r a u s
Introduction
Replacement therapy of patients with inherited coagulation factor VIII deficiency 
(hemophilia A) comprises administration of either plasma derived factor VIII con­
centrates or recombinant factor VIII. Up to 25% of patients may develop antibodies 
against FVIII (FVIII:Ab). Antibodies arise more often in patients with severe form 
of hemophilia A caused by inversion, large deletion or stop codon in FVIII gene 
rather than in patients with mild or moderate forms of the disease (point muta­
tions, small deletion in FVIII gene) [1,2]. It is not known why only some patients 
develop FVIII antibodies whereas others do not in spite of extensive replacement 
therapy.
Factor VIII circulates in plasma as a heterodimer composed of the heavy chain 
(domains A1-A2-B) and the light chain (domains A3-C1-C2), and forms a complex 
with von Willebrand factor (vWF) via the light chain [3] (Fig. 1). Von Willebrand 
factor stabilizes FVIII and can interfere with antibody binding to FVIII either by
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Fig. 1. The structure of FVIII molecule. VWF binding sites and antibody binding sites are indi­
cated
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direct blocking of epitopes on FVIII light chain or by steric hindrance. Most inhibi­
tory antibodies to human factor VIII developed in hemophilia A patients bind to 
epitopes within A2 domain, C2 domain, and A3-C1 domains [4]. Antibodies re­
acting with C2 domain of the FVIII light chain possess a lower ability to neutralize 
FVIII coagulation (FVIII:C) activity, when it is in a complex with vWF (FVIII-vWF) 
[5]. In a previous study we have shown that the decreased neutralization of FVIII in 
the presence of vWF by FVIII antibodies was in good correlation with the level of 
antibodies against FVIII light chain [6]. These in vitro findings suggest that detect­
ing the epitope specificity and the concentration of antibodies can be used for 
selecting FVIII concentrate for replacement therapy and for immune tolerance 
induction. Different protocols of immune tolerance therapy (ITT) like the Bonn 
protocol, the Malmö method, and their modifications demonstrate the similar 
efficacy in suppressing the production of antibodies to a non-detectable level [7]. 
While using FVIII concentrate alone for IT therapy [8, 9], the success rate may 
depend upon the purity of FVIII concentrate used [10].
The effect of different FVIII concentrates on the immune system of hemophilia 
A patients has been intensively studied both in vitro and in vivo. Lymphocytes res­
pond to FVIII with enhanced cytokine production in vitro [11], but in vivo the 
situation is more complicated and depends also on the availability of cytokine 
receptors, which determine the magnitude of immune response to FVIII concentra­
tes. First exposure to FVIII concentrate may cause production of IgM type FVIII 
antibodies, while isotype switch occurs soon in order to produce IgG isotype anti­
bodies. Distribution of different IgG antibody subtypes depends on whether the 
Thl or Th2 phenotype is dominant in a particular patient [12,13].
We investigated the changes of epitope specificity and distribution of IgG sub- 
types of FVIII antibodies in hemophilia A patient during ITT with FVIII-vWF con­
centrate. The IgG subtype distribution of FVIII antibodies was estimated using sen­
sitive ELISA assay and results were compared with those obtained from the samples 
of hemophilia A patients with persistent FVIII antibody titer, and from the samples 
taken from the patient with low titer antibodies during on-demand treatment with 
FVIII concentrates of different purity.
Patients
Patient i Undergoing ITT
A 3-year-old severe hemophilia A patient with intron 22 inversion in FVIII gene 
(type 1) had FVIII antibody titer of 26 BU/ml. Immune tolerance therapy with FVIII 
concentrate, Haemoctin SDH (Biotest, Germany) was begun when he had had 23 
exposure days to FVIII. Haemoctin SDH was the only available FVIII concentrate at 
that time in Estonia. The specific activity of Haemoctin SDH was 100 IU of FVIII 
per mg of protein. The immune tolerance therapy comprised continuous infusion 
(Cl, 40 IU/kg/h for 8 days + 8 days via vascular line), followed by bolus injections 
100 IU/kg/day for 1 month and thereafter treatment was continued with the dose 
100 IU/kg twice a week for 10 months (Fig. 2). After 2 months of ITT, the antibody
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FVIII light-chain antibodies of different IgG subtypes, %
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Fig.2a-e. Immune tolerance therapy in patient 1 with high titer FVIII antibodies, a The course 
of the treatment with FVIII concentrate Haemoctin SDH (Biotest); b Changes in FVIII anti­
body titer measured by Bethesda assay; c Relative distribution of FVIII light chain (rLCh) and 
FVIII heavy chain (rHCh) antibodies measured by an ELISA assay (ELISA) and by a chromo­
genic method; d IgG subtype distribution of FVIII antibodies; e IgG subtype distribution of 
FVIII light chain antibodies
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titer had reduced from 17.5 BU/ml to 0.7 BU/ml. During the course of the treatment 
with a dose of 100 IU/kg twice a week, problems in venous access appeared, which 
were accompanied by an increase in antibody titer to 1.2 BU/ml. Therefore, the 
second continuous infusion for 8 days with a dose of 150 IU/kg/h was given. In 
response to this treatment, the antibody titer peaked to 3.5 BU/ml, and then 
dropped to 0.8 BU/ml after 9 months of IT therapy; The last three samples contained 
only antibodies with non-inhibitory activity (Bethesda titer 0.8 BU/ml). In vivo 
recovery normalized and the patient started prophylactic treatment (dose of 
100 IU/kg twice a week). During ITT the patient had no bleeding episodes.
Patient 2 Treated with FVIII Concentrates with Different Purity 
(On-demand Treatment)
A severe hemophilia A patient with intron 22 inversion in FVIII gene (type 2) deve­
loped FVIII antibodies (1.1 BU/ml) at the age of 6 years. Patient’s HLA genotype 
was DR4 (DRB1*04), DR8 (DRB1*08), DQ4 (DQB1*04), and DQ7 (DQB1*0301) as 
detected by PCR method. He has had 8 exposure days to FVIII concentrates 
Hemofil-M (Baxter, USA), 8 exposure days to cryoprecipitate and 4 to plasma. The 
amount of FVIII concentrates used and the characterization of FVIII antibodies in 
plasma samples taken at different time points are shown in Fig. 3. Treatment of the 
patient with FVIII concentrates Koate-HP (Bayer, USA) and Kryobulin Tim 3 
(Baxter), both of which contain vWF, caused a decrease in FVIII antibodies from 1.0
Kryobulin Koate-HP Octonativ Haemoctin Haemate Afact
w 2
07 .20.95  02 .05.96 08 .23.96 03 .11.97 09 .27.97 04 .15.98 11.01.98 05 .20.99 12.06.99 06 .23.00
Fig. 3. Changes in IgG subtype distribution of FVIII antibodies of hemophilia A patient 2 
during on-demand therapy with FVIII concentrates with different purity. FVIII antibodies of 
different IgG subtypes are shown as follows: IgGl (<0>), IgG2 (□), IgG3 (A), IgG4 (X), Bethesda 
units (Bu/ml) ♦ )
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to 0.3 BU/ml. However, changing to FVIII concentrate, Octonativ-M (Pharmacia 8c 
Upjohn), which was purified by monoclonal antibody, resulted in an increase in 
FVIII antibodies up to 1.7 BU/ml. The respective antibodies reacted with FVIII light 
chain and A2 domain. In vivo FVIII recovery was 32.4% after administration of 
25 IU/kg of body weight of Octonativ-M. After 15 months of treatment with 
Octonativ-M, FVIII concentrate was replaced by Haemoctin SDH (Biotest). In 
September 1998, in vivo recovery was 64.8% (the dosage 25 IU/kg of body weight). 
Antibody titer had slightly decreased (0.8 BU/ml), and antibodies had reactivity 
against the light chain and A2 domain of FVIII. Haemoctin SDH was used for on- 
demand treatment for the next 11 months. The titer of antibodies had decreased to 
0.7 BU/ml and antibody reactivity against the light chain and the A2 domain per­
sisted. In vivo recovery with Haemoctin-SDH was 80.5%. Thereafter treatment was 
switched to FVIII concentrate Octonativ-M for 3 months, followed by treatment 
with Haemate (Aventis Behring, USA) for 5 months, and then monoclonal antibody 
purified FVIII concentrate Aafact (CLB, the Netherlands).
Hemophilia A Patients with Persistent FVIII Antibodies
Plasma samples from 12 hemophilia A patients having FVIII antibodies were stu­
died. The study protocol was approved by the Ethics Committee of the University of 
Tartu, Estonia. Anti-FVIII antibodies had developed in all the patients in response 
to the on-demand treatment with plasma-derived FVIII concentrates. Plasma 
samples were drawn in a clinical stable situation before any immune tolerance 
induction. Plasma samples contained 1 to 300 BU/ml of FVIII antibodies. All in­
vestigated FVIII antibodies reacted with A2 domain and the light chain of FVIII as 
detected by Western blotting using plasma derived FVIII concentrate Haemoctin 
SDH (Biotest, Germany). Moreover, all plasma samples contained antibodies inter­
fering FVIII interactions with vWF and also interaction with phosphatidylserine 
measured by ELISA assays, as described by Shima and coworkers [14]. FVIII anti­
bodies competed with murine monoclonal antibody ESH4 (American Diagnostica, 
USA) for phospholipid binding site at light chain C-terminus of FVIII as detected 
by an ELISA.
Materials
Recombinant FVIII (rFVIII, Recombinate, Baxter) was used throughout the study. 
Recombinant FVIII fragments (recombinant heavy chain, rHCh, and light chain, 
rLCh) were kindly provided by Dr. Mirella Ezban. Bovine serum albumin (BSA) and 
pNPP (p-nitrophenylphosphate) were purchased from Sigma. Other chemicals were 
of analytical grade. Majority of in vitro assays was carried through either in TBS 
(0.02 M Tris buffered saline, pH 7.2) or carbonate buffer (0.05 M carbonate-bi­
carbonate buffer, pH 9.6).
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Methods
FVIII antibodies in plasma samples taken during IT therapy were measured by 
Bethesda assay and by an ELISA method. Recombinant FVIII (Recombinate) was 
used as a coating agent for microplates.
Neutralization of FVIIIcC Activity in the Presence and Absence of vWF
Plasma-derived FVIII-vWF concentrate (Haemoctin SDH) and recombinant FVIII 
(Recombinate) were diluted to 1 IU/ml of FVIILC with TBS buffer containing 1% 
BSA and incubated with an equal volume of serially diluted (1:2 to 1:1000 in 
TBS-BSA) FVIII antibody plasma sample for 1 h at 37 °C. Residual FVIILC was 
determined by chromogenic method according to manufacturer’s instructions 
(Coatest, Chromogenix AB, Italy) on a 96-well microplate. Percentage neutralization 
was calculated relative to a control. The control had the test plasma sample replaced 
by buffer or plasma from CRM negative hemophilia A patient without FVIII anti­
bodies. The test plasma sample dilution giving 50% of neutralization of FVIILC 
activity was found using both concentrates. The results were used to calculate a 
ratio of 50% neutralization of FVIILC with rFVIII to that with FVIII-vWF.
Distribution of FVIII Light Chain and Heavy Chain Neutralizing Antibodies 
Measured by an ELISA Assay
Microplates (PolySorp, Nunc, Denmark) were coated with rFVIII (Recombinate) dilu­
ted to 8 IU/ml in carbonate buffer and incubated overnight at 2-8 °C. The sites of non­
specific binding in the wells of the microplate were blocked with TBS containing 3% 
BSA for 1 h at room temperature and BSA was washed off with TBS-T (washing buf­
fer, TBS with 0.1% Tween 20). Plasma samples with FVIII antibodies were diluted to 
4 BU/ml, except test plasma samples with FVIII antibody titer < 4 BU/ml, which were 
used undiluted. To neutralize FVIII antibodies, plasma samples were incubated with 
an equal volume of recombinant FVIII fragments diluted from 0.2 to 12.6 IU/ml 
according to labelled activity, for 1 h at 37 °C. After incubation, aliquots of incubation 
mixture were transferred to antigen in the wells of the microplate and incubated for 
2 h at 37°C. Bound FVIII antibodies were detected using rabbit anti-human IgG con­
jugated with alkaline phosphatase (AP) diluted 1:1000 (Dako, Denmark) and visuali­
zed with AP-substrate pNPP (p-nitrophenyl phosphate) and the color change was read 
at 405 nm. Two controls were included with each test: one mixture that had the anti­
body plasma sample replaced by buffer (minimal binding), and the second mixture 
that used buffer instead of recombinant FVIII fragments (maximum binding). The 
percentage neutralization was calculated as follows: 100 -  ([binding with fragment -  
minimum binding]/[maximum binding -  minimum binding]) x 100. The plateau was 
defined as the minimal concentration of FVIII fragment, which yielded the maximal 
(plateau) optical density (OD). When FVIII antibodies were partially neutralized by 
recombinant fragments, all values within the plateau region were averaged.
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Distribution Antibodies Neutralized by FVIII Light Chain 
and Heavy Chain Measured by Chromogenic Method
The plasma samples were diluted to neutralization activity of 4 BU/ml, except 
plasma samples, which contained < 4 BU/ml of FVIII antibodies and were used undi­
luted, and incubated with an equal volume of serially diluted recombinant FVIII 
fragments as described in the previous assay. An aliquot was removed for measuring 
FVIII antibodies by an ELISA assay. To the remaining mixture an equal volume of 
rFVIII (Recombinate) diluted to 2 IU/ml was added and incubated for 1 h at 37 °C. 
Residual FVIII coagulation activity (FVIILC) was measured by the chromogenic 
method. Percentage of neutralization was calculated using the above-mentioned for­
mula but binding capacity was substituted with FVIILC activity. Maximum FVIILC 
activity was measured from the mixture of recombinant fragments and rFVIII with­
out an antibody sample, incubated in the same conditions. If the tested plasma con­
tained an FVIII antibody level <10 BU/ml, the plasma sample from the hemophilia 
A patient (CRM-negative and without FVIII antibodies) was used in the mixture to 
obtain the maximum FVIILC activity. Minimum FVIILC activity was found for each 
test sample incubated with rFVIII without any competitive FVIII fragments. The 
plateau value was similarly measured as in the previous assay.
ELISA Assay for Measuring FVIII Antibody IgGl-4  Subtypes
Immunoplates (PolySorp) were coated with 8 IU/ml recombinant FVIII (Recom­
binate) in carbonate buffer and incubated overnight at 2-8 C. After washing with 
washing buffer, the wells were blocked with TBS containing 5% BSA and incubated for 
1 h at room temperature (RT). Plasma samples were diluted from 1:10 to 1:5000 in 
TBS, transferred to the wells and incubated for 2 h at 37 °C. Bound FVIII antibodies 
were detected after washing with sheep monoclonal anti-human IgGl, IgG2, IgG3 or 
IgG4 antibody (CLB, The Netherlands) diluted 1:1000 in TBS by incubating for 1 h at 
37 °C followed by rabbit anti-sheep IgG-biotin conjugate (diluted 1:1000), incubating 
for 1 h at RT. Streptavidin -  AP conjugate was added to the wells at dilution (1:1000) 
and incubated for 30 min at RT. Between all incubation steps the wells were thorough­
ly washed with TBS-T. The reaction was visualized using pNPP solution (maximum 
absorbency was achieved in 30 min) and stopped with 1 M NaOH. Buffer and FVIII 
antibody free plasma from severe hemophilia A patients were used instead of investi­
gated plasma sample as controls. Cut-off value was defined as a mean value of optical 
densities measured for controls plus 3 standard deviations. The ELISA titer was 
defined as the maximal dilution of sample yielding OD exceeding the cut-off value.
ELISA Assay for Estimation of FVIII Light Chain Antibody IgG Subtype 
Distribution
Immunoplates (PolySorp) were coated with recombinant FVIII light chain diluted 
1:1000 in TBS and incubated overnight at 2-8 °C. Afterwards the assay was con­
tinued as described in the section above.
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Immunoblotting Analysis
Human FVIII (Haemoctin SDH) or recombinant FVIII fragments were cleaved by 
thrombin (0.01 IU thrombin per 1 IU of FVIII) for 30 min at 37°C and fragments 
were separated by SDS-PAGE under reduced and unreduced conditions using 
10-15% gradient gel.
Inhibition of FVIII Binding to Phospholipids Measured by an ELISA Assay
One hundred microliters of methanol dissolved L-(-phosphatidyl)-l-serine (Sigma) 
at a concentration of 5 |xg/ml was added to each well of polystyrene microplates 
(PolySorp) and air-dried at room temperature (RT). The wells were blocked by 
adding TBS containing 5% BSA and incubated for 1 h at RT. After washing with 
washing buffer, a mixture containing an equal volume of rFVIII (Recombinate) 
diluted to 2 IU/ml in TBS-BSA (1% of BSA in TBS buffer) and a serially diluted (1:2 
to 1:1000) test plasma sample was added to the wells of the microplate and incu­
bated for 2 h at RT with continuous agitation. Bound FVIII was detected by adding 
mouse anti-human monoclonal antibody ESH5 (against FVIII heavy-chain, 
American Diagnostica, USA) diluted 1:500 in TBS. After washing goat anti-mouse 
IgG conjugated with AP (1:1000, Amersham Pharmacia Biotech) was added and 
incubated at RT for 1 h. The reaction was visualized by adding AP substrate pNPP. 
The control included in each test contained a mixture in which test plasma sample 
dilution was substituted with buffer.
Inhibition of FVIII Binding to von Willebrand Factor Measured by an ELISA Assay
Microplate wells (MaxiSorp, Dako) were coated with 100 [il of rabbit anti-human 
vWF antibody (1:4000, Dako, Denmark) in carbonate buffer and incubated over­
night at 2-8°C. After washing, standard plasma (from a plasma pool of 22 plasmas 
from healthy persons) diluted to 1:20 in TBS-BSA was added and incubated for 1 h 
at RT. Factor VIII was dissociated from vWF by incubating with 0.4 M CaCl2 for 
30 min at RT. After washing, a mixture of a test plasma sample dilution with an 
equal volume of rFVIII (Recombinate) diluted to 2 IU/ml in TBS-BSA and incubated 
previously for 30 min at 37°C was added to the wells of the microplate and incu­
bated for 2 h at RT. Bound FVIII was detected as described in the previous assay.
Competitive Enzyme-Linked Immunosorbent Assay
Microplates were coated with rFVIII (Recombinate) diluted to 8 IU/ml in carbonate 
buffer and incubated overnight. After washing with washing buffer, plates were 
blocked with 5% BSA in TBS for 1 h at RT. Then a mixture containing an equal 
volume of test plasma sample dilution (dilutions 1:10 and 1:100) with either of the 
murine FVIII monoclonal antibodies ESH5 or ESH4 diluted to 25 (ig/ml was added
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to the wells coated with FVIII and incubated for 2 h at RT with continuous agita­
tion. The bound murine FVIII antibody was detected by using goat anti-mouse IgG 
diluted to 1:1000.(AP conjugate) and the reaction was visualized with AP substrate 
pNPP, The competition was calculated relative to the control where test .plasma 
samples were replaced by buffer (no competition of binding to FVIII).
Statistical Analysis
Student f-test was used to compare the level of different IgG subtypes. Correlation 
was calculated according to Spearman rank order correlation coefficient. P value of 
0.05 was considered significant.
Results
Characterization of FVIII Antibodies on Patient Before ITT
Immunoblotting analysis showed antibody reactivity against thrombin cleaved and 
non-cleaved FVIII light chain and A2 domain of FVIII. The neutralization activity 
of FVIII antibodies was reduced in the presence of FVIII-vWF complex (Fig. 4). The 
ratio of 50% neutralization of FVIII:C with rFVIII to FVIIIrvWF complex was 4.5. 
The extent to which each epitope contributed to FVIII inhibition was determined by 
neutralization assay. Antibodies directed towards the heavy chain accounted for 
30% of the FVIII inhibitory antibodies, while adding a recombinant FVIII light
Plasma dilution, 1 :x
Fig. 4. Neutralization of FVIII:C activity by FVIII antibodies from the plasma sample of pati­
ent 1 taken before immune tolerance therapy. Test plasma dilutions were iiicübated with FVIII 
concentrate (rFVIII, Recombinate, Baxter) and FVIII concentrate containing vWF (FVIII-vWF, 
Haemoctin SDH, Biotest). The residual FVIII:C activity was measured by chromogenic 
method. Each data point represents the mean of two individual experiments
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Recombinant fragment, IU/ml
Fig. 5. Neutralization of FVIII antibodies from plasma sample from patient 1 taken before ITT. 
Plasma sample was diluted to 4 BU/ml and incubated with increasing concentration of recom­
binant FVIII light chain (rLCh) and heavy chain (rHCh). The neutralization of antibodies was 
measured by an ELISA assay (ELISA) and by a chromogenic method (FVIILC) as described in 
Materials and Methods. Each data point represents the mean of two individual experiments
chain resulted in 78% of FVIII inhibitory antibody neutralization. In an ELISA assay 
7% of antibodies were neutralized by recombinant heavy chain and 100% by recom­
binant light chain (Fig. 5). Antibodies inhibited FVIII interaction with phospho­
lipids (50% of inhibition was achieved at the dilution 1:100) and FVIII interaction 
with vWF (50% of inhibition was achieved at the dilution 1:50) as measured by 
ELISA assays respectively [15]. FVIII antibodies of tested plasma samples competed 
with the murine monoclonal antibody ESH4 for the phospholipid binding site of 
the C-terminus of the light chain of FVIII as detected by ELISA.
Changes in Epitope Specificity of FVIII Antibodies During ITT
Epitope specificity of FVIII antibodies was measured in samples taken at different 
time points during IT therapy that contained an inhibitor titer of at least 2 BU/ml. 
During first continuous infusion (Cl) treatment the rHCh neutralizing antibodies 
reached a non-detectable level measured by chromogenic method and ELISA assay 
(Fig. 2). However, Western blot analysis using the same recombinant fragments 
showed the presence of antibodies reacting with the light chain and heavy chain of 
FVIII in all investigated plasma samples during ITT. The epitope specificity of anti- 
FVIII light chain antibodies changed towards epitopes without functional activity. 
Factor VIII heavy chain antibodies were detected mostly by ELISA assay (6-21%) 
and the concentration of these antibodies reached an undetectable level at the end 
of the treatment. Theoretically, the total amount of FVIII light chain plus FVIII
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heavy chain neutralizing antibodies should be 100%, but it was true for few plasma 
samples. Samples taken at the early stage of IT therapy contained in summary more 
than 100% of rHCh and rLCh neutralizing antibodies, while last plasma samples 
accounted less than 100%. Recombinant LCh or HCh concentration required for the 
first point of maximum neutralization was significantly different for these plasma 
samples. It can be explained by the presence of antibodies with different affinities 
to recombinant fragments. The lower slope of the neutralization curve of recom­
binant fragments explained this effect.
Changes in IgG Subtype Distribution During ITT
At the beginning of the ITT the patient had 29.8% of IgG4, 25.5% of IgGl, 25% of 
IgG2 and 19.6% of IgG3 subtype FVIII antibodies. Factor VIII light chain antibodies 
were present as follows: 38% of IgG4,24% of IgGl, 21% of IgG3 and 17% of IgG2 
subtypes. Results of IgGl-4 subtype distribution are shown on Fig. 2 D, E. During 
the first continuous infusion changes in FVIII antibody distribution were observed. 
Thereafter the distribution of IgG subtypes of FVIII:Ab remained unchanged con­
comitant with an increased level of IgG4 subtype antibodies. FVIII antibodies 
specific to FVIII light chain (FVIII-LCh:Ab) had a different IgG subtype distri­
bution. During the ITT, factor VIII light chain antibodies of subtypes IgGl, IgG4, 
IgG3 were almost identically expressed and at a significantly higher level than IgG2 
antibodies. At the beginning of treatment a fluctuation in FVIII-LCh:Ab subtype 
distribution was found to be analogous to that of FVIII:Ab. The amount of antibo­
dies neutralized by recombinant FVIII light chain as measured by an ELISA assay 
correlated only with IgG2 subtype of FVIII:LCh:Ab (P=0.02). There were two peaks 
of IgGl subtype levels. The first was observed after 1 month of treatment with the 
dose 100 IU/kg per day and another one after 1 month of the second continuous 
infusion. One of them was accompanied by an increase in the IgGl subtype of FVIII 
light chain antibodies and the second one was associated with the appearance of 
antibodies against epitopes within the FVIII heavy chain.
FVIII Antibody Subtype Distribution in Hemophilia A Patients 
with Persistent FVIII Antibodies
In order to clarify whether the IgG subtype distribution of FVIII antibodies in 
hemophilia A patients with persistent FVIII antibodies differs from that detected 
during ITT, we investigated plasma samples of 12 hemophilia A patients. The 
characterization of patients is shown in Table 1. We used a sensitive ELISA assay for 
the detection of IgG subtypes directly from the plasma or serum sample. The 
estimated cut-off values of optical density for IgGl, IgG2, IgG3, and IgG4 FVIII anti­
bodies were 0.113, 0.103, 0.089, and 0.089 respectively. The results are shown in 
Table 1. The most abundant were IgG4 type FVIII antibodies and the less abundant 
were IgGl antibodies (P=0.02). IgG2 and IgG3 subtype FVIII antibodies were pre­
sent in almost equal concentration, being significantly lower than IgG4 subtype
Table 1. Characterization of FVIII antibodies (n.d. not determined)
Plasma Bethesda Distribution of FVIII antibodies Distribution of FVIII light Distribution of FVIII antibodies Inversion
sample units chain antibodies against recombinant light chain in intron 22
(rLCh) and heavy chain (rHCh) of FVIII gene
IgGl % IgG2 % IgG3 % IgG4 % IgGl % IgG2 % IgG3 % IgG4 % ELISA assay 
rLCh % rHCh %
Chromogenic
method
rLCh % rHCh %
1 140 22 25.2 21 31.6 29.5 23.2 17 33.5 96 7 53 8 Type 1
2 9 25.5 25 19.6 29.8 24 17 21 38 100 7 78 30 Type 1
3 5 25 25 23 26 29.8 10.7 1.8 41.7 97 25 82 .42 Rare
inversion
4 7 30 14.5 21 33.9 74 7.4 0 18.5 92 20 93 3.5 n.d.
5 8 10.6 19 19 51 17 17 22 43.5 62 20 75 27 Type 1
6 37 32 17 21 32 12.5 12.5 25 50 93 58 82 21 Type 2
7 300 32.8 20.4 19.8 26.9 22.6 19.3 30.4 27.6 90 7 95 7 Type 1
8 280 16.2 34.2 17 32.4 3.4 13.7 31 51.7 95 6 96 6 n.d.
9 4 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 90 3 83 15 n.d.
10 1 27.8 12.8 11 27.8 27.4 39.6 17.8 14.8 n.d. n.d. 21 21 Type 2
11 5 26 24.6 24.6 24.6 55 22 11 11 70 74 64 65 n.d.
12 150 30 7 28.9 33.3 24 20 28 28 18 94 26 74 n.d.
Mean 25.3 20.4 20.5 31.8 29.0 18.4 20.1 32.6
SD 6.8 7.5 4.5 7.1 19.7 8.5 9.1 13.8
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concentration (PcO.Ol and PcO.Ol respectively). The amount of antibodies re­
cognizing light chain of FVIII measured by chromogenic method (Table 1) corre­
lated well with the concentration of IgG2 subtype FVIII:Ab (PcO.Ol) in all plasma 
samples. The results of the Bethesda assay correlated fairly well with the ELISA 
titers of all four IgG subtypes of FVIII:Ab.
In another ELISA test, recombinant FVIII light chain was used to coat ELISA 
microplates. The relative distribution of IgG subtype FVIII light chain antibodies 
(FVIII-LCh:Ab) was compared with the relative subtype distribution of antibodies 
against a whole FVIII molecule. The estimated cut-off values for IgGl, IgG2, IgG3 
and IgG4 were 0.222, 0.217, 0.167, and 0.166 respectively. The results of FVIII- 
LCh:Ab IgG subtypes are shown in Table 1. The higher relative amount of FVIII-LCh 
antibodies belonged to IgG4 subtype. The level of FVIII light chain antibodies 
decreased in the order IgG4>IgGl>IgG3>IgG2 and was similar to subtype distribu­
tion of antibodies against a FVIII whole molecule. The amount of FVIII light chain 
antibodies in all the investigated samples measured by the ELISA assay had a good 
correlation with IgG2 (P=0.01).The results of the Bethesda assay correlated with the 
results of all IgG subtypes (PcO.Ol).
Changes in FVIII:Ab IgG Subtype Distribution During the Treatment 
with Different FVIII Concentrates
One low responder hemophilia A patient (patient 2, Fig. 3) was treated with plasma 
derived FVIII concentrates of different purity for a long time. The samples were 
drawn at different time points and the subtype distribution of FVIII:Ab was studied. 
Factor VIII-LCh:Ab was not measured because of the limited amount of plasma. At 
the beginning of the treatment, IgGl subtype FVIII antibodies were predominant; 
during the treatment with Kryobulin TIM 3 the level of IgGl decreased and was 
replaced mainly by IgG4. In July 1997, FVIII concentrate was changed to monoclonal 
affinity purified FVIII concentrate Octonativ-M. A significant increase in IgG4 sub- 
type was accompanied by a decrease in IgGl subtype FVIII:Ab, while the levels IgG2 
and IgG3 subtype remained unchanged. In Sept 1998, treatment was continued with 
FVIII-vWF concentrate and after 7 months of treatment all subtypes except IgGl 
were expressed at almost equal levels. In June and July 1999, FVIII concentrate 
Octonativ-M was again administered. This caused another profound increase in IgG4 
subtype level. Then the patient was treated with Haemate for 5 months and thereaf­
ter with monoclonal antibody purified FVIII concentrate (Aafact) for 6 months. As a 
result of this treatment the levels of FVIII antibodies of IgGl and IgG3 subtypes 
increased while the levels of subtypes IgG4 and IgG2 decreased significantly.
Discussion
We investigated the changes in epitope specificity and IgG subtype distribution of 
FVIII antibodies influenced mainly by the administration of high purity FVIII con­
centrates containing vWF for immune tolerance induction. In vitro experiments
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showed lower neutralization of FVIII concentrate containing vWF by FVIII anti­
bodies of the studied patient and predicted a beneficial outcome using the same 
concentrate for immune tolerance therapy. The ITT effectively suppressed the pro­
duction of inhibitory antibodies reacting mainly with FVIII light chain to a non- 
detectable level. FVIII antibodies of IgG4 subtype dominated over all other sub- 
types, except IgGl subtype at two different time points, where the higher level of 
IgGl was probably caused by the increased dosage of administered FVIII.
The patient was tolerated using FVIII-vWF concentrate. However, FVIII anti­
bodies recognizing the FVIII light chain were expressed during the whole treatment, 
but the subtype distribution of FVIII light chain antibodies differed from that of 
patients with persistent inhibitor antibodies (Table 1). All IgG subtypes, except IgG2 
subtype of FVIII light chain antibodies were expressed at equal levels during ITT. 
This could be due to the fact that the isolated FVIII light chain used in neutralization 
experiments and ELISA assays possesses a higher number of accessible epitopes on 
the surface than the form of heterodimer with FVIII heavy chain, as it circulates in 
plasma. The fact that the ELISA titer of antibodies bound to the FVIII light chain was 
higher than that bound to the whole FVIII molecule in some samples, suggests that 
FVIII light chain is more immunogenic than the whole FVIII molecule. Therefore 
after antigen processing there could be a higher number of small fragments of FVIII 
light chain presented by antigen presenting cells to T-lymphocytes. It has been shown 
that the size of epitope fragments capable of binding to the FVIII antibody is rather 
large (16-66 amino acids) and does not depend on whether the epitopes are linear, 
sequential or completely denaturated [16-18]. The antibody binding to denaturated 
plasma-derived FVIII and isolated recombinant FVIII light chain and heavy chain 
was observed in the investigated patient. The level of FVIII antibody subtypes, and 
the concentration and affinity of antibodies at different time points indicated the 
polyclonal antibody response to the treatment.
The results of our study are in agreement with previous reports, where on- 
demand treatment of hemophilia A patients is associated with the development of 
FVIII antibodies mainly of the IgGl or IgG4 subtypes [19, 20]. The level of IgGl 
subtype antibodies rises quickly after antigen administration (gene locates in 
5’-end), while production of IgG2 and IgG4 subtypes probably needs more support 
of cytokines, produced by Th2 cells, because the genes encoding these subtypes are 
located close to 3’-end [12,13]. FVIII antibodies with inhibitory and non-inhibitory 
antibodies were of the IgG4 subtype predominantly. During immune tolerance 
therapy with FVIII-vWF concentrate, the level of FVIII antibodies of IgGl subtype 
increased significantly after 1 month of treatment and this rise was accompanied 
by the peaking of IgGl subtype antibodies against the FVIII light chain. After the 
second continuous infusion the sudden rise in IgGl subtype FVIII antibodies was 
observed, but the distribution of FVIII light chain antibodies remained unchanged. 
Surprisingly, antibodies neutralizing the FVIII heavy chain were detected in the 
same plasma sample. The enhanced level of the IgGl subtype was observed as a 
result of the higher dosage of FVIII concentrate and could indicate the novel clone 
producing FVIII antibodies with different epitope specificity. One report [21] about 
unsuccessful ITT described an increased level of anti-A2 domain antibodies among 
heterogeneous antibodies in the patient and the authors suggested using the
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epitope mapping as a prediction of the outcome of ITT. We found an increase in the 
FVIII heavy chain antibody level (IgGl subtype), but continued ITT suppressed the 
production of these antibodies to undetectable level. Tolerance induction basis on 
the clonal selection. Therefore it is important that all FVIII antibody-producing 
clones have to become tolerant to FVIII administered at sufficiently high doses for 
a long time.
The effect of different FVIII concentrates used in replacement therapy on hemo­
philia A patients’ immune system has been studied extensively. Results of in vitro stu­
dies showed decreased levels of IL-2, TNF, INF-y and increased levels of IL-4, IL-10 in 
each different leukocyte subset after stimulation with FVIII concentrate of inter­
mediate purity [11]. The immuno-suppressive effect of these concentrates was 
explained by the presence of TGF-p [11], which inhibits the proliferation of T-cells, 
maturation of cytolytic T-cells and the activation of macrophages. In vivo investi­
gations in HIV-negative hemophiliacs have shown increased numbers of CD8+ cells 
and decreased numbers of CD4+ cells, indicating the immuno-stimulatory effect of 
treatment caused probably by the presence of TGF-p, which produces some Th2-like 
effects, like a co-stimulatory effect on CD8+ T-cells [22]. The FVIII concentrates of 
intermediate purity in general are more prone to decreasing the CD4+ cell count than 
immuno-affinity purified concentrates used for treatment of HIV-positive hemophilia 
A patients [23-25]. HIV-negative hemophiliacs who developed FVIII antibodies have 
been investigated so far only in one multicenter study [26]. This study showed no dif­
ference between FVIII-induced IFN-y and IL-10 production by lymphocytes in hemo­
philia A patients who developed FVIII antibodies and those who did not.
We studied changes in FVIII antibody subtype distribution in a low responder 
hemophilia A patient treated with FVIII concentrates with different purities 
(patient 2). An ELISA assay used for estimating IgG subtypes was sensitive to 
detecting very low titers of FVIII antibodies. Analogously to patient 1, the higher 
production of IgG4 subtype FVIII antibodies was more or less pronounced in 
patient 2 at different time points. Long term treatment with FVIII-vWF concentra­
tes in patient 2 resulted in a decrease of FVIII antibody titer measured in Bethesda 
units. The change to affinity purified FVIII concentrate Octonativ-M caused an 
increase in inhibitory antibodies, but isotype distribution of FVIII antibodies 
remained unchanged. An increase in the production of IgGl and IgG3 subtype 
FVIII antibodies was observed during treatment with another immuno-affinity 
purified concentrate, Aafact. Unfortunately, plasma samples were taken occasionally 
and therefore it is not absolutely clear whether the observed changes in IgG subtype 
distribution were caused only by the switch to another concentrate. Apart from the 
purity of FVIII concentrate used for treatment, many other reasons like the dose 
and interval between doses could be responsible for different antibody response.
The usage of vWF in FVIII concentrates for ITT suppressed the production of 
FVIII light chain antibodies with inhibitory activity to non-detectable levels, while 
antibodies with non-inhibitory activity persisted. The beneficial outcome of using 
FVIII-vWF concentrates was observed also in patient 2, who had higher in vivo 
recovery with FVIII-vWF concentrate than with immuno-affinity purified concen­
trates. Probably after injection of FVIII concentrate of very high purity, both vWF 
and FVIII antibodies compete for binding sites on FVIII. If the antibodies possess
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higher affinity than vWFr the antibody-antigen complex is formed and the FVIII 
molecule is removed from the circulation. lt has been reported, that antibodies re­
acting with epitopes within the acidic region of the A3 domain (a3 region), Cl [27] 
and C2 domains [28], inhibit the binding of FVIII to vWF and are able to compete 
with vWF for binding site. As the, intact Üght chain of FVIII has the maximum vWF 
binding affinity [29], we used the recombinant full-length FVIII light chain in the 
neutralization experiment to quantify all antibodies interfering with FVIII-vWF 
interaction. The vWF in the administered FVIII concentrates covers FVIII antibody 
binding sites on FVIII light chain and therefore delays the FVIII neutralization. Still 
half of the FVIII molecules dissociate from the vWF every 10 min [30]. Released 
FVIII is exposed to FVIII antibodies for forming FVIII-antibody complex, which is 
more stable than FVIII-vWF complex.
FVIII antibody response to the treatment is associated with the characteristics of 
the patient. The FVIII gene defect of the patient determines whether a non­
functional FVIII molecule is produced or production of any protein is prevented. 
Hemophilia A patients with mild disease caused by point mutation in the FVIII gene 
may develop antibodies with higher neutralization activity against administered 
FVIII than against endogenous FVIII [31]. Investigated patients 1 and 2 had inversion 
in intron 22 in FVIII gene, which is the most common gene defect among hemophilia 
A patients and accompanies a higher incidence of FVIII antibody development domi­
nantly against the FVIII light chain and the A2 domain of heavy chain [1,32],
In addition to a gene defect causing FVIII deficiency, the antibody response to 
the treatment may be determined by the immune system of the particular patient. 
HLA genotype of MHCII alleles was characterized only in patient 2. DR8, DQ7 and 
DQ4 genotypes, as found in our patient, have been reported by Hay and Oldenburg, 
who detected these genotypes in some patients with inhibitors [33,34]. However, no 
correlation between HLA allele genotypes and inhibitor incidence could be esta­
blished in either of these reports.
So far no efficient treatment option has been found to prevent the development 
of FVIII antibodies and to achieve successful immune tolerance. However, some 
reports are more promising in that respect, Rossi et al. have used the blocking of 
CD40-CD40L interaction in mice [35]. Abolishing another important interaction, 
CD28-B7, caused less development of inhibitory antibodies, but unfortunately 
immune tolerance was not gained [36].
Thus it seems that multiple factors are involved in the development and produc­
tion of FVIII antibodies in hemophilia A patients. Which factor is more relevant 
depends on the particular patient and further studies are needed to clarify their rela­
tive contribution to the success rate of immune tolerance therapy. Our study focused 
on the presence of vWF in FVIII concentrate used for ITT and we conclude that a 
beneficial outcome can be achieved using FVIII concentrate containing vWF in 
hemophilia A patients with antibodies reacting mainly with the FVIII light chain.
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A bstract A collagen type III based collagen-binding as­
say was developed for measuring the functional activity 
of the von Willebrand factor. The assay had a low coeffi­
cient of variance (4.8%) for normal values under opti­
mized conditions. The results of the Collagen-binding ac­
tivity (CBA) assay correlated with ristocetin cofactor ac­
tivity tested in normal plasma samples («=29). We found 
that the CBA of blood group O is lower than that of oth­
er blood groups. The test was used for the diagnosis of 
von Willebrand’s disease (VWD) and for estimating the 
response to treatment with DDAVP (1-deamino-D-argi- 
nine-8 vasopressin) and factor VIII concentrate. A mean 
ratio of VWF antigen (VWF:Ag) to CBA of 1.5 indicat­
ed type 1 and of 2.7 indicated type 2 VWD. The increase 
in the collagen-binding activity of VWF released in type 
1 VWD patients (n=7) after treatment with DDAVP was 
higher than the increase in the VWF antigen; this is char­
acteristic of very high multimers with greater functional 
activity. Factor VIII concentrate Koate-HP (Bayer) ad­
ministered to a patient with VWD type 3 had a mean res­
idence time of 12.6 h for VWF:Ag and 11.2 h for CBA. 
These findings suggest that the collagen-binding assay is 
a useful test for measuring the functional activity of 
VWF in plasma samples, factor VIII concentrates, as 
well as for estimating the outcome of treatment.
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Introduction
The von Willebrand factor (VWF) is a glycoprotein with 
an essential role in primary haemostasis and in blood co­
agulation. VWF mediates the adhesion of platelets to 
subendothelium at the site of vascular injury and stabi­
lizes factor VIII by forming a noncovalent complex [24], 
VWF comprises multimers ranging from 500 kDa to
20,000 kDa linked together by disulfide bridges. Each 
subunit of the VWF carries binding sites for collagen, 
factor VIII, and the platelet receptor glycoprotein Ib/IXa 
and Ilb/IIIa [24].
Different defects of the VWF molecule cause the 
most common inherited bleeding disorder, von Wille­
brand’s disease (VWD), with a prevalence of 0.83% in 
the general population [23]. The simplified classification 
of VWD distinguishes between three groups: partial 
quantitative deficiency (type 1), qualitative deficiency 
(type 2), and total quantitative deficiency (type 3). The 
highly variable clinical picture and the presence of many 
different defects in the molecule of VWF complicate the 
diagnosis of VWD. To date, no single test that gives ap­
propriate information about the various functions of 
VWF is available. Several analyses, such as the ristoce­
tin cofactor aggregation method, the VWF antigen assay, 
assay of factor VIII coagulation activity, and others, are 
required for diagnosing VWD and for characterizing the 
defect in the particular patient. Factor VIII coagulation 
(F VIII:C) activity indirectly reflects the level of its sta­
bilizing protein VWF [24], The von Willebrand factor 
antigen level is measured by an ELISA method for 
which polyclonal VWF antibodies are used and which 
therefore has no effect on the functional activity of 
VWF. The assay of ristocetin cofactor (RCof) activity 
has been used widely for measuring the VWF ability to 
mediate platelet aggregation. The dimeric form of the 
antibiotic ristocetin is able to induce platelet aggregation 
by binding to both VWF and platelets [26]. The disad­
vantages of this test include the poor sensitivity (50%) 
[22], difficulties in standardization [3], and the lack of a 
physiological analogue. The monoclonal VWF antibody
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based commercial ELISA test for describing RCof-like 
activity is less effective in discriminating VWD subtypes 
than the collagen-binding assay is [8]. A recently intro­
duced simple ELISA test for collagen-binding activity 
(CBA) is sensitive and seems useful for screening VWD 
patients [3, 21, 27]. The binding of VWF to the collagen 
in the subendothelium is the first step in the initiation of 
primary haemostasis. The native conformation of VWF 
is essential for the interaction with collagen, but limited 
reduction of multimers to their dimeric form results in 
decreased binding to collagen [20]. We developed an 
ELISA assay using collagen type III for measuring VWF 
binding to collagen in different plasma samples and in 
different factor VIII concentrates. The test was applied 
in the diagnosis of VWD and for estimating the response 
of VWD patients to treatment with DDAVP (1-deamino- 
D-arginine-8 vasopressin) and factor VIII concentrates.
Materials and methods
Collagen-binding assay
Acid-soluble collagen type III from human placenta (C 4407, Sig­
ma, USA) was dissolved in 3% acetic acid. The collagen solution 
was rapidly diluted to a final concentration o f 10 |ig/ml in PBS 
buffer, pH 7.3, and then immobilized on a niicrotitre plate. We 
used different polystyrene plates for coating: Nunc immunoplates 
PolySorp™, MaxiSorp™ (Nunc, Denmark), Nunclon™, and 
Titertek™ soft microplate (Titertek, USA). The collagen solution 
(100 jjI) was incubated for 1 h at room temperature. After the plate 
was coated, it was blocked with 5% bovine serum albumin (BSA) 
in PBS with Tween (0.05%). A normal plasma pool from 22 do­
nors was used as a local standard and calibrated against RCof ac­
tivity of the 3rd International standard for factor VIII and von 
Willebrand in plasma (91/666). The standard plasma dilutions 
1:10 to 1:120 corresponding to 0.1 to 2.0 IU/ml of CBA were used 
for constructing a standard curve. Investigated plasma samples 
were diluted 1:20, 1:40, and 1:60 and incubated in duplicate on a 
mictrotitre plate for 1 h at room temperature. Thereafter a peroxi­
dase (HRP) conjugated rabbit antihuman VWF (P226 Dako, Den­
mark) in dilution 1:2000 was added and incubated for 1 h. The re­
action was visualized by the addition of OPD substrate solution 
(o-phenylenediamine in 0.1 M citrate-phosphate buffer, pH 5.0, 
containing 0.03% H20 2). The reaction was stopped by the addition 
of 3 M H2S 04. The absorbance was read at 450 nm on a micro­
plate reader, Labsystem Multiscan Plus (Labsystem, Finland).
Standards
The local plasma pool from 22 donors was used as a standard and 
calibrated against the WHO 3rd standard for factor VIII and VWF 
in plasma (code 91/666). The 4th International standard for blood 
coagulation F VIILC concentrate (88/804) was used when factor 
VIII concentrates were studied.
Investigated samples
Collagen-binding activity was studied in different samples. Plasma 
samples of 29 blood donors (8 from each blood group except 
blood group AB with 5 samples), plasma samples from 30 diag­
nosed VWD patients, as well as samples of 5 different factor VIII 
concentrates were included in the study. Investigated factor VIII 
concentrates were Haemoctin SDH 250 IU (Biotest, Germany), 
Koate-HP 310 IU (Bayer, USA), lyophilized cryoprecipitate Kryo- 
AHG 400 IU (North Estonian Blood Centre. Estonia) and Hae-
mate 1000 IU (Aventis Behring, USA). The factor VIII concen­
trates were diluted according to the manufacturers’ instructions. 
Blood samples were obtained by vein puncture and centrifuged at 
2000 g. As anticoagulant, 0.129 M sodium citrate was used (1 part 
anticoagulant to 9 parts blood). All samples were stored at -70  °C 
until assayed.
Assay for F VIILC activity
F VIILC activity was measured by a chromogenic method (Coa- 
test F VIILA, Chromogenix Instrumentation Laboratory, SpA, Ita­
ly). Factor VIII concentrates were prediluted to a final activity of 
1 IU/ml of F VIILC in TBS buffer containing 1 % BSA.
ELISA assay for VWF:Ag
Rabbit antihuman VWF antibody (A082, Dako, Denmark) was 
used as a coating antibody and HRP rabbit antihuman VWF anti­
body (P226, Dako, Denmark) was used as a conjugate.
Ristocetin cofactor assay
Ristocetin cofactor activity of VWF was determined with the use of 
formaldehyde fixed washed platelets (FWP) for the agglutination 
test [14]. The FWP reagent was made as described previously [6].
VWF multimer analyses
The analysis of VWF multimers was done by SDS-agarose gel 
electrophoresis with 1.9% gel, according to Metzner et al., by the 
discontinuous submarine technique [18]. VWF multimers were de­
tected with VWF antibody A082 (Dako) and goat anti-rabbit IgG 
alkaline phosphatase conjugate (Sigma). The bands were devel­
oped with substrate solution BC1P/NBT.
In vivo studies
The effect of DDAVP on release of VWF was investigated on sev­
en patients with type 1 VWD. In plasma samples taken before and 
10 min after i.v. injection of 0.3 pg/kg Octostim (Ferring, Swe­
den), F VIILC activity, VWF:Ag, RCof, and CBA activities were 
measured. Multimeric composition before and after treatment was 
measured by Western blotting and bleeding time was measured by 
the Ivy method with the Simple II device.
Pharmacokinetic study
Factor VIII concentrate Koate-HP (Bayer) (dose 45 IU/kg) was in­
jected into a patient (27 years old, body weight 51 kg) with type 3 
VWD. Plasma samples were collected before and 10 min, 30 min, 1,
3, 6, 9,12, 24,26, 28,48 h after administration. The collagen-binding 
activity, VWF:Ag, and F VIILC were measured in all samples. The 
study was repeated after 12 months on the same patient and under the 
same conditions. A model-independent method was used for the cal­
culation of the pharmacokinetic parameters (AUC, MRT) [17]. The 
half-life was calculated as =MRT/1.443. In vivo recovery was cal­
culated as a percentage of the measured post-infusion rise to expected 
rise. The expected rise was calculated by division of the injected dose 
by the estimated plasma volume (45 ml plasma to 1 kg body weight).
The Ethics Committee of the University of Tartu, Estonia ap­
proved the study protocol.
Statistical analysis
Results are expressed as the mean and standard deviation (SD) 
with 95% confidence interval. The differences between the results
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Fig. 1 The effect of different microplates on the collagen-binding 
assay. The results given are the mean values obtained in at least 
two replicated experiments
of the different blood groups were analysed by the t  test for inde­
pendent samples; a P value of 0.02 was considered significant. 
Calculation of the correlation between VWF:Ag and RCof activity 
was based on the Spearman rank order correlation coefficient.
Results
Optimization of the collagen-binding assay
VWF collagen-binding activity was measured by the 
ELISA assay. Microplates were coated with collagen 
type III from human placenta and incubated with stan­
dard plasma dilutions. The bound VWF was detected 
with polyclonal VWF antibody. Different polystyrene 
immunoplates were tested for suitability for the assay. 
VWF had the highest binding ability to collagen immo­
bilized on the Titertek microplate (Fig. 1). With the 
PolySorp immunoplate, the assay had poor sensitivity, 
indicating a lower number of active binding sites on col­
lagen available for the interaction with VWF. Next, we 
compared the use of different collagen concentrations for 
the coating of microplates. At a collagen concentration 
of 20 pg/ml the results were not significantly better than 
at 10 (ig/ml. In the following experiments we used a col­
lagen solution of 10 ng/ml for coating the Titertek micro­
plates. Under these conditions the absorbance curve was 
linear at CBA values from 0.25 IU/ml to 2.0 IU/ml. The 
samples investigated were diluted so that the results 
could be read from the linear part of the standard graph. 
The intra-assay coefficient of variance was 4.8% for 
1 IU/ml of collagen-binding activity and 14% for 
0.5 IU/ml of CBA.
Reference range
The collagen binding of VWF was measured in plasma 
samples of blood donors with the aim to establish normal 
reference values. The mean collagen-binding activity of
Table 1 Von Willebrand factor activity in samples of blood do­
nors. Results shown are the mean and standard deviation (95% Cl)
Blood group n CBA VWF:Ag RCof
IU/ml IU/ml IU/ml
(95% Cl) (95% Cl) (95% Cl)
A 8 1.04±0.47 1.21±0.42 0.97±0.28*
(0.64-1.43) (0.86-1.57) (0.74-1.20)
O 8 0.70±0.26* 0.92+0.22* 0.67±0.27*
(0.48-0.92) (0.73-1.10) (0.44-0.90)
B 8 0.99±0.08* 1.14+0.17* 0.84±0.18
(0.97-1.07) (0.99-1.29) (0.69-0.99)
AB 5 0.96±0.06* 1.05+0.24 1.06+0.24
(0.89-1.04) (0.76-1.34) (0.75-1.35)
Mean 0.92±0.31 1.05+0.29 0.87±0.28
*StatisticaI difference compared with group O (/J<0.02)
Table 2 Von Willebrand factor in plasma samples of VWD pa-
tients
Type of n CBA VWF:Ag RCof F VIII:C
VWD IU/ml IU/ml IU/ml IU/ml
1 17 0.52±0.33 0.63±0.30 0.57+0.21 0.60+0.27
2A 10 0.42±0.25 0.62±0.32 0.43±0.14 0.68+0.48
3 3 0.02±0.01 0.09±0.02 0.14+0.04 0.05+0.03
29 plasma samples was 0.92 IU/ml (Table 1). The results 
of the collagen-binding assay correlated with the VWF 
antigen values (Spearman rank order correlation coeffi­
cient /-0 .76) and with ristocetin cofactor activity 
(r=0.67). Blood group O had the lowest values for 
VWF:Ag, RCof, and CBA (Table 1), compared to blood 
groups A, B, and AB; however, we could not find a sta­
tistically significant difference, because of the small 
number of samples representing each blood group. All 
blood donor samples had the normal multimeric struc­
ture of VWF measured by Western blotting.
Collagen-binding activity in samples of VWD patients
We screened samples of 30 patients diagnosed with 
VWD to evaluate the ability of the collagen-binding as­
say to detect high molecular weight multimers of VWF 
(Table 2). Type 1 VWD was diagnosed in 17 patients, 
type 2A in 10 patients, and type 3 in 3 patients. Diagno­
sis was based on the values of VWF:Ag, F VIII:C, and 
RCof activities and on the agarose gel electrophoresis 
pattern of the VWF multimers. The results of the colla­
gen-binding assay correlated well with the values of the 
VWF antigen (r=0.76). The mean ratio VWF:Ag/CBA 
was l.5±0.9 for type 1, 2.7±1.9 for type 2A, and 7.1+3.9 
for type 3 VWD.
The effect of DDAVP on the release of functional VWF
Patients with VWD can be treated with DDAVP or with 
factor VIII concentrates. The effect of DDAVP on the re­
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Table 3 Von Willebrand factor activity in different factor VIII concentrates
Factor VIII concentrate n F VIII:C 
IU/ml
VWFtAg
IU/ml
RCof
IU/ml
CBA
IU/ml
VWF:Ag/CBA No. of 
multimers
Haemoctin SDH 
(Biotest)
6 58.4±3.5 31.8±4.6 13.3±3.2 8.5±1.9 4.0+1.6 14
Koate-HP
(Bayer)
6 114.4±39.2 251.4+79.5 118.8±1.7 96.5+42.0 2.4+0.4 16
Kryo-AHG
(North Estonian Blood Centre)
6 8.5±2.2 12.2±3.1 8.43±1.7 10.2±3.1 1.4±0.4 16
Haemate
(Aventis Behring)
1 47.6 89.1 85.5 81.8 1.1 17
lease of functional VWF was measured in seven patients 
with type 1 VWD by collagen-binding assay. Treatment 
with DDAVP increased VWF binding to collagen 
4.6±2.5 times, while the VWF antigen level increased 
2.4+1. i times. The ratio VWF:Ag/CBA decreased from 
1,23±0.68 to 0.67±0.30 after treatment. In four patients 
the bleeding time decreased. High molecular weight 
multimers of VWF appeared or their concentration in­
creased after DDAVP treatment; this is in good agree­
ment with the collagen-binding activity of VWF.
Collagen-binding activity of VWF 
in factor VIII concentrates
The collagen-binding activity was investigated in differ­
ent factor VIII concentrates containing VWF available in 
Estonia. Also included in the study were locally pro­
duced single-donor lyophilized cryoprecipitate (Kryo- 
AHG) and one sample of Haemate concentrate (Aventis), 
which is indicated for the treatment of VWD. All investi­
gated concentrates were prediluted with TBS buffer with 
1% bovine serum albumin. No significant changes were 
seen when plasma from a VWD type 3 patient was used 
instead of the buffer in the collagen-binding assay. The 
highest VWF content was in Koate-HP concentrate 
(Table 3), with a good correlation between the results of 
F VIII:C activity and VWF:Ag (r=0.94), and also be­
tween the results of the VWF antigen and the collagen- 
binding activity assays (r=0.96). Factor VIII concentrate 
Haemoctin SDH (Biotest) showed correlation only be­
tween the results of the VWF:Ag and RCof activity 
(r=0.94). The ratio VWF:Ag/CBA of factor VIII concen­
trate Haemate was 1.1, while that for the lyophilized 
cryoprecipitate (Kryo-AHG) was 1.4+0.4; this indicates 
the presence of functional VWF in both products.
Pharmacokinetic studies
Factor VIII concentrate Koate-HP (Bayer) was chosen 
for the in vivo experiments, because previous investiga­
tions indicated that this concentrate has a high content of 
functional VWF. Pharmacokinetic parameters were stud­
ied in the patient with type 3 VWD. A dose of 46 IU/kg 
of F VIII:C (97 IU/kg of VWF:Ag and 38 IU/kg of
Time, h
Fig. 2 The decrease in VWF and factor VIII after administration 
of Koate-HP (Bayer) to the patient with type 3 VWD. The results 
were obtained after the second injection. The injected dose was 
50 IU/kg of F VIII:C, 113 IU/kg of VWF, and 43 IU/kg of CBA
CBA) was administered and the results were compared 
with another experiment carried out 12 months later on 
the same patient and under the same conditions (the sec­
ond dose was 50 IU/kg of F VIII:C, 113 IU/kg of VWF, 
and 43 IU/kg of CBA). In the meantime, the patient’s 
bleeding (mainly in the target left knee joint) was suc­
cessfully treated with the same concentrate. The first and 
second infusions did not differ with regard to dose and 
response. The decreasing VWF:Ag, CBA activity, and F 
VIII:C after administration of the second dose are shown 
in Fig. 2. The average mean residence time (MRT) cal­
culated from the VWF:Ag results was 12.6 h and from 
the CBA assay results was 11.2 h. The VWF adminis­
tered was able to stabilize factor VIII, and the second 
peak of F VIII :C was seen within 12 h after the first in­
jection. The mean residence time for F VIII:C was 18 h. 
The mean half-lives for CBA, VWF:Ag, and F VIII:C 
were 7.7 h, 8.7 h, and 12.6 h, respectively. The mean in 
vivo recovery calculated from the VWF:Ag values was
53.1 %, and was 50% for the CBA results. High molecu­
lar weight multimers appeared in the plasma sample tak­
en 10 min after injection. The multimeric composition of 
VWF was similar to VWF in the Koate-HP and correlat­
ed with the collagen-binding activity of VWF.
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Discussion
We optimized the collagen-binding assay to measure 
VWF activity for discrimination of VWD subtypes and 
for estimating the response to treatment with DDAVP 
and factor V lll concentrates. The assay gives informa­
tion about the functional activity of VWF, indicating the 
presence or absence of high and intermediate molecular 
weight multimers. Results of the optimized collagen- 
binding assay correlated well with VWF antigen values 
and ristocetin cofactor activity when normal plasma 
samples were tested.
Our results demonstrate the importance of optimizing 
the assay conditions to reach an excellent calibration 
curve and a low intra-assay coefficient of variance. The 
different polystyrene microplates had different effects on 
the collagen-VWF interaction: some microplates caused 
a lower number of collagen-binding sites to be available 
for interaction with the VWF molecule. Previous studies 
have used the covalent linkage of collagen onto the sur­
face, which overcomes the problem of steric hindrance 
of the large VWF molecule [9, 27], We had good results 
in the CBA assay with the Titertek non-activated low- 
cost immunoplate. Microplates were coated with colla­
gen type III, which contains the most critical binding site 
for VWF in the sequence 541-558 of the a l(III) chain 
[28]. Compared to type I collagen, type III forms less 
thick fibrils and more surface is available for interaction 
with large ligands such as VWF [20]. The collagen qua­
ternary structure and the native conformation of the 
VWF domains are both essential for effective colla­
gen-VWF interaction [4], Surface plasmon technology 
shows excellent binding of collagen type III to VWF 
[27]. Because of these advantages, collagen type III has 
been widely used in CBA assays [7, 9, 27]. An optimal 
collagen concentration (10 (jg/ml) provided a low varia­
tion coefficient (4.8% for normal values) and good dis­
crimination between different types of VWD. The bor­
derline value of the ratio VWF:Ag/CBA distinguishing 
type 1 and type 2A VWD was 2.7. The results of this 
study agree with those from previous ones that indicated 
the capability of the test for diagnosing subtypes of 
VWD [3, 7],
Favaloro recommended including plasmas of type 2A 
and 2B VWD patients as controls in every test [7], In­
creasing the number of abnormal controls is only reason­
able if the cost of analysis is low. Our CBA assay makes 
it possible for a few plasma samples to be analysed at a 
time, because only the necessary number of microplate 
strips need to be coated with collagen. Therefore, this 
test can be used for the diagnosis and treatment-response 
evaluation in laboratories of haemophilia centres with a 
low number of patients at a reasonable price.
The treatment preferred for VWD type 1 patients is 
administration of DDAVP, which causes the release of 
the endogenous VWF from Weibel-Palade bodies [29]. 
Compared to VWF antigen values, the CBA values of re­
leased VWF were higher (VWF:Ag/CBA before treat­
ment 1.23, after treatment 0.67). The increased interac­
tion between VWF and collagen may be associated with 
the appearance of ultra-high molecular weight multim­
ers, which have the highest thrombogenic potential and 
have been found in the plasma of a VWD type 2A pa­
tient 15 min after DDAVP treatment [2].
The sensitivity of the CBA assay in the detection of 
high molecular weight multimers was tested by analys­
ing VWF containing factor VIII concentrates. The corre­
lation between VWF:Ag and CBA values as well as the 
ratio VWF:Ag/CBA provide information about the de­
gree of degradation of VWF. Ramasamy and co-workers 
demonstrated the capability of the CBA assay to charac­
terize VWF in a small-scale manufacture of the concen­
trate, but they used collagen type I in the assay and the 
assay had a coefficient of variance of 12.5% for normal 
values [21], European Pharmacopoeia (EP) proposes the 
CBA method for the determination of the biological ac­
tivity of VWF in factor VIII concentrates [5]. Our home­
made CBA assay can be used for estimating the content 
of the functional VWF of factor VIII concentrate in vitro 
and for evaluating the outcome of administered factor 
VIII concentrate in vivo. The in vivo recovery of VWF 
measured in samples taken 10 min after injection, calcu­
lated from values of the collagen-binding assay, was 
50%. Proteolytic degradation of the subunit reduces the 
size of the largest VWF multimer in plasma, resulting in 
intermediate and low molecular weight multimers [10]. 
Injected VWF is probably exposed to proteolytic cleav­
age and the concentration of high molecular weight mul­
timers decreases. The mean residence time (MRT) was 
used for characterizing the outcome of the administered 
factor VIII concentrate, because it gives information on 
how long the injected substance is kept in circulation. 
MRT measured by the collagen-binding assay was 12 h; 
this indicates that functionally active VWF circulates in 
plasma for this amount of time.
Among VWD type 1 patients, 70% belonged to blood 
group O [11, 19], Ristocetin cofactor activity, F VIII:C, 
VWF:Ag, as well as factor VIII antigen are about 25% 
lower in healthy persons with blood group O [1, 11, 16, 
23]. VWF contains A'-linked oligosaccharides in the Al 
domain [15], which are essential for VWF binding to GP 
Ib/IXa receptors on the platelet surface. Removal of A and 
B group antigens from the VWF decreases ristocetin co­
factor activity, but binding to collagen remains unchanged 
[25], The main binding sites of the fibrillar collagens type 
1 and 111 are located in the A3 domain, while the collagen 
type VI binding site is in the A 1 domain of the VWF mol­
ecule [12, 13, 20], We found lower CBA values in blood 
group O plasma samples. Probably there is another mech­
anism responsible for the lower CBA. However, the use of 
ABO-adjusted ranges for VWF levels might not be essen­
tial for diagnosis, because bleeding symptoms may de­
pend on the VWF level regardless of the ABO type [ 19], 
In addition to low levels of the VWF antigen and activity, 
the bleeding history as well as inheritance are essential for 
the diagnosis and treatment of VWD type 1.
In conclusion, our results suggest that the ratio 
VWF:Ag/CBA can be used for the diagnosis of VWD
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before analysis of the multimeric composition of VWF. 
Establishing an international standard for collagen-bind­
ing activity could make this method a standardized pro­
cedure for measuring the functional activity of VWF in 
plasma samples, for estimating the dose of VWF con­
taining concentrates, and for evaluating the response to 
treatment.
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